#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Baseline Brain Structural and Functional Predictors of Clinical Outcome in the Early Course of Schizophrenia
#Text=Although schizophrenia is considered a brain disorder, the role of brain organization for symptomatic improvement remains inadequately defined.
1-1	0-8	Baseline	_
1-2	9-14	Brain	_
1-3	15-25	Structural	_
1-4	26-29	and	_
1-5	30-40	Functional	_
1-6	41-51	Predictors	_
1-7	52-54	of	_
1-8	55-63	Clinical	_
1-9	64-71	Outcome	_
1-10	72-74	in	_
1-11	75-78	the	_
1-12	79-84	Early	_
1-13	85-91	Course	_
1-14	92-94	of	_
1-15	95-108	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-16	109-117	Although	_
1-17	118-131	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-18	132-134	is	_
1-19	135-145	considered	_
1-20	146-147	a	_
1-21	148-153	brain	_
1-22	154-162	disorder	_
1-23	162-163	,	_
1-24	164-167	the	_
1-25	168-172	role	_
1-26	173-175	of	_
1-27	176-181	brain	_
1-28	182-194	organization	_
1-29	195-198	for	_
1-30	199-210	symptomatic	_
1-31	211-222	improvement	_
1-32	223-230	remains	_
1-33	231-243	inadequately	_
1-34	244-251	defined	_
1-35	251-252	.	_

#Text=We investigated the relationship between baseline brain morphology, resting-state network connectivity and clinical response after 24-weeks of antipsychotic treatment in patients with schizophrenia (n=95) using integrated multivariate analyses.
2-1	253-255	We	_
2-2	256-268	investigated	_
2-3	269-272	the	_
2-4	273-285	relationship	_
2-5	286-293	between	_
2-6	294-302	baseline	_
2-7	303-308	brain	_
2-8	309-319	morphology	_
2-9	319-320	,	_
2-10	321-334	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-11	335-342	network	_
2-12	343-355	connectivity	_
2-13	356-359	and	_
2-14	360-368	clinical	_
2-15	369-377	response	_
2-16	378-383	after	_
2-17	384-386	24	_
2-18	386-387	-	_
2-19	387-392	weeks	_
2-20	393-395	of	_
2-21	396-409	antipsychotic	_
2-22	410-419	treatment	_
2-23	420-422	in	_
2-24	423-431	patients	_
2-25	432-436	with	_
2-26	437-450	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-27	451-452	(	_
2-28	452-453	n	_
2-29	453-454	=	_
2-30	454-456	95	_
2-31	456-457	)	_
2-32	458-463	using	_
2-33	464-474	integrated	_
2-34	475-487	multivariate	_
2-35	488-496	analyses	_
2-36	496-497	.	_

#Text=There was no significant association between clinical response and measures of cortical thickness (r=0.37, p=0.98) and subcortical volume (r=0.56, p=0.15).
3-1	498-503	There	_
3-2	504-507	was	_
3-3	508-510	no	_
3-4	511-522	significant	_
3-5	523-534	association	_
3-6	535-542	between	_
3-7	543-551	clinical	_
3-8	552-560	response	_
3-9	561-564	and	_
3-10	565-573	measures	_
3-11	574-576	of	_
3-12	577-585	cortical	_
3-13	586-595	thickness	_
3-14	596-597	(	_
3-15	597-598	r	_
3-16	598-599	=	_
3-17	599-603	0.37	_
3-18	603-604	,	_
3-19	605-606	p	_
3-20	606-607	=	_
3-21	607-611	0.98	_
3-22	611-612	)	_
3-23	613-616	and	_
3-24	617-628	subcortical	_
3-25	629-635	volume	_
3-26	636-637	(	_
3-27	637-638	r	_
3-28	638-639	=	_
3-29	639-643	0.56	_
3-30	643-644	,	_
3-31	645-646	p	_
3-32	646-647	=	_
3-33	647-651	0.15	_
3-34	651-652	)	_
3-35	652-653	.	_

#Text=By contrast, we identified a strong mode of covariation linking functional network connectivity to clinical response (r=0.70; p=0.04), and particularly to improvement in positive (weight=0.62) and anxious/depressive symptoms (weight=0.49).
4-1	654-656	By	_
4-2	657-665	contrast	_
4-3	665-666	,	_
4-4	667-669	we	_
4-5	670-680	identified	_
4-6	681-682	a	_
4-7	683-689	strong	_
4-8	690-694	mode	_
4-9	695-697	of	_
4-10	698-709	covariation	_
4-11	710-717	linking	_
4-12	718-728	functional	_
4-13	729-736	network	_
4-14	737-749	connectivity	_
4-15	750-752	to	_
4-16	753-761	clinical	_
4-17	762-770	response	_
4-18	771-772	(	_
4-19	772-773	r	_
4-20	773-774	=	_
4-21	774-778	0.70	_
4-22	778-779	;	_
4-23	780-781	p	_
4-24	781-782	=	_
4-25	782-786	0.04	_
4-26	786-787	)	_
4-27	787-788	,	_
4-28	789-792	and	_
4-29	793-805	particularly	_
4-30	806-808	to	_
4-31	809-820	improvement	_
4-32	821-823	in	_
4-33	824-832	positive	_
4-34	833-834	(	_
4-35	834-840	weight	_
4-36	840-841	=	_
4-37	841-845	0.62	_
4-38	845-846	)	_
4-39	847-850	and	_
4-40	851-858	anxious	_
4-41	858-859	/	_
4-42	859-869	depressive	_
4-43	870-878	symptoms	_
4-44	879-880	(	_
4-45	880-886	weight	_
4-46	886-887	=	_
4-47	887-891	0.49	_
4-48	891-892	)	_
4-49	892-893	.	_

#Text=Higher internal cohesiveness of the default mode network was the single most important positive predictor.
5-1	894-900	Higher	_
5-2	901-909	internal	_
5-3	910-922	cohesiveness	_
5-4	923-925	of	_
5-5	926-929	the	_
5-6	930-937	default	_
5-7	938-942	mode	_
5-8	943-950	network	_
5-9	951-954	was	_
5-10	955-958	the	_
5-11	959-965	single	_
5-12	966-970	most	_
5-13	971-980	important	_
5-14	981-989	positive	_
5-15	990-999	predictor	_
5-16	999-1000	.	_

#Text=Key negative predictors involved the functional cohesiveness of central executive subnetworks anchored in the frontoparietal cortices and subcortical regions (including the thalamus and striatum) and the inter-network integration between the default mode and sensorimotor networks.
6-1	1001-1004	Key	_
6-2	1005-1013	negative	_
6-3	1014-1024	predictors	_
6-4	1025-1033	involved	_
6-5	1034-1037	the	_
6-6	1038-1048	functional	_
6-7	1049-1061	cohesiveness	_
6-8	1062-1064	of	_
6-9	1065-1072	central	_
6-10	1073-1082	executive	_
6-11	1083-1094	subnetworks	_
6-12	1095-1103	anchored	_
6-13	1104-1106	in	_
6-14	1107-1110	the	_
6-15	1111-1125	frontoparietal	_
6-16	1126-1134	cortices	_
6-17	1135-1138	and	_
6-18	1139-1150	subcortical	_
6-19	1151-1158	regions	_
6-20	1159-1160	(	_
6-21	1160-1169	including	_
6-22	1170-1173	the	_
6-23	1174-1182	thalamus	_
6-24	1183-1186	and	_
6-25	1187-1195	striatum	_
6-26	1195-1196	)	_
6-27	1197-1200	and	_
6-28	1201-1204	the	_
6-29	1205-1218	inter-network	_
6-30	1219-1230	integration	_
6-31	1231-1238	between	_
6-32	1239-1242	the	_
6-33	1243-1250	default	_
6-34	1251-1255	mode	_
6-35	1256-1259	and	_
6-36	1260-1272	sensorimotor	_
6-37	1273-1281	networks	_
6-38	1281-1282	.	_

#Text=The present findings establish links between clinical response and the functional organization of brain networks involved both in perception and in spontaneous and goal-directed cognition, thereby advancing our understanding of the pathophysiology of schizophrenia.
7-1	1283-1286	The	_
7-2	1287-1294	present	_
7-3	1295-1303	findings	_
7-4	1304-1313	establish	_
7-5	1314-1319	links	_
7-6	1320-1327	between	_
7-7	1328-1336	clinical	_
7-8	1337-1345	response	_
7-9	1346-1349	and	_
7-10	1350-1353	the	_
7-11	1354-1364	functional	_
7-12	1365-1377	organization	_
7-13	1378-1380	of	_
7-14	1381-1386	brain	_
7-15	1387-1395	networks	_
7-16	1396-1404	involved	_
7-17	1405-1409	both	_
7-18	1410-1412	in	_
7-19	1413-1423	perception	_
7-20	1424-1427	and	_
7-21	1428-1430	in	_
7-22	1431-1442	spontaneous	_
7-23	1443-1446	and	_
7-24	1447-1460	goal-directed	_
7-25	1461-1470	cognition	_
7-26	1470-1471	,	_
7-27	1472-1479	thereby	_
7-28	1480-1489	advancing	_
7-29	1490-1493	our	_
7-30	1494-1507	understanding	_
7-31	1508-1510	of	_
7-32	1511-1514	the	_
7-33	1515-1530	pathophysiology	_
7-34	1531-1533	of	_
7-35	1534-1547	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-36	1547-1548	.	_

#Text=Introduction
#Text=Schizophrenia features amongst the leading causes of disability worldwide because it is associated with chronicity, psychosocial disadvantage and reduced life expectancy.
8-1	1549-1561	Introduction	_
8-2	1562-1575	Schizophrenia	_
8-3	1576-1584	features	_
8-4	1585-1592	amongst	_
8-5	1593-1596	the	_
8-6	1597-1604	leading	_
8-7	1605-1611	causes	_
8-8	1612-1614	of	_
8-9	1615-1625	disability	_
8-10	1626-1635	worldwide	_
8-11	1636-1643	because	_
8-12	1644-1646	it	_
8-13	1647-1649	is	_
8-14	1650-1660	associated	_
8-15	1661-1665	with	_
8-16	1666-1676	chronicity	_
8-17	1676-1677	,	_
8-18	1678-1690	psychosocial	_
8-19	1691-1703	disadvantage	_
8-20	1704-1707	and	_
8-21	1708-1715	reduced	_
8-22	1716-1720	life	_
8-23	1721-1731	expectancy	_
8-24	1731-1732	.	_

#Text=The five years following the first psychotic episode are considered a critical period as the long-term pattern of the disease course is typically established during this time.
9-1	1733-1736	The	_
9-2	1737-1741	five	_
9-3	1742-1747	years	_
9-4	1748-1757	following	_
9-5	1758-1761	the	_
9-6	1762-1767	first	_
9-7	1768-1777	psychotic	_
9-8	1778-1785	episode	_
9-9	1786-1789	are	_
9-10	1790-1800	considered	_
9-11	1801-1802	a	_
9-12	1803-1811	critical	_
9-13	1812-1818	period	_
9-14	1819-1821	as	_
9-15	1822-1825	the	_
9-16	1826-1835	long-term	_
9-17	1836-1843	pattern	_
9-18	1844-1846	of	_
9-19	1847-1850	the	_
9-20	1851-1858	disease	_
9-21	1859-1865	course	_
9-22	1866-1868	is	_
9-23	1869-1878	typically	_
9-24	1879-1890	established	_
9-25	1891-1897	during	_
9-26	1898-1902	this	_
9-27	1903-1907	time	_
9-28	1907-1908	.	_

#Text=Prior research on the prognostic significance of clinical and demographic features has highlighted the importance of symptomatic improvement in response to antipsychotic treatment both in clinical trials and in observational studies.
10-1	1909-1914	Prior	_
10-2	1915-1923	research	_
10-3	1924-1926	on	_
10-4	1927-1930	the	_
10-5	1931-1941	prognostic	_
10-6	1942-1954	significance	_
10-7	1955-1957	of	_
10-8	1958-1966	clinical	_
10-9	1967-1970	and	_
10-10	1971-1982	demographic	_
10-11	1983-1991	features	_
10-12	1992-1995	has	_
10-13	1996-2007	highlighted	_
10-14	2008-2011	the	_
10-15	2012-2022	importance	_
10-16	2023-2025	of	_
10-17	2026-2037	symptomatic	_
10-18	2038-2049	improvement	_
10-19	2050-2052	in	_
10-20	2053-2061	response	_
10-21	2062-2064	to	_
10-22	2065-2078	antipsychotic	_
10-23	2079-2088	treatment	_
10-24	2089-2093	both	_
10-25	2094-2096	in	_
10-26	2097-2105	clinical	_
10-27	2106-2112	trials	_
10-28	2113-2116	and	_
10-29	2117-2119	in	_
10-30	2120-2133	observational	_
10-31	2134-2141	studies	_
10-32	2141-2142	.	_

#Text=Although schizophrenia is reliably associated with alterations in brain structure and functional connectivity the relevance of brain organization for symptomatic response is poorly understood.
11-1	2143-2151	Although	_
11-2	2152-2165	schizophrenia	_
11-3	2166-2168	is	_
11-4	2169-2177	reliably	_
11-5	2178-2188	associated	_
11-6	2189-2193	with	_
11-7	2194-2205	alterations	_
11-8	2206-2208	in	_
11-9	2209-2214	brain	_
11-10	2215-2224	structure	_
11-11	2225-2228	and	_
11-12	2229-2239	functional	_
11-13	2240-2252	connectivity	_
11-14	2253-2256	the	_
11-15	2257-2266	relevance	_
11-16	2267-2269	of	_
11-17	2270-2275	brain	_
11-18	2276-2288	organization	_
11-19	2289-2292	for	_
11-20	2293-2304	symptomatic	_
11-21	2305-2313	response	_
11-22	2314-2316	is	_
11-23	2317-2323	poorly	_
11-24	2324-2334	understood	_
11-25	2334-2335	.	_

#Text=Magnetic resonance imaging (MRI) studies have produced encouraging results in terms of identifying prognostic biomarkers in other brain disorders, such as epilepsy and Alzheimer’s disease and this evidence motivates research efforts to identify brain imaging predictors of treatment response in schizophrenia.
12-1	2336-2344	Magnetic	_
12-2	2345-2354	resonance	_
12-3	2355-2362	imaging	_
12-4	2363-2364	(	_
12-5	2364-2367	MRI	_
12-6	2367-2368	)	_
12-7	2369-2376	studies	_
12-8	2377-2381	have	_
12-9	2382-2390	produced	_
12-10	2391-2402	encouraging	_
12-11	2403-2410	results	_
12-12	2411-2413	in	_
12-13	2414-2419	terms	_
12-14	2420-2422	of	_
12-15	2423-2434	identifying	_
12-16	2435-2445	prognostic	_
12-17	2446-2456	biomarkers	_
12-18	2457-2459	in	_
12-19	2460-2465	other	_
12-20	2466-2471	brain	_
12-21	2472-2481	disorders	_
12-22	2481-2482	,	_
12-23	2483-2487	such	_
12-24	2488-2490	as	_
12-25	2491-2499	epilepsy	_
12-26	2500-2503	and	_
12-27	2504-2513	Alzheimer	_
12-28	2513-2514	’	_
12-29	2514-2515	s	_
12-30	2516-2523	disease	_
12-31	2524-2527	and	_
12-32	2528-2532	this	_
12-33	2533-2541	evidence	_
12-34	2542-2551	motivates	_
12-35	2552-2560	research	_
12-36	2561-2568	efforts	_
12-37	2569-2571	to	_
12-38	2572-2580	identify	_
12-39	2581-2586	brain	_
12-40	2587-2594	imaging	_
12-41	2595-2605	predictors	_
12-42	2606-2608	of	_
12-43	2609-2618	treatment	_
12-44	2619-2627	response	_
12-45	2628-2630	in	_
12-46	2631-2644	schizophrenia	_
12-47	2644-2645	.	_

#Text=The neuroimaging literature thus far has been encouraging but inconclusive.
13-1	2646-2649	The	_
13-2	2650-2662	neuroimaging	_
13-3	2663-2673	literature	_
13-4	2674-2678	thus	_
13-5	2679-2682	far	_
13-6	2683-2686	has	_
13-7	2687-2691	been	_
13-8	2692-2703	encouraging	_
13-9	2704-2707	but	_
13-10	2708-2720	inconclusive	_
13-11	2720-2721	.	_

#Text=Despite negative results, several structural (sMRI) studies have linked poor treatment response to reductions in gyrification in global, prefrontal and temporal cortical gray matter, and in parahippocampal and striatal volumes.
14-1	2722-2729	Despite	_
14-2	2730-2738	negative	_
14-3	2739-2746	results	_
14-4	2746-2747	,	_
14-5	2748-2755	several	_
14-6	2756-2766	structural	_
14-7	2767-2768	(	_
14-8	2768-2772	sMRI	_
14-9	2772-2773	)	_
14-10	2774-2781	studies	_
14-11	2782-2786	have	_
14-12	2787-2793	linked	_
14-13	2794-2798	poor	_
14-14	2799-2808	treatment	_
14-15	2809-2817	response	_
14-16	2818-2820	to	_
14-17	2821-2831	reductions	_
14-18	2832-2834	in	_
14-19	2835-2847	gyrification	_
14-20	2848-2850	in	_
14-21	2851-2857	global	_
14-22	2857-2858	,	_
14-23	2859-2869	prefrontal	_
14-24	2870-2873	and	_
14-25	2874-2882	temporal	_
14-26	2883-2891	cortical	_
14-27	2892-2896	gray	_
14-28	2897-2903	matter	_
14-29	2903-2904	,	_
14-30	2905-2908	and	_
14-31	2909-2911	in	_
14-32	2912-2927	parahippocampal	_
14-33	2928-2931	and	_
14-34	2932-2940	striatal	_
14-35	2941-2948	volumes	_
14-36	2948-2949	.	_

#Text=The functional (fMRI) literature is silent about the role of large-scale brain networks since the few available studies have each examined the connectivity of specific regions of interest.
15-1	2950-2953	The	_
15-2	2954-2964	functional	_
15-3	2965-2966	(	_
15-4	2966-2970	fMRI	_
15-5	2970-2971	)	_
15-6	2972-2982	literature	_
15-7	2983-2985	is	_
15-8	2986-2992	silent	_
15-9	2993-2998	about	_
15-10	2999-3002	the	_
15-11	3003-3007	role	_
15-12	3008-3010	of	_
15-13	3011-3022	large-scale	_
15-14	3023-3028	brain	_
15-15	3029-3037	networks	_
15-16	3038-3043	since	_
15-17	3044-3047	the	_
15-18	3048-3051	few	_
15-19	3052-3061	available	_
15-20	3062-3069	studies	_
15-21	3070-3074	have	_
15-22	3075-3079	each	_
15-23	3080-3088	examined	_
15-24	3089-3092	the	_
15-25	3093-3105	connectivity	_
15-26	3106-3108	of	_
15-27	3109-3117	specific	_
15-28	3118-3125	regions	_
15-29	3126-3128	of	_
15-30	3129-3137	interest	_
15-31	3137-3138	.	_

#Text=Specifically, Nejad and colleagues reported that baseline frontoparietal connectivity during a working-memory task distinguished patients with persistent and non-persistent negative symptoms after 6 months of antipsychotic treatment.
16-1	3139-3151	Specifically	_
16-2	3151-3152	,	_
16-3	3153-3158	Nejad	_
16-4	3159-3162	and	_
16-5	3163-3173	colleagues	_
16-6	3174-3182	reported	_
16-7	3183-3187	that	_
16-8	3188-3196	baseline	_
16-9	3197-3211	frontoparietal	_
16-10	3212-3224	connectivity	_
16-11	3225-3231	during	_
16-12	3232-3233	a	_
16-13	3234-3248	working-memory	_
16-14	3249-3253	task	_
16-15	3254-3267	distinguished	_
16-16	3268-3276	patients	_
16-17	3277-3281	with	_
16-18	3282-3292	persistent	_
16-19	3293-3296	and	_
16-20	3297-3311	non-persistent	_
16-21	3312-3320	negative	_
16-22	3321-3329	symptoms	_
16-23	3330-3335	after	_
16-24	3336-3337	6	_
16-25	3338-3344	months	_
16-26	3345-3347	of	_
16-27	3348-3361	antipsychotic	_
16-28	3362-3371	treatment	_
16-29	3371-3372	.	_

#Text=Kraguljac and colleagues found that higher baseline hippocampal connectivity with the dorsal anterior cingulate, caudate, and auditory cortex coupled with lower connectivity with the lingual gyrus predicted response after 6 weeks of antipsychotic treatment.
17-1	3373-3382	Kraguljac	_
17-2	3383-3386	and	_
17-3	3387-3397	colleagues	_
17-4	3398-3403	found	_
17-5	3404-3408	that	_
17-6	3409-3415	higher	_
17-7	3416-3424	baseline	_
17-8	3425-3436	hippocampal	_
17-9	3437-3449	connectivity	_
17-10	3450-3454	with	_
17-11	3455-3458	the	_
17-12	3459-3465	dorsal	_
17-13	3466-3474	anterior	_
17-14	3475-3484	cingulate	_
17-15	3484-3485	,	_
17-16	3486-3493	caudate	_
17-17	3493-3494	,	_
17-18	3495-3498	and	_
17-19	3499-3507	auditory	_
17-20	3508-3514	cortex	_
17-21	3515-3522	coupled	_
17-22	3523-3527	with	_
17-23	3528-3533	lower	_
17-24	3534-3546	connectivity	_
17-25	3547-3551	with	_
17-26	3552-3555	the	_
17-27	3556-3563	lingual	_
17-28	3564-3569	gyrus	_
17-29	3570-3579	predicted	_
17-30	3580-3588	response	_
17-31	3589-3594	after	_
17-32	3595-3596	6	_
17-33	3597-3602	weeks	_
17-34	3603-3605	of	_
17-35	3606-3619	antipsychotic	_
17-36	3620-3629	treatment	_
17-37	3629-3630	.	_

#Text=Finally, Sarpal and colleagues showed that antipsychotic response at 12 weeks was associated with lower striatal connectivity with the anterior cingulate and medial prefrontal cortex and higher striatal connectivity with posterior brain regions.
18-1	3631-3638	Finally	_
18-2	3638-3639	,	_
18-3	3640-3646	Sarpal	_
18-4	3647-3650	and	_
18-5	3651-3661	colleagues	_
18-6	3662-3668	showed	_
18-7	3669-3673	that	_
18-8	3674-3687	antipsychotic	_
18-9	3688-3696	response	_
18-10	3697-3699	at	_
18-11	3700-3702	12	_
18-12	3703-3708	weeks	_
18-13	3709-3712	was	_
18-14	3713-3723	associated	_
18-15	3724-3728	with	_
18-16	3729-3734	lower	_
18-17	3735-3743	striatal	_
18-18	3744-3756	connectivity	_
18-19	3757-3761	with	_
18-20	3762-3765	the	_
18-21	3766-3774	anterior	_
18-22	3775-3784	cingulate	_
18-23	3785-3788	and	_
18-24	3789-3795	medial	_
18-25	3796-3806	prefrontal	_
18-26	3807-3813	cortex	_
18-27	3814-3817	and	_
18-28	3818-3824	higher	_
18-29	3825-3833	striatal	_
18-30	3834-3846	connectivity	_
18-31	3847-3851	with	_
18-32	3852-3861	posterior	_
18-33	3862-3867	brain	_
18-34	3868-3875	regions	_
18-35	3875-3876	.	_

#Text=There are at least four challenges to be addressed in moving the field forward.
19-1	3877-3882	There	_
19-2	3883-3886	are	_
19-3	3887-3889	at	_
19-4	3890-3895	least	_
19-5	3896-3900	four	_
19-6	3901-3911	challenges	_
19-7	3912-3914	to	_
19-8	3915-3917	be	_
19-9	3918-3927	addressed	_
19-10	3928-3930	in	_
19-11	3931-3937	moving	_
19-12	3938-3941	the	_
19-13	3942-3947	field	_
19-14	3948-3955	forward	_
19-15	3955-3956	.	_

#Text=First, previous studies divided patients into subgroups using various definitions of response derived from consensus statements (e.g., Remission in Schizophrenia Working Group).
20-1	3957-3962	First	_
20-2	3962-3963	,	_
20-3	3964-3972	previous	_
20-4	3973-3980	studies	_
20-5	3981-3988	divided	_
20-6	3989-3997	patients	_
20-7	3998-4002	into	_
20-8	4003-4012	subgroups	_
20-9	4013-4018	using	_
20-10	4019-4026	various	_
20-11	4027-4038	definitions	_
20-12	4039-4041	of	_
20-13	4042-4050	response	_
20-14	4051-4058	derived	_
20-15	4059-4063	from	_
20-16	4064-4073	consensus	_
20-17	4074-4084	statements	_
20-18	4085-4086	(	_
20-19	4086-4089	e.g	_
20-20	4089-4090	.	_
20-21	4090-4091	,	_
20-22	4092-4101	Remission	_
20-23	4102-4104	in	_
20-24	4105-4118	Schizophrenia	_
20-25	4119-4126	Working	_
20-26	4127-4132	Group	_
20-27	4132-4133	)	_
20-28	4133-4134	.	_

#Text=Here we adopt a dimensional rather than a dichotomous approach because regardless of the specific definition, these categorical subgroups do not have meaningful differences in symptom severity and do not resonate with the experience of patients and carers.
21-1	4135-4139	Here	_
21-2	4140-4142	we	_
21-3	4143-4148	adopt	_
21-4	4149-4150	a	_
21-5	4151-4162	dimensional	_
21-6	4163-4169	rather	_
21-7	4170-4174	than	_
21-8	4175-4176	a	_
21-9	4177-4188	dichotomous	_
21-10	4189-4197	approach	_
21-11	4198-4205	because	_
21-12	4206-4216	regardless	_
21-13	4217-4219	of	_
21-14	4220-4223	the	_
21-15	4224-4232	specific	_
21-16	4233-4243	definition	_
21-17	4243-4244	,	_
21-18	4245-4250	these	_
21-19	4251-4262	categorical	_
21-20	4263-4272	subgroups	_
21-21	4273-4275	do	_
21-22	4276-4279	not	_
21-23	4280-4284	have	_
21-24	4285-4295	meaningful	_
21-25	4296-4307	differences	_
21-26	4308-4310	in	_
21-27	4311-4318	symptom	_
21-28	4319-4327	severity	_
21-29	4328-4331	and	_
21-30	4332-4334	do	_
21-31	4335-4338	not	_
21-32	4339-4347	resonate	_
21-33	4348-4352	with	_
21-34	4353-4356	the	_
21-35	4357-4367	experience	_
21-36	4368-4370	of	_
21-37	4371-4379	patients	_
21-38	4380-4383	and	_
21-39	4384-4390	carers	_
21-40	4390-4391	.	_

#Text=Second, we expand previous literature by considering the entire spectrum of psychopathology in schizophrenia, which includes depressive/anxious symptoms and agitation/disorganization37 in addition to positive and negative symptoms.
22-1	4392-4398	Second	_
22-2	4398-4399	,	_
22-3	4400-4402	we	_
22-4	4403-4409	expand	_
22-5	4410-4418	previous	_
22-6	4419-4429	literature	_
22-7	4430-4432	by	_
22-8	4433-4444	considering	_
22-9	4445-4448	the	_
22-10	4449-4455	entire	_
22-11	4456-4464	spectrum	_
22-12	4465-4467	of	_
22-13	4468-4483	psychopathology	_
22-14	4484-4486	in	_
22-15	4487-4500	schizophrenia	_
22-16	4500-4501	,	_
22-17	4502-4507	which	_
22-18	4508-4516	includes	_
22-19	4517-4527	depressive	_
22-20	4527-4528	/	_
22-21	4528-4535	anxious	_
22-22	4536-4544	symptoms	_
22-23	4545-4548	and	_
22-24	4549-4558	agitation	_
22-25	4558-4559	/	_
22-26	4559-4576	disorganization37	_
22-27	4577-4579	in	_
22-28	4580-4588	addition	_
22-29	4589-4591	to	_
22-30	4592-4600	positive	_
22-31	4601-4604	and	_
22-32	4605-4613	negative	_
22-33	4614-4622	symptoms	_
22-34	4622-4623	.	_

#Text=This dimensional symptom structure is present at the first psychotic episode and is longitudinally stable (further details in supplemental information (SI)).
23-1	4624-4628	This	_
23-2	4629-4640	dimensional	_
23-3	4641-4648	symptom	_
23-4	4649-4658	structure	_
23-5	4659-4661	is	_
23-6	4662-4669	present	_
23-7	4670-4672	at	_
23-8	4673-4676	the	_
23-9	4677-4682	first	_
23-10	4683-4692	psychotic	_
23-11	4693-4700	episode	_
23-12	4701-4704	and	_
23-13	4705-4707	is	_
23-14	4708-4722	longitudinally	_
23-15	4723-4729	stable	_
23-16	4730-4731	(	_
23-17	4731-4738	further	_
23-18	4739-4746	details	_
23-19	4747-4749	in	_
23-20	4750-4762	supplemental	_
23-21	4763-4774	information	_
23-22	4775-4776	(	_
23-23	4776-4778	SI	_
23-24	4778-4779	)	_
23-25	4779-4780	)	_
23-26	4780-4781	.	_

#Text=Therefore, inclusion of all four-symptom dimensions should be integral to any attempts to relate neuroimaging measures to clinical improvement.
24-1	4782-4791	Therefore	_
24-2	4791-4792	,	_
24-3	4793-4802	inclusion	_
24-4	4803-4805	of	_
24-5	4806-4809	all	_
24-6	4810-4822	four-symptom	_
24-7	4823-4833	dimensions	_
24-8	4834-4840	should	_
24-9	4841-4843	be	_
24-10	4844-4852	integral	_
24-11	4853-4855	to	_
24-12	4856-4859	any	_
24-13	4860-4868	attempts	_
24-14	4869-4871	to	_
24-15	4872-4878	relate	_
24-16	4879-4891	neuroimaging	_
24-17	4892-4900	measures	_
24-18	4901-4903	to	_
24-19	4904-4912	clinical	_
24-20	4913-4924	improvement	_
24-21	4924-4925	.	_

#Text=Third, our analyses also consider body mass index (BMI) and IQ, that represent robust indices of cardiometabolic health and cognition, respectively, are strongly associated with brain organization and with symptom severity.
25-1	4926-4931	Third	_
25-2	4931-4932	,	_
25-3	4933-4936	our	_
25-4	4937-4945	analyses	_
25-5	4946-4950	also	_
25-6	4951-4959	consider	_
25-7	4960-4964	body	_
25-8	4965-4969	mass	_
25-9	4970-4975	index	_
25-10	4976-4977	(	_
25-11	4977-4980	BMI	_
25-12	4980-4981	)	_
25-13	4982-4985	and	_
25-14	4986-4988	IQ	_
25-15	4988-4989	,	_
25-16	4990-4994	that	_
25-17	4995-5004	represent	_
25-18	5005-5011	robust	_
25-19	5012-5019	indices	_
25-20	5020-5022	of	_
25-21	5023-5038	cardiometabolic	_
25-22	5039-5045	health	_
25-23	5046-5049	and	_
25-24	5050-5059	cognition	_
25-25	5059-5060	,	_
25-26	5061-5073	respectively	_
25-27	5073-5074	,	_
25-28	5075-5078	are	_
25-29	5079-5087	strongly	_
25-30	5088-5098	associated	_
25-31	5099-5103	with	_
25-32	5104-5109	brain	_
25-33	5110-5122	organization	_
25-34	5123-5126	and	_
25-35	5127-5131	with	_
25-36	5132-5139	symptom	_
25-37	5140-5148	severity	_
25-38	5148-5149	.	_

#Text=Inclusion of these key variables when modeling the relationship of neuroimaging features to clinical response increases confidence that the findings reflect schizophrenia–related neurobiological processes.
26-1	5150-5159	Inclusion	_
26-2	5160-5162	of	_
26-3	5163-5168	these	_
26-4	5169-5172	key	_
26-5	5173-5182	variables	_
26-6	5183-5187	when	_
26-7	5188-5196	modeling	_
26-8	5197-5200	the	_
26-9	5201-5213	relationship	_
26-10	5214-5216	of	_
26-11	5217-5229	neuroimaging	_
26-12	5230-5238	features	_
26-13	5239-5241	to	_
26-14	5242-5250	clinical	_
26-15	5251-5259	response	_
26-16	5260-5269	increases	_
26-17	5270-5280	confidence	_
26-18	5281-5285	that	_
26-19	5286-5289	the	_
26-20	5290-5298	findings	_
26-21	5299-5306	reflect	_
26-22	5307-5328	schizophrenia–related	_
26-23	5329-5344	neurobiological	_
26-24	5345-5354	processes	_
26-25	5354-5355	.	_

#Text=Fourth, we extend the scope of enquiry beyond testing regionally specific hypotheses is critical for the detection of functional connectivity predictors of clinical response that are not a priori predicted.
27-1	5356-5362	Fourth	_
27-2	5362-5363	,	_
27-3	5364-5366	we	_
27-4	5367-5373	extend	_
27-5	5374-5377	the	_
27-6	5378-5383	scope	_
27-7	5384-5386	of	_
27-8	5387-5394	enquiry	_
27-9	5395-5401	beyond	_
27-10	5402-5409	testing	_
27-11	5410-5420	regionally	_
27-12	5421-5429	specific	_
27-13	5430-5440	hypotheses	_
27-14	5441-5443	is	_
27-15	5444-5452	critical	_
27-16	5453-5456	for	_
27-17	5457-5460	the	_
27-18	5461-5470	detection	_
27-19	5471-5473	of	_
27-20	5474-5484	functional	_
27-21	5485-5497	connectivity	_
27-22	5498-5508	predictors	_
27-23	5509-5511	of	_
27-24	5512-5520	clinical	_
27-25	5521-5529	response	_
27-26	5530-5534	that	_
27-27	5535-5538	are	_
27-28	5539-5542	not	_
27-29	5543-5544	a	_
27-30	5545-5551	priori	_
27-31	5552-5561	predicted	_
27-32	5561-5562	.	_

#Text=Here, we acquired sMRI and resting-state functional (rs-fMRI) neuroimaging data from patients at the early stages of schizophrenia prior to initiation of antipsychotic treatment.
28-1	5563-5567	Here	_
28-2	5567-5568	,	_
28-3	5569-5571	we	_
28-4	5572-5580	acquired	_
28-5	5581-5585	sMRI	_
28-6	5586-5589	and	_
28-7	5590-5603	resting-state	_
28-8	5604-5614	functional	_
28-9	5615-5616	(	_
28-10	5616-5623	rs-fMRI	_
28-11	5623-5624	)	_
28-12	5625-5637	neuroimaging	_
28-13	5638-5642	data	_
28-14	5643-5647	from	_
28-15	5648-5656	patients	_
28-16	5657-5659	at	_
28-17	5660-5663	the	_
28-18	5664-5669	early	_
28-19	5670-5676	stages	_
28-20	5677-5679	of	_
28-21	5680-5693	schizophrenia	_
28-22	5694-5699	prior	_
28-23	5700-5702	to	_
28-24	5703-5713	initiation	_
28-25	5714-5716	of	_
28-26	5717-5730	antipsychotic	_
28-27	5731-5740	treatment	_
28-28	5740-5741	.	_

#Text=Clinical response was assessed in terms of change in positive, negative, anxious/depressive and agitation/disorganization symptoms 24 weeks later.
29-1	5742-5750	Clinical	_
29-2	5751-5759	response	_
29-3	5760-5763	was	_
29-4	5764-5772	assessed	_
29-5	5773-5775	in	_
29-6	5776-5781	terms	_
29-7	5782-5784	of	_
29-8	5785-5791	change	_
29-9	5792-5794	in	_
29-10	5795-5803	positive	_
29-11	5803-5804	,	_
29-12	5805-5813	negative	_
29-13	5813-5814	,	_
29-14	5815-5822	anxious	_
29-15	5822-5823	/	_
29-16	5823-5833	depressive	_
29-17	5834-5837	and	_
29-18	5838-5847	agitation	_
29-19	5847-5848	/	_
29-20	5848-5863	disorganization	_
29-21	5864-5872	symptoms	_
29-22	5873-5875	24	_
29-23	5876-5881	weeks	_
29-24	5882-5887	later	_
29-25	5887-5888	.	_

#Text=IQ and BMI were also assessed as part of the clinical dataset.
30-1	5889-5891	IQ	_
30-2	5892-5895	and	_
30-3	5896-5899	BMI	_
30-4	5900-5904	were	_
30-5	5905-5909	also	_
30-6	5910-5918	assessed	_
30-7	5919-5921	as	_
30-8	5922-5926	part	_
30-9	5927-5929	of	_
30-10	5930-5933	the	_
30-11	5934-5942	clinical	_
30-12	5943-5950	dataset	_
30-13	5950-5951	.	_

#Text=We used sparse Canonical Correlation Analyses (sCCA) to investigate the underlying relationship between the neuroimaging and clinical datasets as this multivariate method is ideally suited for predicting one dataset from the other while accounting for correlations between variables.
31-1	5952-5954	We	_
31-2	5955-5959	used	_
31-3	5960-5966	sparse	_
31-4	5967-5976	Canonical	_
31-5	5977-5988	Correlation	_
31-6	5989-5997	Analyses	_
31-7	5998-5999	(	_
31-8	5999-6003	sCCA	_
31-9	6003-6004	)	_
31-10	6005-6007	to	_
31-11	6008-6019	investigate	_
31-12	6020-6023	the	_
31-13	6024-6034	underlying	_
31-14	6035-6047	relationship	_
31-15	6048-6055	between	_
31-16	6056-6059	the	_
31-17	6060-6072	neuroimaging	_
31-18	6073-6076	and	_
31-19	6077-6085	clinical	_
31-20	6086-6094	datasets	_
31-21	6095-6097	as	_
31-22	6098-6102	this	_
31-23	6103-6115	multivariate	_
31-24	6116-6122	method	_
31-25	6123-6125	is	_
31-26	6126-6133	ideally	_
31-27	6134-6140	suited	_
31-28	6141-6144	for	_
31-29	6145-6155	predicting	_
31-30	6156-6159	one	_
31-31	6160-6167	dataset	_
31-32	6168-6172	from	_
31-33	6173-6176	the	_
31-34	6177-6182	other	_
31-35	6183-6188	while	_
31-36	6189-6199	accounting	_
31-37	6200-6203	for	_
31-38	6204-6216	correlations	_
31-39	6217-6224	between	_
31-40	6225-6234	variables	_
31-41	6234-6235	.	_

#Text=Our aim of this data-driven approach was to identify previously undetected associations between whole-brain structural and functional neuroimaging features and clinical response following treatment.
32-1	6236-6239	Our	_
32-2	6240-6243	aim	_
32-3	6244-6246	of	_
32-4	6247-6251	this	_
32-5	6252-6263	data-driven	_
32-6	6264-6272	approach	_
32-7	6273-6276	was	_
32-8	6277-6279	to	_
32-9	6280-6288	identify	_
32-10	6289-6299	previously	_
32-11	6300-6310	undetected	_
32-12	6311-6323	associations	_
32-13	6324-6331	between	_
32-14	6332-6343	whole-brain	_
32-15	6344-6354	structural	_
32-16	6355-6358	and	_
32-17	6359-6369	functional	_
32-18	6370-6382	neuroimaging	_
32-19	6383-6391	features	_
32-20	6392-6395	and	_
32-21	6396-6404	clinical	_
32-22	6405-6413	response	_
32-23	6414-6423	following	_
32-24	6424-6433	treatment	_
32-25	6433-6434	.	_

#Text=When considering preexisting evidence our working hypotheses were that measures of cortical thickness and of functional integration between cortical and subcortical regions would emerge as the most significant predictors of symptomatic change.
33-1	6435-6439	When	_
33-2	6440-6451	considering	_
33-3	6452-6463	preexisting	_
33-4	6464-6472	evidence	_
33-5	6473-6476	our	_
33-6	6477-6484	working	_
33-7	6485-6495	hypotheses	_
33-8	6496-6500	were	_
33-9	6501-6505	that	_
33-10	6506-6514	measures	_
33-11	6515-6517	of	_
33-12	6518-6526	cortical	_
33-13	6527-6536	thickness	_
33-14	6537-6540	and	_
33-15	6541-6543	of	_
33-16	6544-6554	functional	_
33-17	6555-6566	integration	_
33-18	6567-6574	between	_
33-19	6575-6583	cortical	_
33-20	6584-6587	and	_
33-21	6588-6599	subcortical	_
33-22	6600-6607	regions	_
33-23	6608-6613	would	_
33-24	6614-6620	emerge	_
33-25	6621-6623	as	_
33-26	6624-6627	the	_
33-27	6628-6632	most	_
33-28	6633-6644	significant	_
33-29	6645-6655	predictors	_
33-30	6656-6658	of	_
33-31	6659-6670	symptomatic	_
33-32	6671-6677	change	_
33-33	6677-6678	.	_

#Text=Materials and Method
#Text=Study Design
#Text=Patients within the first 5 years of being diagnosed with schizophrenia based on the criteria of the Diagnostic and Statistical Manual of Mental disorders, Fifth Edition (DSM-5) were recruited via clinician referrals from the psychiatric services of the Mount Sinai Health System at the Icahn School of Medicine at Mount Sinai (ISMMS), New York.
34-1	6679-6688	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[1]
34-2	6689-6692	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[1]
34-3	6693-6699	Method	http://www.case.edu/ProvCaRe/provcare#StudyMethod[1]
34-4	6700-6705	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-5	6706-6712	Design	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-6	6713-6721	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-7	6722-6728	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-8	6729-6732	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-9	6733-6738	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-10	6739-6740	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-11	6741-6746	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-12	6747-6749	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-13	6750-6755	being	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-14	6756-6765	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-15	6766-6770	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-16	6771-6784	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]
34-17	6785-6790	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-18	6791-6793	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-19	6794-6797	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-20	6798-6806	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-21	6807-6809	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-22	6810-6813	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]
34-23	6814-6824	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-24	6825-6828	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-25	6829-6840	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-26	6841-6847	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-27	6848-6850	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-28	6851-6857	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-29	6858-6867	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-30	6867-6868	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-31	6869-6874	Fifth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-32	6875-6882	Edition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-33	6883-6884	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-34	6884-6887	DSM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-35	6887-6888	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-36	6888-6889	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-37	6889-6890	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-38	6891-6895	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-39	6896-6905	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-40	6906-6909	via	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-41	6910-6919	clinician	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-42	6920-6929	referrals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-43	6930-6934	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-44	6935-6938	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-45	6939-6950	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-46	6951-6959	services	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-47	6960-6962	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]
34-48	6963-6966	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-49	6967-6972	Mount	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-50	6973-6978	Sinai	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-51	6979-6985	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-52	6986-6992	System	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-53	6993-6995	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-54	6996-6999	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-55	7000-7005	Icahn	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-56	7006-7012	School	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-57	7013-7015	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-58	7016-7024	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-59	7025-7027	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-60	7028-7033	Mount	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-61	7034-7039	Sinai	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-62	7040-7041	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-63	7041-7046	ISMMS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-64	7046-7047	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-65	7047-7048	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-66	7049-7052	New	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-67	7053-7057	York	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]
34-68	7057-7058	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]

#Text=Clinicians were asked to refer patients who were willing to re-start antipsychotic treatment following a minimum 2-week medication free period based on patients’ self-report.
35-1	7059-7069	Clinicians	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-2	7070-7074	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-3	7075-7080	asked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-4	7081-7083	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-5	7084-7089	refer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-6	7090-7098	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-7	7099-7102	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-8	7103-7107	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-9	7108-7115	willing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-10	7116-7118	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-11	7119-7127	re-start	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-12	7128-7141	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-13	7142-7151	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-14	7152-7161	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-15	7162-7163	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-16	7164-7171	minimum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-17	7172-7173	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-18	7173-7174	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-19	7174-7178	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-20	7179-7189	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-21	7190-7194	free	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-22	7195-7201	period	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-23	7202-7207	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-24	7208-7210	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-25	7211-7219	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-26	7219-7220	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-27	7221-7232	self-report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]
35-28	7232-7233	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]

#Text=Patients were screened to exclude individuals with IQ<70 and those with treatment refractory illness, history of head trauma or loss of consciousness, pervasive developmental disorder, lifetime history of DSM-5 substance use disorder, medical or neurological disorders that could cause psychiatric symptoms and contraindications to MRI.
36-1	7234-7242	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-2	7243-7247	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-3	7248-7256	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-4	7257-7259	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-5	7260-7267	exclude	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-6	7268-7279	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-7	7280-7284	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-8	7285-7287	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-9	7287-7288	<	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-10	7288-7290	70	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-11	7291-7294	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-12	7295-7300	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-13	7301-7305	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-14	7306-7315	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-15	7316-7326	refractory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-16	7327-7334	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-17	7334-7335	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-18	7336-7343	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-19	7344-7346	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-20	7347-7351	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-21	7352-7358	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-22	7359-7361	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-23	7362-7366	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-24	7367-7369	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
36-25	7370-7383	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-26	7383-7384	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-27	7385-7394	pervasive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-28	7395-7408	developmental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-29	7409-7417	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-30	7417-7418	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-31	7419-7427	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-32	7428-7435	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-33	7436-7438	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-34	7439-7442	DSM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-35	7442-7443	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-36	7443-7444	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-37	7445-7454	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-38	7455-7458	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-39	7459-7467	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-40	7467-7468	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-41	7469-7476	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-42	7477-7479	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-43	7480-7492	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-44	7493-7502	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-45	7503-7507	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-46	7508-7513	could	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]
36-47	7514-7519	cause	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
36-48	7520-7531	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
36-49	7532-7540	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
36-50	7541-7544	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
36-51	7545-7562	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
36-52	7563-7565	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
36-53	7566-7569	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[10]
36-54	7569-7570	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]

#Text=Eligible patients were enrolled prior to restarting antipsychotic treatment.
37-1	7571-7579	Eligible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-2	7580-7588	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-3	7589-7593	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-4	7594-7602	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-5	7603-7608	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-6	7609-7611	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-7	7612-7622	restarting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-8	7623-7636	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-9	7637-7646	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
37-10	7646-7647	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]

#Text=Brain MRI scans were acquired as soon as patients could tolerate this examination to ensure minimal exposure to antipsychotic medications.
38-1	7648-7653	Brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[13]
38-2	7654-7657	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[13]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[14]
38-3	7658-7663	scans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[13]
38-4	7664-7668	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-5	7669-7677	acquired	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-6	7678-7680	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-7	7681-7685	soon	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-8	7686-7688	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-9	7689-7697	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-10	7698-7703	could	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-11	7704-7712	tolerate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-12	7713-7717	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-13	7718-7729	examination	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-14	7730-7732	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-15	7733-7739	ensure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-16	7740-7747	minimal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-17	7748-7756	exposure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-18	7757-7759	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-19	7760-7773	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-20	7774-7785	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
38-21	7785-7786	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]

#Text=Patients were evaluated clinically on the day of scanning and then 24 weeks later.
39-1	7787-7795	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-2	7796-7800	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-3	7801-7810	evaluated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-4	7811-7821	clinically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-5	7822-7824	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-6	7825-7828	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-7	7829-7832	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-8	7833-7835	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-9	7836-7844	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-10	7845-7848	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-11	7849-7853	then	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-12	7854-7856	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-13	7857-7862	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-14	7863-7868	later	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-15	7868-7869	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]

#Text=The study was approved by the institutional review board of the ISMMS; all participants provided written informed consent prior to study enrolment.
40-1	7870-7873	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-2	7874-7879	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-3	7880-7883	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-4	7884-7892	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-5	7893-7895	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-6	7896-7899	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-7	7900-7913	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-8	7914-7920	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-9	7921-7926	board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-10	7927-7929	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-11	7930-7933	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-12	7934-7939	ISMMS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-13	7939-7940	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-14	7941-7944	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-15	7945-7957	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-16	7958-7966	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-17	7967-7974	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-18	7975-7983	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-19	7984-7991	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-20	7992-7997	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-21	7998-8000	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-22	8001-8006	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-23	8007-8016	enrolment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
40-24	8016-8017	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]

#Text=Clinical Assessment
#Text=Enrollment only: The patients’ diagnostic status was confirmed with the Structured Clinical Interview for DSM-5.
41-1	8018-8026	Clinical	_
41-2	8027-8037	Assessment	_
41-3	8038-8048	Enrollment	_
41-4	8049-8053	only	_
41-5	8053-8054	:	_
41-6	8055-8058	The	_
41-7	8059-8067	patients	_
41-8	8067-8068	’	_
41-9	8069-8079	diagnostic	_
41-10	8080-8086	status	_
41-11	8087-8090	was	_
41-12	8091-8100	confirmed	_
41-13	8101-8105	with	_
41-14	8106-8109	the	_
41-15	8110-8120	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder-5[16]
41-16	8121-8129	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder-5[16]
41-17	8130-8139	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder-5[16]
41-18	8140-8143	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder-5[16]
41-19	8144-8147	DSM	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder-5[16]
41-20	8147-8148	-	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder-5[16]
41-21	8148-8149	5	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder-5[16]
41-22	8149-8150	.	_

#Text=Current IQ was obtained with the Wechsler Abbreviated Scale of Intelligence (WASI-II).
42-1	8151-8158	Current	_
42-2	8159-8161	IQ	_
42-3	8162-8165	was	_
42-4	8166-8174	obtained	_
42-5	8175-8179	with	_
42-6	8180-8183	the	_
42-7	8184-8192	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]
42-8	8193-8204	Abbreviated	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]
42-9	8205-8210	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]
42-10	8211-8213	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]
42-11	8214-8226	Intelligence	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]
42-12	8227-8228	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]
42-13	8228-8235	WASI-II	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]
42-14	8235-8236	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[17]
42-15	8236-8237	.	_

#Text=IQ was used as an index of overall cognitive ability because it correlates with domain-specific cognitive tests and accounts for most of the variability in cognitive function.
43-1	8238-8240	IQ	_
43-2	8241-8244	was	_
43-3	8245-8249	used	_
43-4	8250-8252	as	_
43-5	8253-8255	an	_
43-6	8256-8261	index	_
43-7	8262-8264	of	_
43-8	8265-8272	overall	_
43-9	8273-8282	cognitive	_
43-10	8283-8290	ability	_
43-11	8291-8298	because	_
43-12	8299-8301	it	_
43-13	8302-8312	correlates	_
43-14	8313-8317	with	_
43-15	8318-8333	domain-specific	_
43-16	8334-8343	cognitive	_
43-17	8344-8349	tests	_
43-18	8350-8353	and	_
43-19	8354-8362	accounts	_
43-20	8363-8366	for	_
43-21	8367-8371	most	_
43-22	8372-8374	of	_
43-23	8375-8378	the	_
43-24	8379-8390	variability	_
43-25	8391-8393	in	_
43-26	8394-8403	cognitive	_
43-27	8404-8412	function	_
43-28	8412-8413	.	_

#Text=In the context of schizophrenia, IQ is also associated with variability in the clinical profile and brain structure of patients.
44-1	8414-8416	In	_
44-2	8417-8420	the	_
44-3	8421-8428	context	_
44-4	8429-8431	of	_
44-5	8432-8445	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
44-6	8445-8446	,	_
44-7	8447-8449	IQ	_
44-8	8450-8452	is	_
44-9	8453-8457	also	_
44-10	8458-8468	associated	_
44-11	8469-8473	with	_
44-12	8474-8485	variability	_
44-13	8486-8488	in	_
44-14	8489-8492	the	_
44-15	8493-8501	clinical	_
44-16	8502-8509	profile	_
44-17	8510-8513	and	_
44-18	8514-8519	brain	_
44-19	8520-8529	structure	_
44-20	8530-8532	of	_
44-21	8533-8541	patients	_
44-22	8541-8542	.	_

#Text=Day of scanning and at 24-week follow-up: Psychopathology was assessed using the 24-item Brief Psychiatric Rating Scale (BPRS) because it can reliably assess positive and negative symptoms, agitation/disorganization and anxiety/depression (Supplementary Table 1).
45-1	8543-8546	Day	_
45-2	8547-8549	of	_
45-3	8550-8558	scanning	_
45-4	8559-8562	and	_
45-5	8563-8565	at	_
45-6	8566-8568	24	_
45-7	8568-8569	-	_
45-8	8569-8573	week	_
45-9	8574-8583	follow-up	_
45-10	8583-8584	:	_
45-11	8585-8600	Psychopathology	_
45-12	8601-8604	was	_
45-13	8605-8613	assessed	_
45-14	8614-8619	using	_
45-15	8620-8623	the	_
45-16	8624-8626	24	_
45-17	8626-8627	-	_
45-18	8627-8631	item	_
45-19	8632-8637	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[18]
45-20	8638-8649	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[18]
45-21	8650-8656	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[18]
45-22	8657-8662	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[18]
45-23	8663-8664	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[18]
45-24	8664-8668	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[18]
45-25	8668-8669	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[18]
45-26	8670-8677	because	_
45-27	8678-8680	it	_
45-28	8681-8684	can	_
45-29	8685-8693	reliably	_
45-30	8694-8700	assess	_
45-31	8701-8709	positive	_
45-32	8710-8713	and	_
45-33	8714-8722	negative	_
45-34	8723-8731	symptoms	_
45-35	8731-8732	,	_
45-36	8733-8742	agitation	_
45-37	8742-8743	/	_
45-38	8743-8758	disorganization	_
45-39	8759-8762	and	_
45-40	8763-8770	anxiety	_
45-41	8770-8771	/	_
45-42	8771-8781	depression	_
45-43	8782-8783	(	_
45-44	8783-8796	Supplementary	_
45-45	8797-8802	Table	_
45-46	8803-8804	1	_
45-47	8804-8805	)	_
45-48	8805-8806	.	_

#Text=Medication type and dose were recorded in all patients and supplemented with information from their medical records.
46-1	8807-8817	Medication	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[19]
46-2	8818-8822	type	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[19]
46-3	8823-8826	and	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[19]
46-4	8827-8831	dose	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[19]
46-5	8832-8836	were	_
46-6	8837-8845	recorded	_
46-7	8846-8848	in	_
46-8	8849-8852	all	_
46-9	8853-8861	patients	_
46-10	8862-8865	and	_
46-11	8866-8878	supplemented	_
46-12	8879-8883	with	_
46-13	8884-8895	information	_
46-14	8896-8900	from	_
46-15	8901-8906	their	_
46-16	8907-8914	medical	_
46-17	8915-8922	records	_
46-18	8922-8923	.	_

#Text=The daily antipsychotic dose was converted to chlorpromazine equivalents (CPZE).
47-1	8924-8927	The	_
47-2	8928-8933	daily	_
47-3	8934-8947	antipsychotic	_
47-4	8948-8952	dose	_
47-5	8953-8956	was	_
47-6	8957-8966	converted	_
47-7	8967-8969	to	_
47-8	8970-8984	chlorpromazine	_
47-9	8985-8996	equivalents	_
47-10	8997-8998	(	_
47-11	8998-9002	CPZE	_
47-12	9002-9003	)	_
47-13	9003-9004	.	_

#Text=The BMI was included as a general measure of cardiometabolic health with known associations with symptom severity and brain structure in patients with psychosis.
48-1	9005-9008	The	_
48-2	9009-9012	BMI	_
48-3	9013-9016	was	_
48-4	9017-9025	included	_
48-5	9026-9028	as	_
48-6	9029-9030	a	_
48-7	9031-9038	general	_
48-8	9039-9046	measure	_
48-9	9047-9049	of	_
48-10	9050-9065	cardiometabolic	_
48-11	9066-9072	health	_
48-12	9073-9077	with	_
48-13	9078-9083	known	_
48-14	9084-9096	associations	_
48-15	9097-9101	with	_
48-16	9102-9109	symptom	_
48-17	9110-9118	severity	_
48-18	9119-9122	and	_
48-19	9123-9128	brain	_
48-20	9129-9138	structure	_
48-21	9139-9141	in	_
48-22	9142-9150	patients	_
48-23	9151-9155	with	_
48-24	9156-9165	psychosis	_
48-25	9165-9166	.	_

#Text=Treatment and Evaluation of Clinical Outcome
#Text=The choice and dosing of the antipsychotic agent was based on the judgment of the patients’ treating psychiatrists since differences in the effectiveness of individual antipsychotics are small and appropriate treatment decisions crucially depend on patients’ history, preference and circumstances.
49-1	9167-9176	Treatment	_
49-2	9177-9180	and	_
49-3	9181-9191	Evaluation	_
49-4	9192-9194	of	_
49-5	9195-9203	Clinical	_
49-6	9204-9211	Outcome	_
49-7	9212-9215	The	_
49-8	9216-9222	choice	_
49-9	9223-9226	and	_
49-10	9227-9233	dosing	_
49-11	9234-9236	of	_
49-12	9237-9240	the	_
49-13	9241-9254	antipsychotic	_
49-14	9255-9260	agent	_
49-15	9261-9264	was	_
49-16	9265-9270	based	_
49-17	9271-9273	on	_
49-18	9274-9277	the	_
49-19	9278-9286	judgment	_
49-20	9287-9289	of	_
49-21	9290-9293	the	_
49-22	9294-9302	patients	_
49-23	9302-9303	’	_
49-24	9304-9312	treating	_
49-25	9313-9326	psychiatrists	_
49-26	9327-9332	since	_
49-27	9333-9344	differences	_
49-28	9345-9347	in	_
49-29	9348-9351	the	_
49-30	9352-9365	effectiveness	_
49-31	9366-9368	of	_
49-32	9369-9379	individual	_
49-33	9380-9394	antipsychotics	_
49-34	9395-9398	are	_
49-35	9399-9404	small	_
49-36	9405-9408	and	_
49-37	9409-9420	appropriate	_
49-38	9421-9430	treatment	_
49-39	9431-9440	decisions	_
49-40	9441-9450	crucially	_
49-41	9451-9457	depend	_
49-42	9458-9460	on	_
49-43	9461-9469	patients	_
49-44	9469-9470	’	_
49-45	9471-9478	history	_
49-46	9478-9479	,	_
49-47	9480-9490	preference	_
49-48	9491-9494	and	_
49-49	9495-9508	circumstances	_
49-50	9508-9509	.	_

#Text=During the inter-assessment interval, patients received routine clinical care which consisted of outpatient appointments with their treating psychiatrist.
50-1	9510-9516	During	_
50-2	9517-9520	the	_
50-3	9521-9537	inter-assessment	_
50-4	9538-9546	interval	_
50-5	9546-9547	,	_
50-6	9548-9556	patients	_
50-7	9557-9565	received	_
50-8	9566-9573	routine	_
50-9	9574-9582	clinical	_
50-10	9583-9587	care	_
50-11	9588-9593	which	_
50-12	9594-9603	consisted	_
50-13	9604-9606	of	_
50-14	9607-9617	outpatient	_
50-15	9618-9630	appointments	_
50-16	9631-9635	with	_
50-17	9636-9641	their	_
50-18	9642-9650	treating	_
50-19	9651-9663	psychiatrist	_
50-20	9663-9664	.	_

#Text=These appointments involved informal supportive therapy and monitoring of mental state, adverse events and adherence.
51-1	9665-9670	These	_
51-2	9671-9683	appointments	_
51-3	9684-9692	involved	_
51-4	9693-9701	informal	_
51-5	9702-9712	supportive	_
51-6	9713-9720	therapy	_
51-7	9721-9724	and	_
51-8	9725-9735	monitoring	_
51-9	9736-9738	of	_
51-10	9739-9745	mental	_
51-11	9746-9751	state	_
51-12	9751-9752	,	_
51-13	9753-9760	adverse	_
51-14	9761-9767	events	_
51-15	9768-9771	and	_
51-16	9772-9781	adherence	_
51-17	9781-9782	.	_

#Text=Patients were seen weekly for the first three weeks post-treatment initiation.
52-1	9783-9791	Patients	_
52-2	9792-9796	were	_
52-3	9797-9801	seen	_
52-4	9802-9808	weekly	_
52-5	9809-9812	for	_
52-6	9813-9816	the	_
52-7	9817-9822	first	_
52-8	9823-9828	three	_
52-9	9829-9834	weeks	_
52-10	9835-9849	post-treatment	_
52-11	9850-9860	initiation	_
52-12	9860-9861	.	_

#Text=Thereafter, planned appointments occurred depending on individual patient’s needs and preferences.
53-1	9862-9872	Thereafter	_
53-2	9872-9873	,	_
53-3	9874-9881	planned	_
53-4	9882-9894	appointments	_
53-5	9895-9903	occurred	_
53-6	9904-9913	depending	_
53-7	9914-9916	on	_
53-8	9917-9927	individual	_
53-9	9928-9935	patient	_
53-10	9935-9936	’	_
53-11	9936-9937	s	_
53-12	9938-9943	needs	_
53-13	9944-9947	and	_
53-14	9948-9959	preferences	_
53-15	9959-9960	.	_

#Text=Adherence was monitored via self-report during appointments and though the Mount Sinai electronic prescription records (also in SI).
54-1	9961-9970	Adherence	_
54-2	9971-9974	was	_
54-3	9975-9984	monitored	_
54-4	9985-9988	via	_
54-5	9989-10000	self-report	_
54-6	10001-10007	during	_
54-7	10008-10020	appointments	_
54-8	10021-10024	and	_
54-9	10025-10031	though	_
54-10	10032-10035	the	_
54-11	10036-10041	Mount	_
54-12	10042-10047	Sinai	_
54-13	10048-10058	electronic	_
54-14	10059-10071	prescription	_
54-15	10072-10079	records	_
54-16	10080-10081	(	_
54-17	10081-10085	also	_
54-18	10086-10088	in	_
54-19	10089-10091	SI	_
54-20	10091-10092	)	_
54-21	10092-10093	.	_

#Text=None received psychological or electroconvulsive therapy.
55-1	10094-10098	None	_
55-2	10099-10107	received	_
55-3	10108-10121	psychological	_
55-4	10122-10124	or	_
55-5	10125-10142	electroconvulsive	_
55-6	10143-10150	therapy	_
55-7	10150-10151	.	_

#Text=Additional support was provided by social workers in connection to disability benefits and accommodation.
56-1	10152-10162	Additional	_
56-2	10163-10170	support	_
56-3	10171-10174	was	_
56-4	10175-10183	provided	_
56-5	10184-10186	by	_
56-6	10187-10193	social	_
56-7	10194-10201	workers	_
56-8	10202-10204	in	_
56-9	10205-10215	connection	_
56-10	10216-10218	to	_
56-11	10219-10229	disability	_
56-12	10230-10238	benefits	_
56-13	10239-10242	and	_
56-14	10243-10256	accommodation	_
56-15	10256-10257	.	_

#Text=The primary outcome was the change in the BPRS subscale scores for positive, negative, anxious/depressive and agitation/disorganization symptoms between initial (T1) and 24-week follow-up assessment (T2) calculated as ; positive and negative values respectively represent symptomatic improvement or worsening.
57-1	10258-10261	The	_
57-2	10262-10269	primary	_
57-3	10270-10277	outcome	_
57-4	10278-10281	was	_
57-5	10282-10285	the	_
57-6	10286-10292	change	_
57-7	10293-10295	in	_
57-8	10296-10299	the	_
57-9	10300-10304	BPRS	_
57-10	10305-10313	subscale	_
57-11	10314-10320	scores	_
57-12	10321-10324	for	_
57-13	10325-10333	positive	_
57-14	10333-10334	,	_
57-15	10335-10343	negative	_
57-16	10343-10344	,	_
57-17	10345-10352	anxious	_
57-18	10352-10353	/	_
57-19	10353-10363	depressive	_
57-20	10364-10367	and	_
57-21	10368-10377	agitation	_
57-22	10377-10378	/	_
57-23	10378-10393	disorganization	_
57-24	10394-10402	symptoms	_
57-25	10403-10410	between	_
57-26	10411-10418	initial	_
57-27	10419-10420	(	_
57-28	10420-10422	T1	_
57-29	10422-10423	)	_
57-30	10424-10427	and	_
57-31	10428-10430	24	_
57-32	10430-10431	-	_
57-33	10431-10435	week	_
57-34	10436-10445	follow-up	_
57-35	10446-10456	assessment	_
57-36	10457-10458	(	_
57-37	10458-10460	T2	_
57-38	10460-10461	)	_
57-39	10462-10472	calculated	_
57-40	10473-10475	as	_
57-41	10476-10477	;	_
57-42	10478-10486	positive	_
57-43	10487-10490	and	_
57-44	10491-10499	negative	_
57-45	10500-10506	values	_
57-46	10507-10519	respectively	_
57-47	10520-10529	represent	_
57-48	10530-10541	symptomatic	_
57-49	10542-10553	improvement	_
57-50	10554-10556	or	_
57-51	10557-10566	worsening	_
57-52	10566-10567	.	_

#Text=We adopted a dimensional approach to symptomatic change rather than dichotomous remission/non-remission categorizations for the following reasons: (i) although there are several criteria for remission there is still no consensus on the cut-offs that define remission in schizophrenia; (ii) it is questionable whether clinically defined remitted and non-remitted patients (regardless of the criteria applied) represent biologically distinct groups; (iii) although there is some evidence that treatment resistant patients may have a distinct neurobiological profile such patients were excluded here by design.
58-1	10568-10570	We	_
58-2	10571-10578	adopted	_
58-3	10579-10580	a	_
58-4	10581-10592	dimensional	_
58-5	10593-10601	approach	_
58-6	10602-10604	to	_
58-7	10605-10616	symptomatic	_
58-8	10617-10623	change	_
58-9	10624-10630	rather	_
58-10	10631-10635	than	_
58-11	10636-10647	dichotomous	_
58-12	10648-10657	remission	_
58-13	10657-10658	/	_
58-14	10658-10671	non-remission	_
58-15	10672-10687	categorizations	_
58-16	10688-10691	for	_
58-17	10692-10695	the	_
58-18	10696-10705	following	_
58-19	10706-10713	reasons	_
58-20	10713-10714	:	_
58-21	10715-10716	(	_
58-22	10716-10717	i	_
58-23	10717-10718	)	_
58-24	10719-10727	although	_
58-25	10728-10733	there	_
58-26	10734-10737	are	_
58-27	10738-10745	several	_
58-28	10746-10754	criteria	_
58-29	10755-10758	for	_
58-30	10759-10768	remission	_
58-31	10769-10774	there	_
58-32	10775-10777	is	_
58-33	10778-10783	still	_
58-34	10784-10786	no	_
58-35	10787-10796	consensus	_
58-36	10797-10799	on	_
58-37	10800-10803	the	_
58-38	10804-10812	cut-offs	_
58-39	10813-10817	that	_
58-40	10818-10824	define	_
58-41	10825-10834	remission	_
58-42	10835-10837	in	_
58-43	10838-10851	schizophrenia	_
58-44	10851-10852	;	_
58-45	10853-10854	(	_
58-46	10854-10856	ii	_
58-47	10856-10857	)	_
58-48	10858-10860	it	_
58-49	10861-10863	is	_
58-50	10864-10876	questionable	_
58-51	10877-10884	whether	_
58-52	10885-10895	clinically	_
58-53	10896-10903	defined	_
58-54	10904-10912	remitted	_
58-55	10913-10916	and	_
58-56	10917-10929	non-remitted	_
58-57	10930-10938	patients	_
58-58	10939-10940	(	_
58-59	10940-10950	regardless	_
58-60	10951-10953	of	_
58-61	10954-10957	the	_
58-62	10958-10966	criteria	_
58-63	10967-10974	applied	_
58-64	10974-10975	)	_
58-65	10976-10985	represent	_
58-66	10986-10998	biologically	_
58-67	10999-11007	distinct	_
58-68	11008-11014	groups	_
58-69	11014-11015	;	_
58-70	11016-11017	(	_
58-71	11017-11020	iii	_
58-72	11020-11021	)	_
58-73	11022-11030	although	_
58-74	11031-11036	there	_
58-75	11037-11039	is	_
58-76	11040-11044	some	_
58-77	11045-11053	evidence	_
58-78	11054-11058	that	_
58-79	11059-11068	treatment	_
58-80	11069-11078	resistant	_
58-81	11079-11087	patients	_
58-82	11088-11091	may	_
58-83	11092-11096	have	_
58-84	11097-11098	a	_
58-85	11099-11107	distinct	_
58-86	11108-11123	neurobiological	_
58-87	11124-11131	profile	_
58-88	11132-11136	such	_
58-89	11137-11145	patients	_
58-90	11146-11150	were	_
58-91	11151-11159	excluded	_
58-92	11160-11164	here	_
58-93	11165-11167	by	_
58-94	11168-11174	design	_
58-95	11174-11175	.	_

#Text=In support of these statements we conducted supplemental analyses detailed in SI.
59-1	11176-11178	In	_
59-2	11179-11186	support	_
59-3	11187-11189	of	_
59-4	11190-11195	these	_
59-5	11196-11206	statements	_
59-6	11207-11209	we	_
59-7	11210-11219	conducted	_
59-8	11220-11232	supplemental	_
59-9	11233-11241	analyses	_
59-10	11242-11250	detailed	_
59-11	11251-11253	in	_
59-12	11254-11256	SI	_
59-13	11256-11257	.	_

#Text=Neuroimaging
#Text=MRI Acquisition and Processing:
#Text=We acquired high-resolution structural (sMRI) and resting-state functional MRI (rs-fMRI) data on the same 3T Skyra scanner (Siemens Medical Systems, Erlangen, Germany) using identical protocols for all participants.
60-1	11258-11270	Neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[20]
60-2	11271-11274	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[20]
60-3	11275-11286	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[20]
60-4	11287-11290	and	_
60-5	11291-11301	Processing	_
60-6	11301-11302	:	_
60-7	11303-11305	We	_
60-8	11306-11314	acquired	_
60-9	11315-11330	high-resolution	_
60-10	11331-11341	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[21]
60-11	11342-11343	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[21]
60-12	11343-11347	sMRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[21]
60-13	11347-11348	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[21]
60-14	11349-11352	and	_
60-15	11353-11366	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]
60-16	11367-11377	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]
60-17	11378-11381	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]
60-18	11382-11383	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]
60-19	11383-11390	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]
60-20	11390-11391	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]
60-21	11392-11396	data	_
60-22	11397-11399	on	_
60-23	11400-11403	the	_
60-24	11404-11408	same	_
60-25	11409-11411	3T	_
60-26	11412-11417	Skyra	_
60-27	11418-11425	scanner	_
60-28	11426-11427	(	_
60-29	11427-11434	Siemens	_
60-30	11435-11442	Medical	_
60-31	11443-11450	Systems	_
60-32	11450-11451	,	_
60-33	11452-11460	Erlangen	_
60-34	11460-11461	,	_
60-35	11462-11469	Germany	_
60-36	11469-11470	)	_
60-37	11471-11476	using	_
60-38	11477-11486	identical	_
60-39	11487-11496	protocols	_
60-40	11497-11500	for	_
60-41	11501-11504	all	_
60-42	11505-11517	participants	_
60-43	11517-11518	.	_

#Text=Comprehensive quality control (including head motion) was carried out on all neuroimaging datasets using previously published quality control procedures.
61-1	11519-11532	Comprehensive	_
61-2	11533-11540	quality	_
61-3	11541-11548	control	_
61-4	11549-11550	(	_
61-5	11550-11559	including	_
61-6	11560-11564	head	_
61-7	11565-11571	motion	_
61-8	11571-11572	)	_
61-9	11573-11576	was	_
61-10	11577-11584	carried	_
61-11	11585-11588	out	_
61-12	11589-11591	on	_
61-13	11592-11595	all	_
61-14	11596-11608	neuroimaging	_
61-15	11609-11617	datasets	_
61-16	11618-11623	using	_
61-17	11624-11634	previously	_
61-18	11635-11644	published	_
61-19	11645-11652	quality	_
61-20	11653-11660	control	_
61-21	11661-11671	procedures	_
61-22	11671-11672	.	_

#Text=Details of the image acquisition, preprocessing and quality assurance are provided in the Supplement Information (SI).
62-1	11673-11680	Details	_
62-2	11681-11683	of	_
62-3	11684-11687	the	_
62-4	11688-11693	image	_
62-5	11694-11705	acquisition	_
62-6	11705-11706	,	_
62-7	11707-11720	preprocessing	_
62-8	11721-11724	and	_
62-9	11725-11732	quality	_
62-10	11733-11742	assurance	_
62-11	11743-11746	are	_
62-12	11747-11755	provided	_
62-13	11756-11758	in	_
62-14	11759-11762	the	_
62-15	11763-11773	Supplement	_
62-16	11774-11785	Information	_
62-17	11786-11787	(	_
62-18	11787-11789	SI	_
62-19	11789-11790	)	_
62-20	11790-11791	.	_

#Text=Cortical reconstruction and volumetric segmentation:
#Text=In each individual sMRI dataset, we used FreeSurfer image analysis suite (v.5.3.0) (http://surfer.nmr.mgh.harvard.edu/) to derive 64 cortical thickness measures and 18 subcortical volumetric measures from the Desikan atlas(details in SI and Supplementary Figure 1).
63-1	11792-11800	Cortical	_
63-2	11801-11815	reconstruction	_
63-3	11816-11819	and	_
63-4	11820-11830	volumetric	_
63-5	11831-11843	segmentation	_
63-6	11843-11844	:	_
63-7	11845-11847	In	_
63-8	11848-11852	each	_
63-9	11853-11863	individual	_
63-10	11864-11868	sMRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
63-11	11869-11876	dataset	_
63-12	11876-11877	,	_
63-13	11878-11880	we	_
63-14	11881-11885	used	_
63-15	11886-11896	FreeSurfer	_
63-16	11897-11902	image	_
63-17	11903-11911	analysis	_
63-18	11912-11917	suite	_
63-19	11918-11919	(	_
63-20	11919-11920	v	_
63-21	11920-11926	.5.3.0	_
63-22	11926-11927	)	_
63-23	11928-11929	(	_
63-24	11929-11933	http	_
63-25	11933-11934	:	_
63-26	11934-11935	/	_
63-27	11935-11936	/	_
63-28	11936-11962	surfer.nmr.mgh.harvard.edu	_
63-29	11962-11963	/	_
63-30	11963-11964	)	_
63-31	11965-11967	to	_
63-32	11968-11974	derive	_
63-33	11975-11977	64	_
63-34	11978-11986	cortical	_
63-35	11987-11996	thickness	_
63-36	11997-12005	measures	_
63-37	12006-12009	and	_
63-38	12010-12012	18	_
63-39	12013-12024	subcortical	_
63-40	12025-12035	volumetric	_
63-41	12036-12044	measures	_
63-42	12045-12049	from	_
63-43	12050-12053	the	_
63-44	12054-12061	Desikan	_
63-45	12062-12067	atlas	_
63-46	12067-12068	(	_
63-47	12068-12075	details	_
63-48	12076-12078	in	_
63-49	12079-12081	SI	_
63-50	12082-12085	and	_
63-51	12086-12099	Supplementary	_
63-52	12100-12106	Figure	_
63-53	12107-12108	1	_
63-54	12108-12109	)	_
63-55	12109-12110	.	_

#Text=Computation of Resting-state Connectivity:
#Text=We used previously established and reproducible templates based data from 496 participants of the Human Connectome Project (www.humanconnectomeproject.com) to partition the functional connectome into the 5 most replicated resting-state networks (RSNs) and their subdivisions: default mode (DMN; 5 subnetworks), salience (SAL), central executive (CEN; 3 subnetworks), sensorimotor (SMN; 2 subnetworks) and visual (VIS; 2 subnetworks) (Figure 1, Supplementary Table 2).
64-1	12111-12122	Computation	_
64-2	12123-12125	of	_
64-3	12126-12139	Resting-state	_
64-4	12140-12152	Connectivity	_
64-5	12152-12153	:	_
64-6	12154-12156	We	_
64-7	12157-12161	used	_
64-8	12162-12172	previously	_
64-9	12173-12184	established	_
64-10	12185-12188	and	_
64-11	12189-12201	reproducible	_
64-12	12202-12211	templates	_
64-13	12212-12217	based	_
64-14	12218-12222	data	_
64-15	12223-12227	from	_
64-16	12228-12231	496	_
64-17	12232-12244	participants	_
64-18	12245-12247	of	_
64-19	12248-12251	the	_
64-20	12252-12257	Human	_
64-21	12258-12268	Connectome	_
64-22	12269-12276	Project	_
64-23	12277-12278	(	_
64-24	12278-12308	www.humanconnectomeproject.com	_
64-25	12308-12309	)	_
64-26	12310-12312	to	_
64-27	12313-12322	partition	_
64-28	12323-12326	the	_
64-29	12327-12337	functional	_
64-30	12338-12348	connectome	_
64-31	12349-12353	into	_
64-32	12354-12357	the	_
64-33	12358-12359	5	_
64-34	12360-12364	most	_
64-35	12365-12375	replicated	_
64-36	12376-12389	resting-state	_
64-37	12390-12398	networks	_
64-38	12399-12400	(	_
64-39	12400-12404	RSNs	_
64-40	12404-12405	)	_
64-41	12406-12409	and	_
64-42	12410-12415	their	_
64-43	12416-12428	subdivisions	_
64-44	12428-12429	:	_
64-45	12430-12437	default	_
64-46	12438-12442	mode	_
64-47	12443-12444	(	_
64-48	12444-12447	DMN	_
64-49	12447-12448	;	_
64-50	12449-12450	5	_
64-51	12451-12462	subnetworks	_
64-52	12462-12463	)	_
64-53	12463-12464	,	_
64-54	12465-12473	salience	_
64-55	12474-12475	(	_
64-56	12475-12478	SAL	_
64-57	12478-12479	)	_
64-58	12479-12480	,	_
64-59	12481-12488	central	_
64-60	12489-12498	executive	_
64-61	12499-12500	(	_
64-62	12500-12503	CEN	_
64-63	12503-12504	;	_
64-64	12505-12506	3	_
64-65	12507-12518	subnetworks	_
64-66	12518-12519	)	_
64-67	12519-12520	,	_
64-68	12521-12533	sensorimotor	_
64-69	12534-12535	(	_
64-70	12535-12538	SMN	_
64-71	12538-12539	;	_
64-72	12540-12541	2	_
64-73	12542-12553	subnetworks	_
64-74	12553-12554	)	_
64-75	12555-12558	and	_
64-76	12559-12565	visual	_
64-77	12566-12567	(	_
64-78	12567-12570	VIS	_
64-79	12570-12571	;	_
64-80	12572-12573	2	_
64-81	12574-12585	subnetworks	_
64-82	12585-12586	)	_
64-83	12587-12588	(	_
64-84	12588-12594	Figure	_
64-85	12595-12596	1	_
64-86	12596-12597	,	_
64-87	12598-12611	Supplementary	_
64-88	12612-12617	Table	_
64-89	12618-12619	2	_
64-90	12619-12620	)	_
64-91	12620-12621	.	_

#Text=This partition was based on averaged regional blood oxygen-level-dependent (BOLD) time series from each of 638 brain regions chosen to maximize the likelihood of detecting subtle effects at the level of subnetworks as per Zalesky et al. and Crossley et al..
65-1	12622-12626	This	_
65-2	12627-12636	partition	_
65-3	12637-12640	was	_
65-4	12641-12646	based	_
65-5	12647-12649	on	_
65-6	12650-12658	averaged	_
65-7	12659-12667	regional	_
65-8	12668-12673	blood	_
65-9	12674-12696	oxygen-level-dependent	_
65-10	12697-12698	(	_
65-11	12698-12702	BOLD	_
65-12	12702-12703	)	_
65-13	12704-12708	time	_
65-14	12709-12715	series	_
65-15	12716-12720	from	_
65-16	12721-12725	each	_
65-17	12726-12728	of	_
65-18	12729-12732	638	_
65-19	12733-12738	brain	_
65-20	12739-12746	regions	_
65-21	12747-12753	chosen	_
65-22	12754-12756	to	_
65-23	12757-12765	maximize	_
65-24	12766-12769	the	_
65-25	12770-12780	likelihood	_
65-26	12781-12783	of	_
65-27	12784-12793	detecting	_
65-28	12794-12800	subtle	_
65-29	12801-12808	effects	_
65-30	12809-12811	at	_
65-31	12812-12815	the	_
65-32	12816-12821	level	_
65-33	12822-12824	of	_
65-34	12825-12836	subnetworks	_
65-35	12837-12839	as	_
65-36	12840-12843	per	_
65-37	12844-12851	Zalesky	_
65-38	12852-12854	et	_
65-39	12855-12857	al	_
65-40	12857-12858	.	_
65-41	12859-12862	and	_
65-42	12863-12871	Crossley	_
65-43	12872-12874	et	_
65-44	12875-12877	al	_
65-45	12877-12878	.	_
65-46	12878-12879	.	_

#Text=In each participant, Fisher Z-transformed Pearson’s correlation coefficients were computed to calculate functional connectivity within (i.e., cohesiveness) and between (i.e., integration) subnetworks.
66-1	12880-12882	In	_
66-2	12883-12887	each	_
66-3	12888-12899	participant	_
66-4	12899-12900	,	_
66-5	12901-12907	Fisher	_
66-6	12908-12921	Z-transformed	_
66-7	12922-12929	Pearson	_
66-8	12929-12930	’	_
66-9	12930-12931	s	_
66-10	12932-12943	correlation	_
66-11	12944-12956	coefficients	_
66-12	12957-12961	were	_
66-13	12962-12970	computed	_
66-14	12971-12973	to	_
66-15	12974-12983	calculate	_
66-16	12984-12994	functional	_
66-17	12995-13007	connectivity	_
66-18	13008-13014	within	_
66-19	13015-13016	(	_
66-20	13016-13019	i.e	_
66-21	13019-13020	.	_
66-22	13020-13021	,	_
66-23	13022-13034	cohesiveness	_
66-24	13034-13035	)	_
66-25	13036-13039	and	_
66-26	13040-13047	between	_
66-27	13048-13049	(	_
66-28	13049-13052	i.e	_
66-29	13052-13053	.	_
66-30	13053-13054	,	_
66-31	13055-13066	integration	_
66-32	13066-13067	)	_
66-33	13068-13079	subnetworks	_
66-34	13079-13080	.	_

#Text=Cohesiveness was computed as the average correlation of each voxel’s BOLD signal time series with every other gray matter voxel within the subnetwork.
67-1	13081-13093	Cohesiveness	_
67-2	13094-13097	was	_
67-3	13098-13106	computed	_
67-4	13107-13109	as	_
67-5	13110-13113	the	_
67-6	13114-13121	average	_
67-7	13122-13133	correlation	_
67-8	13134-13136	of	_
67-9	13137-13141	each	_
67-10	13142-13147	voxel	_
67-11	13147-13148	’	_
67-12	13148-13149	s	_
67-13	13150-13154	BOLD	_
67-14	13155-13161	signal	_
67-15	13162-13166	time	_
67-16	13167-13173	series	_
67-17	13174-13178	with	_
67-18	13179-13184	every	_
67-19	13185-13190	other	_
67-20	13191-13195	gray	_
67-21	13196-13202	matter	_
67-22	13203-13208	voxel	_
67-23	13209-13215	within	_
67-24	13216-13219	the	_
67-25	13220-13230	subnetwork	_
67-26	13230-13231	.	_

#Text=Integration was computed as the correlation between the average time-series of each pair of subnetworks.
68-1	13232-13243	Integration	_
68-2	13244-13247	was	_
68-3	13248-13256	computed	_
68-4	13257-13259	as	_
68-5	13260-13263	the	_
68-6	13264-13275	correlation	_
68-7	13276-13283	between	_
68-8	13284-13287	the	_
68-9	13288-13295	average	_
68-10	13296-13307	time-series	_
68-11	13308-13310	of	_
68-12	13311-13315	each	_
68-13	13316-13320	pair	_
68-14	13321-13323	of	_
68-15	13324-13335	subnetworks	_
68-16	13335-13336	.	_

#Text=These computations yielded 91 connectivity measures.
69-1	13337-13342	These	_
69-2	13343-13355	computations	_
69-3	13356-13363	yielded	_
69-4	13364-13366	91	_
69-5	13367-13379	connectivity	_
69-6	13380-13388	measures	_
69-7	13388-13389	.	_

#Text=Statistical Analyses
#Text=We used paired t-tests to examine differences in symptom severity, BMI and antipsychotic dose between initial and 24-week assessments.
70-1	13390-13401	Statistical	_
70-2	13402-13410	Analyses	_
70-3	13411-13413	We	_
70-4	13414-13418	used	_
70-5	13419-13425	paired	_
70-6	13426-13433	t-tests	_
70-7	13434-13436	to	_
70-8	13437-13444	examine	_
70-9	13445-13456	differences	_
70-10	13457-13459	in	_
70-11	13460-13467	symptom	_
70-12	13468-13476	severity	_
70-13	13476-13477	,	_
70-14	13478-13481	BMI	_
70-15	13482-13485	and	_
70-16	13486-13499	antipsychotic	_
70-17	13500-13504	dose	_
70-18	13505-13512	between	_
70-19	13513-13520	initial	_
70-20	13521-13524	and	_
70-21	13525-13527	24	_
70-22	13527-13528	-	_
70-23	13528-13532	week	_
70-24	13533-13544	assessments	_
70-25	13544-13545	.	_

#Text=We used univariate correlations and curve estimation to determine the zero-order associations between clinical and neuroimaging features (Supplementary Figure 2).
71-1	13546-13548	We	_
71-2	13549-13553	used	_
71-3	13554-13564	univariate	_
71-4	13565-13577	correlations	_
71-5	13578-13581	and	_
71-6	13582-13587	curve	_
71-7	13588-13598	estimation	_
71-8	13599-13601	to	_
71-9	13602-13611	determine	_
71-10	13612-13615	the	_
71-11	13616-13626	zero-order	_
71-12	13627-13639	associations	_
71-13	13640-13647	between	_
71-14	13648-13656	clinical	_
71-15	13657-13660	and	_
71-16	13661-13673	neuroimaging	_
71-17	13674-13682	features	_
71-18	13683-13684	(	_
71-19	13684-13697	Supplementary	_
71-20	13698-13704	Figure	_
71-21	13705-13706	2	_
71-22	13706-13707	)	_
71-23	13707-13708	.	_

#Text=We conducted sCCA to determine the covariation patterns between clinical features (clinical dataset) with sMRI (sMRI dataset) and with rs-fMRI (rs-fMRI dataset) neuroimaging measures.
72-1	13709-13711	We	_
72-2	13712-13721	conducted	_
72-3	13722-13726	sCCA	_
72-4	13727-13729	to	_
72-5	13730-13739	determine	_
72-6	13740-13743	the	_
72-7	13744-13755	covariation	_
72-8	13756-13764	patterns	_
72-9	13765-13772	between	_
72-10	13773-13781	clinical	_
72-11	13782-13790	features	_
72-12	13791-13792	(	_
72-13	13792-13800	clinical	_
72-14	13801-13808	dataset	_
72-15	13808-13809	)	_
72-16	13810-13814	with	_
72-17	13815-13819	sMRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
72-18	13820-13821	(	_
72-19	13821-13825	sMRI	_
72-20	13826-13833	dataset	_
72-21	13833-13834	)	_
72-22	13835-13838	and	_
72-23	13839-13843	with	_
72-24	13844-13851	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
72-25	13852-13853	(	_
72-26	13853-13860	rs-fMRI	_
72-27	13861-13868	dataset	_
72-28	13868-13869	)	_
72-29	13870-13882	neuroimaging	_
72-30	13883-13891	measures	_
72-31	13891-13892	.	_

#Text=The clinical dataset comprised sex, IQ and change in the each of the BPRS subscale scores and in BMI and antipsychotic dose (Supplementary Table 1).
73-1	13893-13896	The	_
73-2	13897-13905	clinical	_
73-3	13906-13913	dataset	_
73-4	13914-13923	comprised	_
73-5	13924-13927	sex	_
73-6	13927-13928	,	_
73-7	13929-13931	IQ	_
73-8	13932-13935	and	_
73-9	13936-13942	change	_
73-10	13943-13945	in	_
73-11	13946-13949	the	_
73-12	13950-13954	each	_
73-13	13955-13957	of	_
73-14	13958-13961	the	_
73-15	13962-13966	BPRS	_
73-16	13967-13975	subscale	_
73-17	13976-13982	scores	_
73-18	13983-13986	and	_
73-19	13987-13989	in	_
73-20	13990-13993	BMI	_
73-21	13994-13997	and	_
73-22	13998-14011	antipsychotic	_
73-23	14012-14016	dose	_
73-24	14017-14018	(	_
73-25	14018-14031	Supplementary	_
73-26	14032-14037	Table	_
73-27	14038-14039	1	_
73-28	14039-14040	)	_
73-29	14040-14041	.	_

#Text=The sCCA can be considered as a generalization of multiple linear regression and aims to identify those linear combinations (pairs of canonical variates or otherwise modes) of variables in each dataset that best express the maximal correlation (i.e., canonical correlation) between the two datasets.
74-1	14042-14045	The	_
74-2	14046-14050	sCCA	_
74-3	14051-14054	can	_
74-4	14055-14057	be	_
74-5	14058-14068	considered	_
74-6	14069-14071	as	_
74-7	14072-14073	a	_
74-8	14074-14088	generalization	_
74-9	14089-14091	of	_
74-10	14092-14100	multiple	_
74-11	14101-14107	linear	_
74-12	14108-14118	regression	_
74-13	14119-14122	and	_
74-14	14123-14127	aims	_
74-15	14128-14130	to	_
74-16	14131-14139	identify	_
74-17	14140-14145	those	_
74-18	14146-14152	linear	_
74-19	14153-14165	combinations	_
74-20	14166-14167	(	_
74-21	14167-14172	pairs	_
74-22	14173-14175	of	_
74-23	14176-14185	canonical	_
74-24	14186-14194	variates	_
74-25	14195-14197	or	_
74-26	14198-14207	otherwise	_
74-27	14208-14213	modes	_
74-28	14213-14214	)	_
74-29	14215-14217	of	_
74-30	14218-14227	variables	_
74-31	14228-14230	in	_
74-32	14231-14235	each	_
74-33	14236-14243	dataset	_
74-34	14244-14248	that	_
74-35	14249-14253	best	_
74-36	14254-14261	express	_
74-37	14262-14265	the	_
74-38	14266-14273	maximal	_
74-39	14274-14285	correlation	_
74-40	14286-14287	(	_
74-41	14287-14290	i.e	_
74-42	14290-14291	.	_
74-43	14291-14292	,	_
74-44	14293-14302	canonical	_
74-45	14303-14314	correlation	_
74-46	14314-14315	)	_
74-47	14316-14323	between	_
74-48	14324-14327	the	_
74-49	14328-14331	two	_
74-50	14332-14340	datasets	_
74-51	14340-14341	.	_

#Text=The weight of association between a variable of one dataset to the variate of the other dataset can be conceptually construed as an extension of a correlation coefficient (additional details in SI).
75-1	14342-14345	The	_
75-2	14346-14352	weight	_
75-3	14353-14355	of	_
75-4	14356-14367	association	_
75-5	14368-14375	between	_
75-6	14376-14377	a	_
75-7	14378-14386	variable	_
75-8	14387-14389	of	_
75-9	14390-14393	one	_
75-10	14394-14401	dataset	_
75-11	14402-14404	to	_
75-12	14405-14408	the	_
75-13	14409-14416	variate	_
75-14	14417-14419	of	_
75-15	14420-14423	the	_
75-16	14424-14429	other	_
75-17	14430-14437	dataset	_
75-18	14438-14441	can	_
75-19	14442-14444	be	_
75-20	14445-14457	conceptually	_
75-21	14458-14467	construed	_
75-22	14468-14470	as	_
75-23	14471-14473	an	_
75-24	14474-14483	extension	_
75-25	14484-14486	of	_
75-26	14487-14488	a	_
75-27	14489-14500	correlation	_
75-28	14501-14512	coefficient	_
75-29	14513-14514	(	_
75-30	14514-14524	additional	_
75-31	14525-14532	details	_
75-32	14533-14535	in	_
75-33	14536-14538	SI	_
75-34	14538-14539	)	_
75-35	14539-14540	.	_

#Text=All sCCAs were implemented in MatlabR2015b using an in-house script according to our previously published work.
76-1	14541-14544	All	_
76-2	14545-14550	sCCAs	_
76-3	14551-14555	were	_
76-4	14556-14567	implemented	_
76-5	14568-14570	in	_
76-6	14571-14583	MatlabR2015b	_
76-7	14584-14589	using	_
76-8	14590-14592	an	_
76-9	14593-14601	in-house	_
76-10	14602-14608	script	_
76-11	14609-14618	according	_
76-12	14619-14621	to	_
76-13	14622-14625	our	_
76-14	14626-14636	previously	_
76-15	14637-14646	published	_
76-16	14647-14651	work	_
76-17	14651-14652	.	_

#Text=Age and the interval between T1 and T2 were then regressed out of the change scores.
77-1	14653-14656	Age	_
77-2	14657-14660	and	_
77-3	14661-14664	the	_
77-4	14665-14673	interval	_
77-5	14674-14681	between	_
77-6	14682-14684	T1	_
77-7	14685-14688	and	_
77-8	14689-14691	T2	_
77-9	14692-14696	were	_
77-10	14697-14701	then	_
77-11	14702-14711	regressed	_
77-12	14712-14715	out	_
77-13	14716-14718	of	_
77-14	14719-14722	the	_
77-15	14723-14729	change	_
77-16	14730-14736	scores	_
77-17	14736-14737	.	_

#Text=Continuous variables were z-standardized prior to being entered into the sCCA.
78-1	14738-14748	Continuous	_
78-2	14749-14758	variables	_
78-3	14759-14763	were	_
78-4	14764-14778	z-standardized	_
78-5	14779-14784	prior	_
78-6	14785-14787	to	_
78-7	14788-14793	being	_
78-8	14794-14801	entered	_
78-9	14802-14806	into	_
78-10	14807-14810	the	_
78-11	14811-14815	sCCA	_
78-12	14815-14816	.	_

#Text=The sMRI dataset comprised 82 variables corresponding to measures of cortical thickness and subcortical volume (Supplementary Figure 1).
79-1	14817-14820	The	_
79-2	14821-14825	sMRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
79-3	14826-14833	dataset	_
79-4	14834-14843	comprised	_
79-5	14844-14846	82	_
79-6	14847-14856	variables	_
79-7	14857-14870	corresponding	_
79-8	14871-14873	to	_
79-9	14874-14882	measures	_
79-10	14883-14885	of	_
79-11	14886-14894	cortical	_
79-12	14895-14904	thickness	_
79-13	14905-14908	and	_
79-14	14909-14920	subcortical	_
79-15	14921-14927	volume	_
79-16	14928-14929	(	_
79-17	14929-14942	Supplementary	_
79-18	14943-14949	Figure	_
79-19	14950-14951	1	_
79-20	14951-14952	)	_
79-21	14952-14953	.	_

#Text=The rs-fMRI dataset comprised 91 variables corresponding to measures of RSN cohesiveness and integration.
80-1	14954-14957	The	_
80-2	14958-14965	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
80-3	14966-14973	dataset	_
80-4	14974-14983	comprised	_
80-5	14984-14986	91	_
80-6	14987-14996	variables	_
80-7	14997-15010	corresponding	_
80-8	15011-15013	to	_
80-9	15014-15022	measures	_
80-10	15023-15025	of	_
80-11	15026-15029	RSN	_
80-12	15030-15042	cohesiveness	_
80-13	15043-15046	and	_
80-14	15047-15058	integration	_
80-15	15058-15059	.	_

#Text=Age was regressed out of the sMRI and fMRI variables before they were z-standardized and entered in the sCCA.
81-1	15060-15063	Age	_
81-2	15064-15067	was	_
81-3	15068-15077	regressed	_
81-4	15078-15081	out	_
81-5	15082-15084	of	_
81-6	15085-15088	the	_
81-7	15089-15093	sMRI	_
81-8	15094-15097	and	_
81-9	15098-15102	fMRI	_
81-10	15103-15112	variables	_
81-11	15113-15119	before	_
81-12	15120-15124	they	_
81-13	15125-15129	were	_
81-14	15130-15144	z-standardized	_
81-15	15145-15148	and	_
81-16	15149-15156	entered	_
81-17	15157-15159	in	_
81-18	15160-15163	the	_
81-19	15164-15168	sCCA	_
81-20	15168-15169	.	_

#Text=For each sCCA, we (a) computed the sparse parameters for range of candidate values from to 0.1×√p (high sparsity) to 1×√p (low sparsity) at 0.1 increments (where p is the number of features in that view of the data) and fitted the resulting models; (b) selected the optimal sparse criteria combination based on the parameters that corresponded to the values of the model that maximized the sCCA correlation value; (c) determined the optimal sCCA model and established its significance at p<0.05 using permutations (n=10,000).
82-1	15170-15173	For	_
82-2	15174-15178	each	_
82-3	15179-15183	sCCA	_
82-4	15183-15184	,	_
82-5	15185-15187	we	_
82-6	15188-15189	(	_
82-7	15189-15190	a	_
82-8	15190-15191	)	_
82-9	15192-15200	computed	_
82-10	15201-15204	the	_
82-11	15205-15211	sparse	_
82-12	15212-15222	parameters	_
82-13	15223-15226	for	_
82-14	15227-15232	range	_
82-15	15233-15235	of	_
82-16	15236-15245	candidate	_
82-17	15246-15252	values	_
82-18	15253-15257	from	_
82-19	15258-15260	to	_
82-20	15261-15264	0.1	_
82-21	15264-15265	×	_
82-22	15265-15266	√	_
82-23	15266-15267	p	_
82-24	15268-15269	(	_
82-25	15269-15273	high	_
82-26	15274-15282	sparsity	_
82-27	15282-15283	)	_
82-28	15284-15286	to	_
82-29	15287-15288	1	_
82-30	15288-15289	×	_
82-31	15289-15290	√	_
82-32	15290-15291	p	_
82-33	15292-15293	(	_
82-34	15293-15296	low	_
82-35	15297-15305	sparsity	_
82-36	15305-15306	)	_
82-37	15307-15309	at	_
82-38	15310-15313	0.1	_
82-39	15314-15324	increments	_
82-40	15325-15326	(	_
82-41	15326-15331	where	_
82-42	15332-15333	p	_
82-43	15334-15336	is	_
82-44	15337-15340	the	_
82-45	15341-15347	number	_
82-46	15348-15350	of	_
82-47	15351-15359	features	_
82-48	15360-15362	in	_
82-49	15363-15367	that	_
82-50	15368-15372	view	_
82-51	15373-15375	of	_
82-52	15376-15379	the	_
82-53	15380-15384	data	_
82-54	15384-15385	)	_
82-55	15386-15389	and	_
82-56	15390-15396	fitted	_
82-57	15397-15400	the	_
82-58	15401-15410	resulting	_
82-59	15411-15417	models	_
82-60	15417-15418	;	_
82-61	15419-15420	(	_
82-62	15420-15421	b	_
82-63	15421-15422	)	_
82-64	15423-15431	selected	_
82-65	15432-15435	the	_
82-66	15436-15443	optimal	_
82-67	15444-15450	sparse	_
82-68	15451-15459	criteria	_
82-69	15460-15471	combination	_
82-70	15472-15477	based	_
82-71	15478-15480	on	_
82-72	15481-15484	the	_
82-73	15485-15495	parameters	_
82-74	15496-15500	that	_
82-75	15501-15513	corresponded	_
82-76	15514-15516	to	_
82-77	15517-15520	the	_
82-78	15521-15527	values	_
82-79	15528-15530	of	_
82-80	15531-15534	the	_
82-81	15535-15540	model	_
82-82	15541-15545	that	_
82-83	15546-15555	maximized	_
82-84	15556-15559	the	_
82-85	15560-15564	sCCA	_
82-86	15565-15576	correlation	_
82-87	15577-15582	value	_
82-88	15582-15583	;	_
82-89	15584-15585	(	_
82-90	15585-15586	c	_
82-91	15586-15587	)	_
82-92	15588-15598	determined	_
82-93	15599-15602	the	_
82-94	15603-15610	optimal	_
82-95	15611-15615	sCCA	_
82-96	15616-15621	model	_
82-97	15622-15625	and	_
82-98	15626-15637	established	_
82-99	15638-15641	its	_
82-100	15642-15654	significance	_
82-101	15655-15657	at	_
82-102	15658-15659	p	_
82-103	15659-15660	<	_
82-104	15660-15664	0.05	_
82-105	15665-15670	using	_
82-106	15671-15683	permutations	_
82-107	15684-15685	(	_
82-108	15685-15686	n	_
82-109	15686-15687	=	_
82-110	15687-15693	10,000	_
82-111	15693-15694	)	_
82-112	15694-15695	.	_

#Text=The p-value was defined as the number of permutations that resulted in a higher correlation than the original data divided by the total number of permutations.
83-1	15696-15699	The	_
83-2	15700-15707	p-value	_
83-3	15708-15711	was	_
83-4	15712-15719	defined	_
83-5	15720-15722	as	_
83-6	15723-15726	the	_
83-7	15727-15733	number	_
83-8	15734-15736	of	_
83-9	15737-15749	permutations	_
83-10	15750-15754	that	_
83-11	15755-15763	resulted	_
83-12	15764-15766	in	_
83-13	15767-15768	a	_
83-14	15769-15775	higher	_
83-15	15776-15787	correlation	_
83-16	15788-15792	than	_
83-17	15793-15796	the	_
83-18	15797-15805	original	_
83-19	15806-15810	data	_
83-20	15811-15818	divided	_
83-21	15819-15821	by	_
83-22	15822-15825	the	_
83-23	15826-15831	total	_
83-24	15832-15838	number	_
83-25	15839-15841	of	_
83-26	15842-15854	permutations	_
83-27	15854-15855	.	_

#Text=Thus the p-value is explicitly corrected for multiple testing as it is compared against the null distribution of maximal correlation values across all estimated sCCAs.
84-1	15856-15860	Thus	_
84-2	15861-15864	the	_
84-3	15865-15872	p-value	_
84-4	15873-15875	is	_
84-5	15876-15886	explicitly	_
84-6	15887-15896	corrected	_
84-7	15897-15900	for	_
84-8	15901-15909	multiple	_
84-9	15910-15917	testing	_
84-10	15918-15920	as	_
84-11	15921-15923	it	_
84-12	15924-15926	is	_
84-13	15927-15935	compared	_
84-14	15936-15943	against	_
84-15	15944-15947	the	_
84-16	15948-15952	null	_
84-17	15953-15965	distribution	_
84-18	15966-15968	of	_
84-19	15969-15976	maximal	_
84-20	15977-15988	correlation	_
84-21	15989-15995	values	_
84-22	15996-16002	across	_
84-23	16003-16006	all	_
84-24	16007-16016	estimated	_
84-25	16017-16022	sCCAs	_
84-26	16022-16023	.	_

#Text=For each permutation, we tested all sparsity criteria combinations as for the original data and then extracted the sCCA correlation with the highest coefficient among the tested options, independently of whether this combination was the same as in the original data.
85-1	16024-16027	For	_
85-2	16028-16032	each	_
85-3	16033-16044	permutation	_
85-4	16044-16045	,	_
85-5	16046-16048	we	_
85-6	16049-16055	tested	_
85-7	16056-16059	all	_
85-8	16060-16068	sparsity	_
85-9	16069-16077	criteria	_
85-10	16078-16090	combinations	_
85-11	16091-16093	as	_
85-12	16094-16097	for	_
85-13	16098-16101	the	_
85-14	16102-16110	original	_
85-15	16111-16115	data	_
85-16	16116-16119	and	_
85-17	16120-16124	then	_
85-18	16125-16134	extracted	_
85-19	16135-16138	the	_
85-20	16139-16143	sCCA	_
85-21	16144-16155	correlation	_
85-22	16156-16160	with	_
85-23	16161-16164	the	_
85-24	16165-16172	highest	_
85-25	16173-16184	coefficient	_
85-26	16185-16190	among	_
85-27	16191-16194	the	_
85-28	16195-16201	tested	_
85-29	16202-16209	options	_
85-30	16209-16210	,	_
85-31	16211-16224	independently	_
85-32	16225-16227	of	_
85-33	16228-16235	whether	_
85-34	16236-16240	this	_
85-35	16241-16252	combination	_
85-36	16253-16256	was	_
85-37	16257-16260	the	_
85-38	16261-16265	same	_
85-39	16266-16268	as	_
85-40	16269-16271	in	_
85-41	16272-16275	the	_
85-42	16276-16284	original	_
85-43	16285-16289	data	_
85-44	16289-16290	.	_

#Text=In this way we ensured that we did not underestimate the chance of a permutation achieving the same or higher value than the original data.
86-1	16291-16293	In	_
86-2	16294-16298	this	_
86-3	16299-16302	way	_
86-4	16303-16305	we	_
86-5	16306-16313	ensured	_
86-6	16314-16318	that	_
86-7	16319-16321	we	_
86-8	16322-16325	did	_
86-9	16326-16329	not	_
86-10	16330-16343	underestimate	_
86-11	16344-16347	the	_
86-12	16348-16354	chance	_
86-13	16355-16357	of	_
86-14	16358-16359	a	_
86-15	16360-16371	permutation	_
86-16	16372-16381	achieving	_
86-17	16382-16385	the	_
86-18	16386-16390	same	_
86-19	16391-16393	or	_
86-20	16394-16400	higher	_
86-21	16401-16406	value	_
86-22	16407-16411	than	_
86-23	16412-16415	the	_
86-24	16416-16424	original	_
86-25	16425-16429	data	_
86-26	16429-16430	.	_

#Text=If the sCCA was significant, we reported the canonical correlation weight of each variable.
87-1	16431-16433	If	_
87-2	16434-16437	the	_
87-3	16438-16442	sCCA	_
87-4	16443-16446	was	_
87-5	16447-16458	significant	_
87-6	16458-16459	,	_
87-7	16460-16462	we	_
87-8	16463-16471	reported	_
87-9	16472-16475	the	_
87-10	16476-16485	canonical	_
87-11	16486-16497	correlation	_
87-12	16498-16504	weight	_
87-13	16505-16507	of	_
87-14	16508-16512	each	_
87-15	16513-16521	variable	_
87-16	16521-16522	.	_

#Text=Reliability analyses
#Text=We confirmed that the results reported were not influenced by the choice of functional partition, by repeating the analyses using measures of functional cohesiveness and integration extracted from publicly available RSN masks.
88-1	16523-16534	Reliability	_
88-2	16535-16543	analyses	_
88-3	16544-16546	We	_
88-4	16547-16556	confirmed	_
88-5	16557-16561	that	_
88-6	16562-16565	the	_
88-7	16566-16573	results	_
88-8	16574-16582	reported	_
88-9	16583-16587	were	_
88-10	16588-16591	not	_
88-11	16592-16602	influenced	_
88-12	16603-16605	by	_
88-13	16606-16609	the	_
88-14	16610-16616	choice	_
88-15	16617-16619	of	_
88-16	16620-16630	functional	_
88-17	16631-16640	partition	_
88-18	16640-16641	,	_
88-19	16642-16644	by	_
88-20	16645-16654	repeating	_
88-21	16655-16658	the	_
88-22	16659-16667	analyses	_
88-23	16668-16673	using	_
88-24	16674-16682	measures	_
88-25	16683-16685	of	_
88-26	16686-16696	functional	_
88-27	16697-16709	cohesiveness	_
88-28	16710-16713	and	_
88-29	16714-16725	integration	_
88-30	16726-16735	extracted	_
88-31	16736-16740	from	_
88-32	16741-16749	publicly	_
88-33	16750-16759	available	_
88-34	16760-16763	RSN	_
88-35	16764-16769	masks	_
88-36	16769-16770	.	_

#Text=These analyses are detailed in the SI.
89-1	16771-16776	These	_
89-2	16777-16785	analyses	_
89-3	16786-16789	are	_
89-4	16790-16798	detailed	_
89-5	16799-16801	in	_
89-6	16802-16805	the	_
89-7	16806-16808	SI	_
89-8	16808-16809	.	_

#Text=Supplemental categorical analyses
#Text=Although we adopted a dimensional approach for our core analyses, we also tested the usefulness of categorical definitions of remission as we detail in SI.
90-1	16810-16822	Supplemental	_
90-2	16823-16834	categorical	_
90-3	16835-16843	analyses	_
90-4	16844-16852	Although	_
90-5	16853-16855	we	_
90-6	16856-16863	adopted	_
90-7	16864-16865	a	_
90-8	16866-16877	dimensional	_
90-9	16878-16886	approach	_
90-10	16887-16890	for	_
90-11	16891-16894	our	_
90-12	16895-16899	core	_
90-13	16900-16908	analyses	_
90-14	16908-16909	,	_
90-15	16910-16912	we	_
90-16	16913-16917	also	_
90-17	16918-16924	tested	_
90-18	16925-16928	the	_
90-19	16929-16939	usefulness	_
90-20	16940-16942	of	_
90-21	16943-16954	categorical	_
90-22	16955-16966	definitions	_
90-23	16967-16969	of	_
90-24	16970-16979	remission	_
90-25	16980-16982	as	_
90-26	16983-16985	we	_
90-27	16986-16992	detail	_
90-28	16993-16995	in	_
90-29	16996-16998	SI	_
90-30	16998-16999	.	_

#Text=Specifically we investigated (a) whether we could identify differences in neuroimaging features when patients were categorized into remitted and non-remitted using the three most widely used criteria, and (b) whether we could identify clusters of patients based on their imaging features that differed in terms of their remission status.
91-1	17000-17012	Specifically	_
91-2	17013-17015	we	_
91-3	17016-17028	investigated	_
91-4	17029-17030	(	_
91-5	17030-17031	a	_
91-6	17031-17032	)	_
91-7	17033-17040	whether	_
91-8	17041-17043	we	_
91-9	17044-17049	could	_
91-10	17050-17058	identify	_
91-11	17059-17070	differences	_
91-12	17071-17073	in	_
91-13	17074-17086	neuroimaging	_
91-14	17087-17095	features	_
91-15	17096-17100	when	_
91-16	17101-17109	patients	_
91-17	17110-17114	were	_
91-18	17115-17126	categorized	_
91-19	17127-17131	into	_
91-20	17132-17140	remitted	_
91-21	17141-17144	and	_
91-22	17145-17157	non-remitted	_
91-23	17158-17163	using	_
91-24	17164-17167	the	_
91-25	17168-17173	three	_
91-26	17174-17178	most	_
91-27	17179-17185	widely	_
91-28	17186-17190	used	_
91-29	17191-17199	criteria	_
91-30	17199-17200	,	_
91-31	17201-17204	and	_
91-32	17205-17206	(	_
91-33	17206-17207	b	_
91-34	17207-17208	)	_
91-35	17209-17216	whether	_
91-36	17217-17219	we	_
91-37	17220-17225	could	_
91-38	17226-17234	identify	_
91-39	17235-17243	clusters	_
91-40	17244-17246	of	_
91-41	17247-17255	patients	_
91-42	17256-17261	based	_
91-43	17262-17264	on	_
91-44	17265-17270	their	_
91-45	17271-17278	imaging	_
91-46	17279-17287	features	_
91-47	17288-17292	that	_
91-48	17293-17301	differed	_
91-49	17302-17304	in	_
91-50	17305-17310	terms	_
91-51	17311-17313	of	_
91-52	17314-17319	their	_
91-53	17320-17329	remission	_
91-54	17330-17336	status	_
91-55	17336-17337	.	_

#Text=Results
#Text=Clinical Features
#Text=Ninety-five patients were initially enrolled and 19 were excluded from the final analyses (7 because poor quality scans and 12 because they declined the follow-up interview).
92-1	17338-17345	Results	_
92-2	17346-17354	Clinical	_
92-3	17355-17363	Features	_
92-4	17364-17375	Ninety-five	_
92-5	17376-17384	patients	_
92-6	17385-17389	were	_
92-7	17390-17399	initially	_
92-8	17400-17408	enrolled	_
92-9	17409-17412	and	_
92-10	17413-17415	19	_
92-11	17416-17420	were	_
92-12	17421-17429	excluded	_
92-13	17430-17434	from	_
92-14	17435-17438	the	_
92-15	17439-17444	final	_
92-16	17445-17453	analyses	_
92-17	17454-17455	(	_
92-18	17455-17456	7	_
92-19	17457-17464	because	_
92-20	17465-17469	poor	_
92-21	17470-17477	quality	_
92-22	17478-17483	scans	_
92-23	17484-17487	and	_
92-24	17488-17490	12	_
92-25	17491-17498	because	_
92-26	17499-17503	they	_
92-27	17504-17512	declined	_
92-28	17513-17516	the	_
92-29	17517-17526	follow-up	_
92-30	17527-17536	interview	_
92-31	17536-17537	)	_
92-32	17537-17538	.	_

#Text=The demographic and clinical characteristics of the final sample are shown in Table 1.
93-1	17539-17542	The	_
93-2	17543-17554	demographic	_
93-3	17555-17558	and	_
93-4	17559-17567	clinical	_
93-5	17568-17583	characteristics	_
93-6	17584-17586	of	_
93-7	17587-17590	the	_
93-8	17591-17596	final	_
93-9	17597-17603	sample	_
93-10	17604-17607	are	_
93-11	17608-17613	shown	_
93-12	17614-17616	in	_
93-13	17617-17622	Table	_
93-14	17623-17624	1	_
93-15	17624-17625	.	_

#Text=The majority of the patients were started on second generation antipsychotics [most commonly risperidone/paliperidone (64%) and olanzapine (26%)] while 12 patients (15.8%) were prescribed first generation agents [most commonly haloperidol (58%) and fluphenazine (41%)].
94-1	17626-17629	The	_
94-2	17630-17638	majority	_
94-3	17639-17641	of	_
94-4	17642-17645	the	_
94-5	17646-17654	patients	_
94-6	17655-17659	were	_
94-7	17660-17667	started	_
94-8	17668-17670	on	_
94-9	17671-17677	second	_
94-10	17678-17688	generation	_
94-11	17689-17703	antipsychotics	_
94-12	17704-17705	[	_
94-13	17705-17709	most	_
94-14	17710-17718	commonly	_
94-15	17719-17730	risperidone	_
94-16	17730-17731	/	_
94-17	17731-17743	paliperidone	_
94-18	17744-17745	(	_
94-19	17745-17748	64%	_
94-20	17748-17749	)	_
94-21	17750-17753	and	_
94-22	17754-17764	olanzapine	_
94-23	17765-17766	(	_
94-24	17766-17769	26%	_
94-25	17769-17770	)	_
94-26	17770-17771	]	_
94-27	17772-17777	while	_
94-28	17778-17780	12	_
94-29	17781-17789	patients	_
94-30	17790-17791	(	_
94-31	17791-17796	15.8%	_
94-32	17796-17797	)	_
94-33	17798-17802	were	_
94-34	17803-17813	prescribed	_
94-35	17814-17819	first	_
94-36	17820-17830	generation	_
94-37	17831-17837	agents	_
94-38	17838-17839	[	_
94-39	17839-17843	most	_
94-40	17844-17852	commonly	_
94-41	17853-17864	haloperidol	_
94-42	17865-17866	(	_
94-43	17866-17869	58%	_
94-44	17869-17870	)	_
94-45	17871-17874	and	_
94-46	17875-17887	fluphenazine	_
94-47	17888-17889	(	_
94-48	17889-17892	41%	_
94-49	17892-17893	)	_
94-50	17893-17894	]	_
94-51	17894-17895	.	_

#Text=Overall, there was a significant reduction in all symptom dimensions at the follow-up assessment (Table 1).
95-1	17896-17903	Overall	_
95-2	17903-17904	,	_
95-3	17905-17910	there	_
95-4	17911-17914	was	_
95-5	17915-17916	a	_
95-6	17917-17928	significant	_
95-7	17929-17938	reduction	_
95-8	17939-17941	in	_
95-9	17942-17945	all	_
95-10	17946-17953	symptom	_
95-11	17954-17964	dimensions	_
95-12	17965-17967	at	_
95-13	17968-17971	the	_
95-14	17972-17981	follow-up	_
95-15	17982-17992	assessment	_
95-16	17993-17994	(	_
95-17	17994-17999	Table	_
95-18	18000-18001	1	_
95-19	18001-18002	)	_
95-20	18002-18003	.	_

#Text=There were no significant differences in any clinical or demographic information (i.e., age, disease duration, age at onset, BMI, medication change, IQ, change in symptoms) between men and women (all p>0.07 at an uncorrected threshold).
96-1	18004-18009	There	_
96-2	18010-18014	were	_
96-3	18015-18017	no	_
96-4	18018-18029	significant	_
96-5	18030-18041	differences	_
96-6	18042-18044	in	_
96-7	18045-18048	any	_
96-8	18049-18057	clinical	_
96-9	18058-18060	or	_
96-10	18061-18072	demographic	_
96-11	18073-18084	information	_
96-12	18085-18086	(	_
96-13	18086-18089	i.e	_
96-14	18089-18090	.	_
96-15	18090-18091	,	_
96-16	18092-18095	age	_
96-17	18095-18096	,	_
96-18	18097-18104	disease	_
96-19	18105-18113	duration	_
96-20	18113-18114	,	_
96-21	18115-18118	age	_
96-22	18119-18121	at	_
96-23	18122-18127	onset	_
96-24	18127-18128	,	_
96-25	18129-18132	BMI	_
96-26	18132-18133	,	_
96-27	18134-18144	medication	_
96-28	18145-18151	change	_
96-29	18151-18152	,	_
96-30	18153-18155	IQ	_
96-31	18155-18156	,	_
96-32	18157-18163	change	_
96-33	18164-18166	in	_
96-34	18167-18175	symptoms	_
96-35	18175-18176	)	_
96-36	18177-18184	between	_
96-37	18185-18188	men	_
96-38	18189-18192	and	_
96-39	18193-18198	women	_
96-40	18199-18200	(	_
96-41	18200-18203	all	_
96-42	18204-18205	p	_
96-43	18205-18206	>	_
96-44	18206-18210	0.07	_
96-45	18211-18213	at	_
96-46	18214-18216	an	_
96-47	18217-18228	uncorrected	_
96-48	18229-18238	threshold	_
96-49	18238-18239	)	_
96-50	18239-18240	.	_

#Text=Although we adopted a dimensional approach, here we also report rates of remission based on the Remission in Schizophrenia Working Group (RSWG) criteria to allow comparisons of the clinical data with other studies that have used dichotomous categorizations.
97-1	18241-18249	Although	_
97-2	18250-18252	we	_
97-3	18253-18260	adopted	_
97-4	18261-18262	a	_
97-5	18263-18274	dimensional	_
97-6	18275-18283	approach	_
97-7	18283-18284	,	_
97-8	18285-18289	here	_
97-9	18290-18292	we	_
97-10	18293-18297	also	_
97-11	18298-18304	report	_
97-12	18305-18310	rates	_
97-13	18311-18313	of	_
97-14	18314-18323	remission	_
97-15	18324-18329	based	_
97-16	18330-18332	on	_
97-17	18333-18336	the	_
97-18	18337-18346	Remission	_
97-19	18347-18349	in	_
97-20	18350-18363	Schizophrenia	_
97-21	18364-18371	Working	_
97-22	18372-18377	Group	_
97-23	18378-18379	(	_
97-24	18379-18383	RSWG	_
97-25	18383-18384	)	_
97-26	18385-18393	criteria	_
97-27	18394-18396	to	_
97-28	18397-18402	allow	_
97-29	18403-18414	comparisons	_
97-30	18415-18417	of	_
97-31	18418-18421	the	_
97-32	18422-18430	clinical	_
97-33	18431-18435	data	_
97-34	18436-18440	with	_
97-35	18441-18446	other	_
97-36	18447-18454	studies	_
97-37	18455-18459	that	_
97-38	18460-18464	have	_
97-39	18465-18469	used	_
97-40	18470-18481	dichotomous	_
97-41	18482-18497	categorizations	_
97-42	18497-18498	.	_

#Text=Consistent with the rates reported in prior literature, 50 (65.8%) patients were remitted based on RSWG criteria; as expected there was significant overlap in the distribution of symptom scores between remitted and non-remitted patients (Supplementary Figure 2).
98-1	18499-18509	Consistent	_
98-2	18510-18514	with	_
98-3	18515-18518	the	_
98-4	18519-18524	rates	_
98-5	18525-18533	reported	_
98-6	18534-18536	in	_
98-7	18537-18542	prior	_
98-8	18543-18553	literature	_
98-9	18553-18554	,	_
98-10	18555-18557	50	_
98-11	18558-18559	(	_
98-12	18559-18564	65.8%	_
98-13	18564-18565	)	_
98-14	18566-18574	patients	_
98-15	18575-18579	were	_
98-16	18580-18588	remitted	_
98-17	18589-18594	based	_
98-18	18595-18597	on	_
98-19	18598-18602	RSWG	_
98-20	18603-18611	criteria	_
98-21	18611-18612	;	_
98-22	18613-18615	as	_
98-23	18616-18624	expected	_
98-24	18625-18630	there	_
98-25	18631-18634	was	_
98-26	18635-18646	significant	_
98-27	18647-18654	overlap	_
98-28	18655-18657	in	_
98-29	18658-18661	the	_
98-30	18662-18674	distribution	_
98-31	18675-18677	of	_
98-32	18678-18685	symptom	_
98-33	18686-18692	scores	_
98-34	18693-18700	between	_
98-35	18701-18709	remitted	_
98-36	18710-18713	and	_
98-37	18714-18726	non-remitted	_
98-38	18727-18735	patients	_
98-39	18736-18737	(	_
98-40	18737-18750	Supplementary	_
98-41	18751-18757	Figure	_
98-42	18758-18759	2	_
98-43	18759-18760	)	_
98-44	18760-18761	.	_

#Text=Brain structural predictors of clinical response
#Text=sCCA models that considered all the structural data simultaneously (r=0.54, p=0.3) and models that were restricted to either subcortical (r=0.56, p=0.15) or cortical measures (r=0.37, p=0.98) were not significant.
99-1	18762-18767	Brain	_
99-2	18768-18778	structural	_
99-3	18779-18789	predictors	_
99-4	18790-18792	of	_
99-5	18793-18801	clinical	_
99-6	18802-18810	response	_
99-7	18811-18815	sCCA	_
99-8	18816-18822	models	_
99-9	18823-18827	that	_
99-10	18828-18838	considered	_
99-11	18839-18842	all	_
99-12	18843-18846	the	_
99-13	18847-18857	structural	_
99-14	18858-18862	data	_
99-15	18863-18877	simultaneously	_
99-16	18878-18879	(	_
99-17	18879-18880	r	_
99-18	18880-18881	=	_
99-19	18881-18885	0.54	_
99-20	18885-18886	,	_
99-21	18887-18888	p	_
99-22	18888-18889	=	_
99-23	18889-18892	0.3	_
99-24	18892-18893	)	_
99-25	18894-18897	and	_
99-26	18898-18904	models	_
99-27	18905-18909	that	_
99-28	18910-18914	were	_
99-29	18915-18925	restricted	_
99-30	18926-18928	to	_
99-31	18929-18935	either	_
99-32	18936-18947	subcortical	_
99-33	18948-18949	(	_
99-34	18949-18950	r	_
99-35	18950-18951	=	_
99-36	18951-18955	0.56	_
99-37	18955-18956	,	_
99-38	18957-18958	p	_
99-39	18958-18959	=	_
99-40	18959-18963	0.15	_
99-41	18963-18964	)	_
99-42	18965-18967	or	_
99-43	18968-18976	cortical	_
99-44	18977-18985	measures	_
99-45	18986-18987	(	_
99-46	18987-18988	r	_
99-47	18988-18989	=	_
99-48	18989-18993	0.37	_
99-49	18993-18994	,	_
99-50	18995-18996	p	_
99-51	18996-18997	=	_
99-52	18997-19001	0.98	_
99-53	19001-19002	)	_
99-54	19003-19007	were	_
99-55	19008-19011	not	_
99-56	19012-19023	significant	_
99-57	19023-19024	.	_

#Text=This pattern was also seen at the level of univariate correlations between clinical and sMRI measures were small (r values) not significant after correction for multiple comparisons (Supplementary Figure 3A and B).
100-1	19025-19029	This	_
100-2	19030-19037	pattern	_
100-3	19038-19041	was	_
100-4	19042-19046	also	_
100-5	19047-19051	seen	_
100-6	19052-19054	at	_
100-7	19055-19058	the	_
100-8	19059-19064	level	_
100-9	19065-19067	of	_
100-10	19068-19078	univariate	_
100-11	19079-19091	correlations	_
100-12	19092-19099	between	_
100-13	19100-19108	clinical	_
100-14	19109-19112	and	_
100-15	19113-19117	sMRI	_
100-16	19118-19126	measures	_
100-17	19127-19131	were	_
100-18	19132-19137	small	_
100-19	19138-19139	(	_
100-20	19139-19140	r	_
100-21	19141-19147	values	_
100-22	19147-19148	)	_
100-23	19149-19152	not	_
100-24	19153-19164	significant	_
100-25	19165-19170	after	_
100-26	19171-19181	correction	_
100-27	19182-19185	for	_
100-28	19186-19194	multiple	_
100-29	19195-19206	comparisons	_
100-30	19207-19208	(	_
100-31	19208-19221	Supplementary	_
100-32	19222-19228	Figure	_
100-33	19229-19231	3A	_
100-34	19232-19235	and	_
100-35	19236-19237	B	_
100-36	19237-19238	)	_
100-37	19238-19239	.	_

#Text=Brain functional connectivity predictors of clinical response
#Text=Only the first mode of the sCCA of the clinical and rs-fMRI datasets was significant (r=0.70, p=0.04) (Figure 2A).
101-1	19240-19245	Brain	_
101-2	19246-19256	functional	_
101-3	19257-19269	connectivity	_
101-4	19270-19280	predictors	_
101-5	19281-19283	of	_
101-6	19284-19292	clinical	_
101-7	19293-19301	response	_
101-8	19302-19306	Only	_
101-9	19307-19310	the	_
101-10	19311-19316	first	_
101-11	19317-19321	mode	_
101-12	19322-19324	of	_
101-13	19325-19328	the	_
101-14	19329-19333	sCCA	_
101-15	19334-19336	of	_
101-16	19337-19340	the	_
101-17	19341-19349	clinical	_
101-18	19350-19353	and	_
101-19	19354-19361	rs-fMRI	_
101-20	19362-19370	datasets	_
101-21	19371-19374	was	_
101-22	19375-19386	significant	_
101-23	19387-19388	(	_
101-24	19388-19389	r	_
101-25	19389-19390	=	_
101-26	19390-19394	0.70	_
101-27	19394-19395	,	_
101-28	19396-19397	p	_
101-29	19397-19398	=	_
101-30	19398-19402	0.04	_
101-31	19402-19403	)	_
101-32	19404-19405	(	_
101-33	19405-19411	Figure	_
101-34	19412-19414	2A	_
101-35	19414-19415	)	_
101-36	19415-19416	.	_

#Text=The weight of the association with imaging variate was highest for positive symptoms (weight=0.62) followed by anxiety/depression (weight=0.49), negative symptoms (weight=0.33) and agitation/disorganization (weight=0.32) (Figure 2B).
102-1	19417-19420	The	_
102-2	19421-19427	weight	_
102-3	19428-19430	of	_
102-4	19431-19434	the	_
102-5	19435-19446	association	_
102-6	19447-19451	with	_
102-7	19452-19459	imaging	_
102-8	19460-19467	variate	_
102-9	19468-19471	was	_
102-10	19472-19479	highest	_
102-11	19480-19483	for	_
102-12	19484-19492	positive	_
102-13	19493-19501	symptoms	_
102-14	19502-19503	(	_
102-15	19503-19509	weight	_
102-16	19509-19510	=	_
102-17	19510-19514	0.62	_
102-18	19514-19515	)	_
102-19	19516-19524	followed	_
102-20	19525-19527	by	_
102-21	19528-19535	anxiety	_
102-22	19535-19536	/	_
102-23	19536-19546	depression	_
102-24	19547-19548	(	_
102-25	19548-19554	weight	_
102-26	19554-19555	=	_
102-27	19555-19559	0.49	_
102-28	19559-19560	)	_
102-29	19560-19561	,	_
102-30	19562-19570	negative	_
102-31	19571-19579	symptoms	_
102-32	19580-19581	(	_
102-33	19581-19587	weight	_
102-34	19587-19588	=	_
102-35	19588-19592	0.33	_
102-36	19592-19593	)	_
102-37	19594-19597	and	_
102-38	19598-19607	agitation	_
102-39	19607-19608	/	_
102-40	19608-19623	disorganization	_
102-41	19624-19625	(	_
102-42	19625-19631	weight	_
102-43	19631-19632	=	_
102-44	19632-19636	0.32	_
102-45	19636-19637	)	_
102-46	19638-19639	(	_
102-47	19639-19645	Figure	_
102-48	19646-19648	2B	_
102-49	19648-19649	)	_
102-50	19649-19650	.	_

#Text=The weights for BMI or antipsychotic dose were zero.
103-1	19651-19654	The	_
103-2	19655-19662	weights	_
103-3	19663-19666	for	_
103-4	19667-19670	BMI	_
103-5	19671-19673	or	_
103-6	19674-19687	antipsychotic	_
103-7	19688-19692	dose	_
103-8	19693-19697	were	_
103-9	19698-19702	zero	_
103-10	19702-19703	.	_

#Text=The association between clinical variables and the rs-fMRI variate was higher for women (Supplementary Figure 4); however, removal of sex did not change the overall results.
104-1	19704-19707	The	_
104-2	19708-19719	association	_
104-3	19720-19727	between	_
104-4	19728-19736	clinical	_
104-5	19737-19746	variables	_
104-6	19747-19750	and	_
104-7	19751-19754	the	_
104-8	19755-19762	rs-fMRI	_
104-9	19763-19770	variate	_
104-10	19771-19774	was	_
104-11	19775-19781	higher	_
104-12	19782-19785	for	_
104-13	19786-19791	women	_
104-14	19792-19793	(	_
104-15	19793-19806	Supplementary	_
104-16	19807-19813	Figure	_
104-17	19814-19815	4	_
104-18	19815-19816	)	_
104-19	19816-19817	;	_
104-20	19818-19825	however	_
104-21	19825-19826	,	_
104-22	19827-19834	removal	_
104-23	19835-19837	of	_
104-24	19838-19841	sex	_
104-25	19842-19845	did	_
104-26	19846-19849	not	_
104-27	19850-19856	change	_
104-28	19857-19860	the	_
104-29	19861-19868	overall	_
104-30	19869-19876	results	_
104-31	19876-19877	.	_

#Text=We focus on variables with at least moderate absolute weights (≥0.20, Figure 3) and we provide details of all the weights of association between the rs-fMRI measures and the clinical variate in Supplementary Table 4.
105-1	19878-19880	We	_
105-2	19881-19886	focus	_
105-3	19887-19889	on	_
105-4	19890-19899	variables	_
105-5	19900-19904	with	_
105-6	19905-19907	at	_
105-7	19908-19913	least	_
105-8	19914-19922	moderate	_
105-9	19923-19931	absolute	_
105-10	19932-19939	weights	_
105-11	19940-19941	(	_
105-12	19941-19942	≥	_
105-13	19942-19946	0.20	_
105-14	19946-19947	,	_
105-15	19948-19954	Figure	_
105-16	19955-19956	3	_
105-17	19956-19957	)	_
105-18	19958-19961	and	_
105-19	19962-19964	we	_
105-20	19965-19972	provide	_
105-21	19973-19980	details	_
105-22	19981-19983	of	_
105-23	19984-19987	all	_
105-24	19988-19991	the	_
105-25	19992-19999	weights	_
105-26	20000-20002	of	_
105-27	20003-20014	association	_
105-28	20015-20022	between	_
105-29	20023-20026	the	_
105-30	20027-20034	rs-fMRI	_
105-31	20035-20043	measures	_
105-32	20044-20047	and	_
105-33	20048-20051	the	_
105-34	20052-20060	clinical	_
105-35	20061-20068	variate	_
105-36	20069-20071	in	_
105-37	20072-20085	Supplementary	_
105-38	20086-20091	Table	_
105-39	20092-20093	4	_
105-40	20093-20094	.	_

#Text=Positive weights indicate that the corresponding variables are positive predictors while negative weights denote negative predictors.
106-1	20095-20103	Positive	_
106-2	20104-20111	weights	_
106-3	20112-20120	indicate	_
106-4	20121-20125	that	_
106-5	20126-20129	the	_
106-6	20130-20143	corresponding	_
106-7	20144-20153	variables	_
106-8	20154-20157	are	_
106-9	20158-20166	positive	_
106-10	20167-20177	predictors	_
106-11	20178-20183	while	_
106-12	20184-20192	negative	_
106-13	20193-20200	weights	_
106-14	20201-20207	denote	_
106-15	20208-20216	negative	_
106-16	20217-20227	predictors	_
106-17	20227-20228	.	_

#Text=Higher functional integration of DMN subnetworks (DMN1 with DMN4 and DMN5), and particularly higher connectivity between medial temporal regions and the dorsal precuneus (PCu), emerged as the main positive predictor of response (Figure 3).
107-1	20229-20235	Higher	_
107-2	20236-20246	functional	_
107-3	20247-20258	integration	_
107-4	20259-20261	of	_
107-5	20262-20265	DMN	_
107-6	20266-20277	subnetworks	_
107-7	20278-20279	(	_
107-8	20279-20283	DMN1	_
107-9	20284-20288	with	_
107-10	20289-20293	DMN4	_
107-11	20294-20297	and	_
107-12	20298-20302	DMN5	_
107-13	20302-20303	)	_
107-14	20303-20304	,	_
107-15	20305-20308	and	_
107-16	20309-20321	particularly	_
107-17	20322-20328	higher	_
107-18	20329-20341	connectivity	_
107-19	20342-20349	between	_
107-20	20350-20356	medial	_
107-21	20357-20365	temporal	_
107-22	20366-20373	regions	_
107-23	20374-20377	and	_
107-24	20378-20381	the	_
107-25	20382-20388	dorsal	_
107-26	20389-20398	precuneus	_
107-27	20399-20400	(	_
107-28	20400-20403	PCu	_
107-29	20403-20404	)	_
107-30	20404-20405	,	_
107-31	20406-20413	emerged	_
107-32	20414-20416	as	_
107-33	20417-20420	the	_
107-34	20421-20425	main	_
107-35	20426-20434	positive	_
107-36	20435-20444	predictor	_
107-37	20445-20447	of	_
107-38	20448-20456	response	_
107-39	20457-20458	(	_
107-40	20458-20464	Figure	_
107-41	20465-20466	3	_
107-42	20466-20467	)	_
107-43	20467-20468	.	_

#Text=The negative predictors comprised features of cross-network integration and within-network cohesiveness.
108-1	20469-20472	The	_
108-2	20473-20481	negative	_
108-3	20482-20492	predictors	_
108-4	20493-20502	comprised	_
108-5	20503-20511	features	_
108-6	20512-20514	of	_
108-7	20515-20528	cross-network	_
108-8	20529-20540	integration	_
108-9	20541-20544	and	_
108-10	20545-20559	within-network	_
108-11	20560-20572	cohesiveness	_
108-12	20572-20573	.	_

#Text=Key negative predictors consisted of the connectivity between the DMN3 and SMN2 (i.e., functional connectivity between the PCu/posterior cingulate cortex and sensorimotor cortices), between the DMN5 and SAL (i.e., functional connectivity between the PCu and regions of the salience network that mainly involve the insula and anterior cingulate cortex) and between the CEN1 and the VIS1 (i.e., functional connectivity between the lateral frontoparietal and lateral visual cortices) (Figure 3).
109-1	20574-20577	Key	_
109-2	20578-20586	negative	_
109-3	20587-20597	predictors	_
109-4	20598-20607	consisted	_
109-5	20608-20610	of	_
109-6	20611-20614	the	_
109-7	20615-20627	connectivity	_
109-8	20628-20635	between	_
109-9	20636-20639	the	_
109-10	20640-20644	DMN3	_
109-11	20645-20648	and	_
109-12	20649-20653	SMN2	_
109-13	20654-20655	(	_
109-14	20655-20658	i.e	_
109-15	20658-20659	.	_
109-16	20659-20660	,	_
109-17	20661-20671	functional	_
109-18	20672-20684	connectivity	_
109-19	20685-20692	between	_
109-20	20693-20696	the	_
109-21	20697-20700	PCu	_
109-22	20700-20701	/	_
109-23	20701-20710	posterior	_
109-24	20711-20720	cingulate	_
109-25	20721-20727	cortex	_
109-26	20728-20731	and	_
109-27	20732-20744	sensorimotor	_
109-28	20745-20753	cortices	_
109-29	20753-20754	)	_
109-30	20754-20755	,	_
109-31	20756-20763	between	_
109-32	20764-20767	the	_
109-33	20768-20772	DMN5	_
109-34	20773-20776	and	_
109-35	20777-20780	SAL	_
109-36	20781-20782	(	_
109-37	20782-20785	i.e	_
109-38	20785-20786	.	_
109-39	20786-20787	,	_
109-40	20788-20798	functional	_
109-41	20799-20811	connectivity	_
109-42	20812-20819	between	_
109-43	20820-20823	the	_
109-44	20824-20827	PCu	_
109-45	20828-20831	and	_
109-46	20832-20839	regions	_
109-47	20840-20842	of	_
109-48	20843-20846	the	_
109-49	20847-20855	salience	_
109-50	20856-20863	network	_
109-51	20864-20868	that	_
109-52	20869-20875	mainly	_
109-53	20876-20883	involve	_
109-54	20884-20887	the	_
109-55	20888-20894	insula	_
109-56	20895-20898	and	_
109-57	20899-20907	anterior	_
109-58	20908-20917	cingulate	_
109-59	20918-20924	cortex	_
109-60	20924-20925	)	_
109-61	20926-20929	and	_
109-62	20930-20937	between	_
109-63	20938-20941	the	_
109-64	20942-20946	CEN1	_
109-65	20947-20950	and	_
109-66	20951-20954	the	_
109-67	20955-20959	VIS1	_
109-68	20960-20961	(	_
109-69	20961-20964	i.e	_
109-70	20964-20965	.	_
109-71	20965-20966	,	_
109-72	20967-20977	functional	_
109-73	20978-20990	connectivity	_
109-74	20991-20998	between	_
109-75	20999-21002	the	_
109-76	21003-21010	lateral	_
109-77	21011-21025	frontoparietal	_
109-78	21026-21029	and	_
109-79	21030-21037	lateral	_
109-80	21038-21044	visual	_
109-81	21045-21053	cortices	_
109-82	21053-21054	)	_
109-83	21055-21056	(	_
109-84	21056-21062	Figure	_
109-85	21063-21064	3	_
109-86	21064-21065	)	_
109-87	21065-21066	.	_

#Text=Key functional cohesiveness predictors implicated the CEN1 (comprising frontoparietal regions) and CEN3 (comprising the thalamus, striatum and posterior hippocampus).
110-1	21067-21070	Key	_
110-2	21071-21081	functional	_
110-3	21082-21094	cohesiveness	_
110-4	21095-21105	predictors	_
110-5	21106-21116	implicated	_
110-6	21117-21120	the	_
110-7	21121-21125	CEN1	_
110-8	21126-21127	(	_
110-9	21127-21137	comprising	_
110-10	21138-21152	frontoparietal	_
110-11	21153-21160	regions	_
110-12	21160-21161	)	_
110-13	21162-21165	and	_
110-14	21166-21170	CEN3	_
110-15	21171-21172	(	_
110-16	21172-21182	comprising	_
110-17	21183-21186	the	_
110-18	21187-21195	thalamus	_
110-19	21195-21196	,	_
110-20	21197-21205	striatum	_
110-21	21206-21209	and	_
110-22	21210-21219	posterior	_
110-23	21220-21231	hippocampus	_
110-24	21231-21232	)	_
110-25	21232-21233	.	_

#Text=Supplemental Results
#Text=As detailed in SI, adopting a categorical approach to data analysis did not yield statistically significant results suggesting that remission and non-remission are more likely to represent a continuum rather than biological distinct states.
111-1	21234-21246	Supplemental	_
111-2	21247-21254	Results	_
111-3	21255-21257	As	_
111-4	21258-21266	detailed	_
111-5	21267-21269	in	_
111-6	21270-21272	SI	_
111-7	21272-21273	,	_
111-8	21274-21282	adopting	_
111-9	21283-21284	a	_
111-10	21285-21296	categorical	_
111-11	21297-21305	approach	_
111-12	21306-21308	to	_
111-13	21309-21313	data	_
111-14	21314-21322	analysis	_
111-15	21323-21326	did	_
111-16	21327-21330	not	_
111-17	21331-21336	yield	_
111-18	21337-21350	statistically	_
111-19	21351-21362	significant	_
111-20	21363-21370	results	_
111-21	21371-21381	suggesting	_
111-22	21382-21386	that	_
111-23	21387-21396	remission	_
111-24	21397-21400	and	_
111-25	21401-21414	non-remission	_
111-26	21415-21418	are	_
111-27	21419-21423	more	_
111-28	21424-21430	likely	_
111-29	21431-21433	to	_
111-30	21434-21443	represent	_
111-31	21444-21445	a	_
111-32	21446-21455	continuum	_
111-33	21456-21462	rather	_
111-34	21463-21467	than	_
111-35	21468-21478	biological	_
111-36	21479-21487	distinct	_
111-37	21488-21494	states	_
111-38	21494-21495	.	_

#Text=Discussion
#Text=We investigated the role of baseline sMRI and rs-fMRI measures as predictors of symptomatic improvement in response to antipsychotic treatment in the early course of schizophrenia.
112-1	21496-21506	Discussion	_
112-2	21507-21509	We	_
112-3	21510-21522	investigated	_
112-4	21523-21526	the	_
112-5	21527-21531	role	_
112-6	21532-21534	of	_
112-7	21535-21543	baseline	_
112-8	21544-21548	sMRI	_
112-9	21549-21552	and	_
112-10	21553-21560	rs-fMRI	_
112-11	21561-21569	measures	_
112-12	21570-21572	as	_
112-13	21573-21583	predictors	_
112-14	21584-21586	of	_
112-15	21587-21598	symptomatic	_
112-16	21599-21610	improvement	_
112-17	21611-21613	in	_
112-18	21614-21622	response	_
112-19	21623-21625	to	_
112-20	21626-21639	antipsychotic	_
112-21	21640-21649	treatment	_
112-22	21650-21652	in	_
112-23	21653-21656	the	_
112-24	21657-21662	early	_
112-25	21663-21669	course	_
112-26	21670-21672	of	_
112-27	21673-21686	schizophrenia	_
112-28	21686-21687	.	_

#Text=The present results establish the importance of system-level functional brain organization and clinical response.
113-1	21688-21691	The	_
113-2	21692-21699	present	_
113-3	21700-21707	results	_
113-4	21708-21717	establish	_
113-5	21718-21721	the	_
113-6	21722-21732	importance	_
113-7	21733-21735	of	_
113-8	21736-21748	system-level	_
113-9	21749-21759	functional	_
113-10	21760-21765	brain	_
113-11	21766-21778	organization	_
113-12	21779-21782	and	_
113-13	21783-21791	clinical	_
113-14	21792-21800	response	_
113-15	21800-21801	.	_

#Text=Specifically, the cohesiveness of the DMN and CEN and their cross-network integration with the salience, somatosensory and visual networks emerged as key predictors of short-term symptomatic change in schizophrenia.
114-1	21802-21814	Specifically	_
114-2	21814-21815	,	_
114-3	21816-21819	the	_
114-4	21820-21832	cohesiveness	_
114-5	21833-21835	of	_
114-6	21836-21839	the	_
114-7	21840-21843	DMN	_
114-8	21844-21847	and	_
114-9	21848-21851	CEN	_
114-10	21852-21855	and	_
114-11	21856-21861	their	_
114-12	21862-21875	cross-network	_
114-13	21876-21887	integration	_
114-14	21888-21892	with	_
114-15	21893-21896	the	_
114-16	21897-21905	salience	_
114-17	21905-21906	,	_
114-18	21907-21920	somatosensory	_
114-19	21921-21924	and	_
114-20	21925-21931	visual	_
114-21	21932-21940	networks	_
114-22	21941-21948	emerged	_
114-23	21949-21951	as	_
114-24	21952-21955	key	_
114-25	21956-21966	predictors	_
114-26	21967-21969	of	_
114-27	21970-21980	short-term	_
114-28	21981-21992	symptomatic	_
114-29	21993-21999	change	_
114-30	22000-22002	in	_
114-31	22003-22016	schizophrenia	_
114-32	22016-22017	.	_

#Text=Moreover, our supplemental analyses argue against the notion that remission can be predicted by distinct functional connectivity features and suggest that short-term symptomatic change in schizophrenia is dimensionally linked to alterations in functional connectivity.
115-1	22018-22026	Moreover	_
115-2	22026-22027	,	_
115-3	22028-22031	our	_
115-4	22032-22044	supplemental	_
115-5	22045-22053	analyses	_
115-6	22054-22059	argue	_
115-7	22060-22067	against	_
115-8	22068-22071	the	_
115-9	22072-22078	notion	_
115-10	22079-22083	that	_
115-11	22084-22093	remission	_
115-12	22094-22097	can	_
115-13	22098-22100	be	_
115-14	22101-22110	predicted	_
115-15	22111-22113	by	_
115-16	22114-22122	distinct	_
115-17	22123-22133	functional	_
115-18	22134-22146	connectivity	_
115-19	22147-22155	features	_
115-20	22156-22159	and	_
115-21	22160-22167	suggest	_
115-22	22168-22172	that	_
115-23	22173-22183	short-term	_
115-24	22184-22195	symptomatic	_
115-25	22196-22202	change	_
115-26	22203-22205	in	_
115-27	22206-22219	schizophrenia	_
115-28	22220-22222	is	_
115-29	22223-22236	dimensionally	_
115-30	22237-22243	linked	_
115-31	22244-22246	to	_
115-32	22247-22258	alterations	_
115-33	22259-22261	in	_
115-34	22262-22272	functional	_
115-35	22273-22285	connectivity	_
115-36	22285-22286	.	_

#Text=These findings can be best understood within the context of the developmental trajectories and organizational principles of the human connectome.
116-1	22287-22292	These	_
116-2	22293-22301	findings	_
116-3	22302-22305	can	_
116-4	22306-22308	be	_
116-5	22309-22313	best	_
116-6	22314-22324	understood	_
116-7	22325-22331	within	_
116-8	22332-22335	the	_
116-9	22336-22343	context	_
116-10	22344-22346	of	_
116-11	22347-22350	the	_
116-12	22351-22364	developmental	_
116-13	22365-22377	trajectories	_
116-14	22378-22381	and	_
116-15	22382-22396	organizational	_
116-16	22397-22407	principles	_
116-17	22408-22410	of	_
116-18	22411-22414	the	_
116-19	22415-22420	human	_
116-20	22421-22431	connectome	_
116-21	22431-22432	.	_

#Text=At the highest level, the functional connectome of healthy adults is intrinsically organized into two anticorrelated large-scale neural systems: the DMN which comprises midline brain regions associated with unconstrained mental activity and a neural system preferentially engaged by goal-directed cognition and sensorimotor processes.
117-1	22433-22435	At	_
117-2	22436-22439	the	_
117-3	22440-22447	highest	_
117-4	22448-22453	level	_
117-5	22453-22454	,	_
117-6	22455-22458	the	_
117-7	22459-22469	functional	_
117-8	22470-22480	connectome	_
117-9	22481-22483	of	_
117-10	22484-22491	healthy	_
117-11	22492-22498	adults	_
117-12	22499-22501	is	_
117-13	22502-22515	intrinsically	_
117-14	22516-22525	organized	_
117-15	22526-22530	into	_
117-16	22531-22534	two	_
117-17	22535-22549	anticorrelated	_
117-18	22550-22561	large-scale	_
117-19	22562-22568	neural	_
117-20	22569-22576	systems	_
117-21	22576-22577	:	_
117-22	22578-22581	the	_
117-23	22582-22585	DMN	_
117-24	22586-22591	which	_
117-25	22592-22601	comprises	_
117-26	22602-22609	midline	_
117-27	22610-22615	brain	_
117-28	22616-22623	regions	_
117-29	22624-22634	associated	_
117-30	22635-22639	with	_
117-31	22640-22653	unconstrained	_
117-32	22654-22660	mental	_
117-33	22661-22669	activity	_
117-34	22670-22673	and	_
117-35	22674-22675	a	_
117-36	22676-22682	neural	_
117-37	22683-22689	system	_
117-38	22690-22704	preferentially	_
117-39	22705-22712	engaged	_
117-40	22713-22715	by	_
117-41	22716-22729	goal-directed	_
117-42	22730-22739	cognition	_
117-43	22740-22743	and	_
117-44	22744-22756	sensorimotor	_
117-45	22757-22766	processes	_
117-46	22766-22767	.	_

#Text=The latter is functionally distinguished into higher-order networks, notably the CEN (concerned with maintenance and manipulation of goal-directed mental operations) and the SAL (involved in switching activity between the DMN to CEN) and in lower-order sensory and motor networks.
118-1	22768-22771	The	_
118-2	22772-22778	latter	_
118-3	22779-22781	is	_
118-4	22782-22794	functionally	_
118-5	22795-22808	distinguished	_
118-6	22809-22813	into	_
118-7	22814-22826	higher-order	_
118-8	22827-22835	networks	_
118-9	22835-22836	,	_
118-10	22837-22844	notably	_
118-11	22845-22848	the	_
118-12	22849-22852	CEN	_
118-13	22853-22854	(	_
118-14	22854-22863	concerned	_
118-15	22864-22868	with	_
118-16	22869-22880	maintenance	_
118-17	22881-22884	and	_
118-18	22885-22897	manipulation	_
118-19	22898-22900	of	_
118-20	22901-22914	goal-directed	_
118-21	22915-22921	mental	_
118-22	22922-22932	operations	_
118-23	22932-22933	)	_
118-24	22934-22937	and	_
118-25	22938-22941	the	_
118-26	22942-22945	SAL	_
118-27	22946-22947	(	_
118-28	22947-22955	involved	_
118-29	22956-22958	in	_
118-30	22959-22968	switching	_
118-31	22969-22977	activity	_
118-32	22978-22985	between	_
118-33	22986-22989	the	_
118-34	22990-22993	DMN	_
118-35	22994-22996	to	_
118-36	22997-23000	CEN	_
118-37	23000-23001	)	_
118-38	23002-23005	and	_
118-39	23006-23008	in	_
118-40	23009-23020	lower-order	_
118-41	23021-23028	sensory	_
118-42	23029-23032	and	_
118-43	23033-23038	motor	_
118-44	23039-23047	networks	_
118-45	23047-23048	.	_

#Text=Transition from childhood to adulthood typically is associated with changes in the intrinsic functional connectivity of these networks.
119-1	23049-23059	Transition	_
119-2	23060-23064	from	_
119-3	23065-23074	childhood	_
119-4	23075-23077	to	_
119-5	23078-23087	adulthood	_
119-6	23088-23097	typically	_
119-7	23098-23100	is	_
119-8	23101-23111	associated	_
119-9	23112-23116	with	_
119-10	23117-23124	changes	_
119-11	23125-23127	in	_
119-12	23128-23131	the	_
119-13	23132-23141	intrinsic	_
119-14	23142-23152	functional	_
119-15	23153-23165	connectivity	_
119-16	23166-23168	of	_
119-17	23169-23174	these	_
119-18	23175-23183	networks	_
119-19	23183-23184	.	_

#Text=For the DMN this entails greater intra-network cohesiveness and greater inter-network integration with the higher-order networks.
120-1	23185-23188	For	_
120-2	23189-23192	the	_
120-3	23193-23196	DMN	_
120-4	23197-23201	this	_
120-5	23202-23209	entails	_
120-6	23210-23217	greater	_
120-7	23218-23231	intra-network	_
120-8	23232-23244	cohesiveness	_
120-9	23245-23248	and	_
120-10	23249-23256	greater	_
120-11	23257-23270	inter-network	_
120-12	23271-23282	integration	_
120-13	23283-23287	with	_
120-14	23288-23291	the	_
120-15	23292-23304	higher-order	_
120-16	23305-23313	networks	_
120-17	23313-23314	.	_

#Text=Gu et al. proposed that this pattern of connectivity allows the DMN to function as cohesive driver of intrinsic brain function that supports a range of mental operations relating mostly to self-referential processes and spontaneous thought.
121-1	23315-23317	Gu	_
121-2	23318-23320	et	_
121-3	23321-23323	al	_
121-4	23323-23324	.	_
121-5	23325-23333	proposed	_
121-6	23334-23338	that	_
121-7	23339-23343	this	_
121-8	23344-23351	pattern	_
121-9	23352-23354	of	_
121-10	23355-23367	connectivity	_
121-11	23368-23374	allows	_
121-12	23375-23378	the	_
121-13	23379-23382	DMN	_
121-14	23383-23385	to	_
121-15	23386-23394	function	_
121-16	23395-23397	as	_
121-17	23398-23406	cohesive	_
121-18	23407-23413	driver	_
121-19	23414-23416	of	_
121-20	23417-23426	intrinsic	_
121-21	23427-23432	brain	_
121-22	23433-23441	function	_
121-23	23442-23446	that	_
121-24	23447-23455	supports	_
121-25	23456-23457	a	_
121-26	23458-23463	range	_
121-27	23464-23466	of	_
121-28	23467-23473	mental	_
121-29	23474-23484	operations	_
121-30	23485-23493	relating	_
121-31	23494-23500	mostly	_
121-32	23501-23503	to	_
121-33	23504-23520	self-referential	_
121-34	23521-23530	processes	_
121-35	23531-23534	and	_
121-36	23535-23546	spontaneous	_
121-37	23547-23554	thought	_
121-38	23554-23555	.	_

#Text=The development of critical DMN connectivity may be disrupted in schizophrenia based on previous reports of reduced functional cohesiveness between DMN nodes and particularly the hippocampus, coupled with hyperconnectivty of the posterior DMN with brain regions outside the network.
122-1	23556-23559	The	_
122-2	23560-23571	development	_
122-3	23572-23574	of	_
122-4	23575-23583	critical	_
122-5	23584-23587	DMN	_
122-6	23588-23600	connectivity	_
122-7	23601-23604	may	_
122-8	23605-23607	be	_
122-9	23608-23617	disrupted	_
122-10	23618-23620	in	_
122-11	23621-23634	schizophrenia	_
122-12	23635-23640	based	_
122-13	23641-23643	on	_
122-14	23644-23652	previous	_
122-15	23653-23660	reports	_
122-16	23661-23663	of	_
122-17	23664-23671	reduced	_
122-18	23672-23682	functional	_
122-19	23683-23695	cohesiveness	_
122-20	23696-23703	between	_
122-21	23704-23707	DMN	_
122-22	23708-23713	nodes	_
122-23	23714-23717	and	_
122-24	23718-23730	particularly	_
122-25	23731-23734	the	_
122-26	23735-23746	hippocampus	_
122-27	23746-23747	,	_
122-28	23748-23755	coupled	_
122-29	23756-23760	with	_
122-30	23761-23777	hyperconnectivty	_
122-31	23778-23780	of	_
122-32	23781-23784	the	_
122-33	23785-23794	posterior	_
122-34	23795-23798	DMN	_
122-35	23799-23803	with	_
122-36	23804-23809	brain	_
122-37	23810-23817	regions	_
122-38	23818-23825	outside	_
122-39	23826-23829	the	_
122-40	23830-23837	network	_
122-41	23837-23838	.	_

#Text=In the present study, higher intranetwork cohesiveness and lower cross-network connectivity of the DMN were associated with symptomatic improvement (Figure 3).
123-1	23839-23841	In	_
123-2	23842-23845	the	_
123-3	23846-23853	present	_
123-4	23854-23859	study	_
123-5	23859-23860	,	_
123-6	23861-23867	higher	_
123-7	23868-23880	intranetwork	_
123-8	23881-23893	cohesiveness	_
123-9	23894-23897	and	_
123-10	23898-23903	lower	_
123-11	23904-23917	cross-network	_
123-12	23918-23930	connectivity	_
123-13	23931-23933	of	_
123-14	23934-23937	the	_
123-15	23938-23941	DMN	_
123-16	23942-23946	were	_
123-17	23947-23957	associated	_
123-18	23958-23962	with	_
123-19	23963-23974	symptomatic	_
123-20	23975-23986	improvement	_
123-21	23987-23988	(	_
123-22	23988-23994	Figure	_
123-23	23995-23996	3	_
123-24	23996-23997	)	_
123-25	23997-23998	.	_

#Text=These findings complement previous observations and indicate that the functional properties of the DMN may play a pivotal role both in disease expression and in treatment response in schizophrenia.
124-1	23999-24004	These	_
124-2	24005-24013	findings	_
124-3	24014-24024	complement	_
124-4	24025-24033	previous	_
124-5	24034-24046	observations	_
124-6	24047-24050	and	_
124-7	24051-24059	indicate	_
124-8	24060-24064	that	_
124-9	24065-24068	the	_
124-10	24069-24079	functional	_
124-11	24080-24090	properties	_
124-12	24091-24093	of	_
124-13	24094-24097	the	_
124-14	24098-24101	DMN	_
124-15	24102-24105	may	_
124-16	24106-24110	play	_
124-17	24111-24112	a	_
124-18	24113-24120	pivotal	_
124-19	24121-24125	role	_
124-20	24126-24130	both	_
124-21	24131-24133	in	_
124-22	24134-24141	disease	_
124-23	24142-24152	expression	_
124-24	24153-24156	and	_
124-25	24157-24159	in	_
124-26	24160-24169	treatment	_
124-27	24170-24178	response	_
124-28	24179-24181	in	_
124-29	24182-24195	schizophrenia	_
124-30	24195-24196	.	_

#Text=In higher-order networks typical development is associated with decreased intra-network cohesiveness indicating that in the adult brain the nodes of these networks show inherently divergent activity profiles, that likely reflect their engagement in numerous and diverse cognitive operations.
125-1	24197-24199	In	_
125-2	24200-24212	higher-order	_
125-3	24213-24221	networks	_
125-4	24222-24229	typical	_
125-5	24230-24241	development	_
125-6	24242-24244	is	_
125-7	24245-24255	associated	_
125-8	24256-24260	with	_
125-9	24261-24270	decreased	_
125-10	24271-24284	intra-network	_
125-11	24285-24297	cohesiveness	_
125-12	24298-24308	indicating	_
125-13	24309-24313	that	_
125-14	24314-24316	in	_
125-15	24317-24320	the	_
125-16	24321-24326	adult	_
125-17	24327-24332	brain	_
125-18	24333-24336	the	_
125-19	24337-24342	nodes	_
125-20	24343-24345	of	_
125-21	24346-24351	these	_
125-22	24352-24360	networks	_
125-23	24361-24365	show	_
125-24	24366-24376	inherently	_
125-25	24377-24386	divergent	_
125-26	24387-24395	activity	_
125-27	24396-24404	profiles	_
125-28	24404-24405	,	_
125-29	24406-24410	that	_
125-30	24411-24417	likely	_
125-31	24418-24425	reflect	_
125-32	24426-24431	their	_
125-33	24432-24442	engagement	_
125-34	24443-24445	in	_
125-35	24446-24454	numerous	_
125-36	24455-24458	and	_
125-37	24459-24466	diverse	_
125-38	24467-24476	cognitive	_
125-39	24477-24487	operations	_
125-40	24487-24488	.	_

#Text=The present results implicate mainly the CEN which is known to support multiple aspects of cognitive and attentional control and in goal-directed selection of stimuli and responses.
126-1	24489-24492	The	_
126-2	24493-24500	present	_
126-3	24501-24508	results	_
126-4	24509-24518	implicate	_
126-5	24519-24525	mainly	_
126-6	24526-24529	the	_
126-7	24530-24533	CEN	_
126-8	24534-24539	which	_
126-9	24540-24542	is	_
126-10	24543-24548	known	_
126-11	24549-24551	to	_
126-12	24552-24559	support	_
126-13	24560-24568	multiple	_
126-14	24569-24576	aspects	_
126-15	24577-24579	of	_
126-16	24580-24589	cognitive	_
126-17	24590-24593	and	_
126-18	24594-24605	attentional	_
126-19	24606-24613	control	_
126-20	24614-24617	and	_
126-21	24618-24620	in	_
126-22	24621-24634	goal-directed	_
126-23	24635-24644	selection	_
126-24	24645-24647	of	_
126-25	24648-24655	stimuli	_
126-26	24656-24659	and	_
126-27	24660-24669	responses	_
126-28	24669-24670	.	_

#Text=Increased cohesiveness of the CEN has been associated with positive psychotic symptoms in schizophrenia and lower baseline cohesiveness within the subcortical subnetwork of the CEN has been shown to predict antipsychotic response.
127-1	24671-24680	Increased	_
127-2	24681-24693	cohesiveness	_
127-3	24694-24696	of	_
127-4	24697-24700	the	_
127-5	24701-24704	CEN	_
127-6	24705-24708	has	_
127-7	24709-24713	been	_
127-8	24714-24724	associated	_
127-9	24725-24729	with	_
127-10	24730-24738	positive	_
127-11	24739-24748	psychotic	_
127-12	24749-24757	symptoms	_
127-13	24758-24760	in	_
127-14	24761-24774	schizophrenia	_
127-15	24775-24778	and	_
127-16	24779-24784	lower	_
127-17	24785-24793	baseline	_
127-18	24794-24806	cohesiveness	_
127-19	24807-24813	within	_
127-20	24814-24817	the	_
127-21	24818-24829	subcortical	_
127-22	24830-24840	subnetwork	_
127-23	24841-24843	of	_
127-24	24844-24847	the	_
127-25	24848-24851	CEN	_
127-26	24852-24855	has	_
127-27	24856-24860	been	_
127-28	24861-24866	shown	_
127-29	24867-24869	to	_
127-30	24870-24877	predict	_
127-31	24878-24891	antipsychotic	_
127-32	24892-24900	response	_
127-33	24900-24901	.	_

#Text=In accordance with these reports, we found that higher cohesiveness with the frontoparietal and subcortical subnetworks of the CEN was a negative predictor of response.
128-1	24902-24904	In	_
128-2	24905-24915	accordance	_
128-3	24916-24920	with	_
128-4	24921-24926	these	_
128-5	24927-24934	reports	_
128-6	24934-24935	,	_
128-7	24936-24938	we	_
128-8	24939-24944	found	_
128-9	24945-24949	that	_
128-10	24950-24956	higher	_
128-11	24957-24969	cohesiveness	_
128-12	24970-24974	with	_
128-13	24975-24978	the	_
128-14	24979-24993	frontoparietal	_
128-15	24994-24997	and	_
128-16	24998-25009	subcortical	_
128-17	25010-25021	subnetworks	_
128-18	25022-25024	of	_
128-19	25025-25028	the	_
128-20	25029-25032	CEN	_
128-21	25033-25036	was	_
128-22	25037-25038	a	_
128-23	25039-25047	negative	_
128-24	25048-25057	predictor	_
128-25	25058-25060	of	_
128-26	25061-25069	response	_
128-27	25069-25070	.	_

#Text=Based on the multivariate analyses employed here, the predictive value of sMRI features for clinical response was not significant.
129-1	25071-25076	Based	_
129-2	25077-25079	on	_
129-3	25080-25083	the	_
129-4	25084-25096	multivariate	_
129-5	25097-25105	analyses	_
129-6	25106-25114	employed	_
129-7	25115-25119	here	_
129-8	25119-25120	,	_
129-9	25121-25124	the	_
129-10	25125-25135	predictive	_
129-11	25136-25141	value	_
129-12	25142-25144	of	_
129-13	25145-25149	sMRI	_
129-14	25150-25158	features	_
129-15	25159-25162	for	_
129-16	25163-25171	clinical	_
129-17	25172-25180	response	_
129-18	25181-25184	was	_
129-19	25185-25188	not	_
129-20	25189-25200	significant	_
129-21	25200-25201	.	_

#Text=Nevertheless, the univariate contrasts between responders and non-responders (described in the SI), although not statistical significant in the context of the multiple comparisons undertaken, implicated the hippocampus bilaterally, and thus align with previous literature.
130-1	25202-25214	Nevertheless	_
130-2	25214-25215	,	_
130-3	25216-25219	the	_
130-4	25220-25230	univariate	_
130-5	25231-25240	contrasts	_
130-6	25241-25248	between	_
130-7	25249-25259	responders	_
130-8	25260-25263	and	_
130-9	25264-25278	non-responders	_
130-10	25279-25280	(	_
130-11	25280-25289	described	_
130-12	25290-25292	in	_
130-13	25293-25296	the	_
130-14	25297-25299	SI	_
130-15	25299-25300	)	_
130-16	25300-25301	,	_
130-17	25302-25310	although	_
130-18	25311-25314	not	_
130-19	25315-25326	statistical	_
130-20	25327-25338	significant	_
130-21	25339-25341	in	_
130-22	25342-25345	the	_
130-23	25346-25353	context	_
130-24	25354-25356	of	_
130-25	25357-25360	the	_
130-26	25361-25369	multiple	_
130-27	25370-25381	comparisons	_
130-28	25382-25392	undertaken	_
130-29	25392-25393	,	_
130-30	25394-25404	implicated	_
130-31	25405-25408	the	_
130-32	25409-25420	hippocampus	_
130-33	25421-25432	bilaterally	_
130-34	25432-25433	,	_
130-35	25434-25437	and	_
130-36	25438-25442	thus	_
130-37	25443-25448	align	_
130-38	25449-25453	with	_
130-39	25454-25462	previous	_
130-40	25463-25473	literature	_
130-41	25473-25474	.	_

#Text=The present study has a number of strengths.
131-1	25475-25478	The	_
131-2	25479-25486	present	_
131-3	25487-25492	study	_
131-4	25493-25496	has	_
131-5	25497-25498	a	_
131-6	25499-25505	number	_
131-7	25506-25508	of	_
131-8	25509-25518	strengths	_
131-9	25518-25519	.	_

#Text=To our knowledge, this is the first study to capture the association between neuroimaging measures and clinical improvement across the entire spectrum of psychopathology without being limited to positive symptoms.
132-1	25520-25522	To	_
132-2	25523-25526	our	_
132-3	25527-25536	knowledge	_
132-4	25536-25537	,	_
132-5	25538-25542	this	_
132-6	25543-25545	is	_
132-7	25546-25549	the	_
132-8	25550-25555	first	_
132-9	25556-25561	study	_
132-10	25562-25564	to	_
132-11	25565-25572	capture	_
132-12	25573-25576	the	_
132-13	25577-25588	association	_
132-14	25589-25596	between	_
132-15	25597-25609	neuroimaging	_
132-16	25610-25618	measures	_
132-17	25619-25622	and	_
132-18	25623-25631	clinical	_
132-19	25632-25643	improvement	_
132-20	25644-25650	across	_
132-21	25651-25654	the	_
132-22	25655-25661	entire	_
132-23	25662-25670	spectrum	_
132-24	25671-25673	of	_
132-25	25674-25689	psychopathology	_
132-26	25690-25697	without	_
132-27	25698-25703	being	_
132-28	25704-25711	limited	_
132-29	25712-25714	to	_
132-30	25715-25723	positive	_
132-31	25724-25732	symptoms	_
132-32	25732-25733	.	_

#Text=We used continuous measures of clinical improvement that represent the actual structure of the symptom scores (Supplementary Figure 2).
133-1	25734-25736	We	_
133-2	25737-25741	used	_
133-3	25742-25752	continuous	_
133-4	25753-25761	measures	_
133-5	25762-25764	of	_
133-6	25765-25773	clinical	_
133-7	25774-25785	improvement	_
133-8	25786-25790	that	_
133-9	25791-25800	represent	_
133-10	25801-25804	the	_
133-11	25805-25811	actual	_
133-12	25812-25821	structure	_
133-13	25822-25824	of	_
133-14	25825-25828	the	_
133-15	25829-25836	symptom	_
133-16	25837-25843	scores	_
133-17	25844-25845	(	_
133-18	25845-25858	Supplementary	_
133-19	25859-25865	Figure	_
133-20	25866-25867	2	_
133-21	25867-25868	)	_
133-22	25868-25869	.	_

#Text=We used a data-driven approach that is conducive to discovery and is more stringent that hypothesis-led analyses that are limited to specific brain regions or networks.
134-1	25870-25872	We	_
134-2	25873-25877	used	_
134-3	25878-25879	a	_
134-4	25880-25891	data-driven	_
134-5	25892-25900	approach	_
134-6	25901-25905	that	_
134-7	25906-25908	is	_
134-8	25909-25918	conducive	_
134-9	25919-25921	to	_
134-10	25922-25931	discovery	_
134-11	25932-25935	and	_
134-12	25936-25938	is	_
134-13	25939-25943	more	_
134-14	25944-25953	stringent	_
134-15	25954-25958	that	_
134-16	25959-25973	hypothesis-led	_
134-17	25974-25982	analyses	_
134-18	25983-25987	that	_
134-19	25988-25991	are	_
134-20	25992-25999	limited	_
134-21	26000-26002	to	_
134-22	26003-26011	specific	_
134-23	26012-26017	brain	_
134-24	26018-26025	regions	_
134-25	26026-26028	or	_
134-26	26029-26037	networks	_
134-27	26037-26038	.	_

#Text=We demonstrated the reliability of our main results using alternate brain functional parcellations.
135-1	26039-26041	We	_
135-2	26042-26054	demonstrated	_
135-3	26055-26058	the	_
135-4	26059-26070	reliability	_
135-5	26071-26073	of	_
135-6	26074-26077	our	_
135-7	26078-26082	main	_
135-8	26083-26090	results	_
135-9	26091-26096	using	_
135-10	26097-26106	alternate	_
135-11	26107-26112	brain	_
135-12	26113-26123	functional	_
135-13	26124-26137	parcellations	_
135-14	26137-26138	.	_

#Text=In considering the study limitations, we note that currently available neuroimaging techniques include other modalities (such as diffusion weighted imaging) and other analytic methods (such as graph theory) that were not considered here.
136-1	26139-26141	In	_
136-2	26142-26153	considering	_
136-3	26154-26157	the	_
136-4	26158-26163	study	_
136-5	26164-26175	limitations	_
136-6	26175-26176	,	_
136-7	26177-26179	we	_
136-8	26180-26184	note	_
136-9	26185-26189	that	_
136-10	26190-26199	currently	_
136-11	26200-26209	available	_
136-12	26210-26222	neuroimaging	_
136-13	26223-26233	techniques	_
136-14	26234-26241	include	_
136-15	26242-26247	other	_
136-16	26248-26258	modalities	_
136-17	26259-26260	(	_
136-18	26260-26264	such	_
136-19	26265-26267	as	_
136-20	26268-26277	diffusion	_
136-21	26278-26286	weighted	_
136-22	26287-26294	imaging	_
136-23	26294-26295	)	_
136-24	26296-26299	and	_
136-25	26300-26305	other	_
136-26	26306-26314	analytic	_
136-27	26315-26322	methods	_
136-28	26323-26324	(	_
136-29	26324-26328	such	_
136-30	26329-26331	as	_
136-31	26332-26337	graph	_
136-32	26338-26344	theory	_
136-33	26344-26345	)	_
136-34	26346-26350	that	_
136-35	26351-26355	were	_
136-36	26356-26359	not	_
136-37	26360-26370	considered	_
136-38	26371-26375	here	_
136-39	26375-26376	.	_

#Text=We chose to focus on sMRI and rs-fMRI as these represent the most commonly used neuroimaging approaches in psychosis and are also easier to implement in clinical settings because of their relative brevity and lack of requirement for active patient engagement.
137-1	26377-26379	We	_
137-2	26380-26385	chose	_
137-3	26386-26388	to	_
137-4	26389-26394	focus	_
137-5	26395-26397	on	_
137-6	26398-26402	sMRI	_
137-7	26403-26406	and	_
137-8	26407-26414	rs-fMRI	_
137-9	26415-26417	as	_
137-10	26418-26423	these	_
137-11	26424-26433	represent	_
137-12	26434-26437	the	_
137-13	26438-26442	most	_
137-14	26443-26451	commonly	_
137-15	26452-26456	used	_
137-16	26457-26469	neuroimaging	_
137-17	26470-26480	approaches	_
137-18	26481-26483	in	_
137-19	26484-26493	psychosis	_
137-20	26494-26497	and	_
137-21	26498-26501	are	_
137-22	26502-26506	also	_
137-23	26507-26513	easier	_
137-24	26514-26516	to	_
137-25	26517-26526	implement	_
137-26	26527-26529	in	_
137-27	26530-26538	clinical	_
137-28	26539-26547	settings	_
137-29	26548-26555	because	_
137-30	26556-26558	of	_
137-31	26559-26564	their	_
137-32	26565-26573	relative	_
137-33	26574-26581	brevity	_
137-34	26582-26585	and	_
137-35	26586-26590	lack	_
137-36	26591-26593	of	_
137-37	26594-26605	requirement	_
137-38	26606-26609	for	_
137-39	26610-26616	active	_
137-40	26617-26624	patient	_
137-41	26625-26635	engagement	_
137-42	26635-26636	.	_

#Text=Sex differences have been reported in incidence, clinical characteristics and mental health service use in schizophrenia.
138-1	26637-26640	Sex	_
138-2	26641-26652	differences	_
138-3	26653-26657	have	_
138-4	26658-26662	been	_
138-5	26663-26671	reported	_
138-6	26672-26674	in	_
138-7	26675-26684	incidence	_
138-8	26684-26685	,	_
138-9	26686-26694	clinical	_
138-10	26695-26710	characteristics	_
138-11	26711-26714	and	_
138-12	26715-26721	mental	_
138-13	26722-26728	health	_
138-14	26729-26736	service	_
138-15	26737-26740	use	_
138-16	26741-26743	in	_
138-17	26744-26757	schizophrenia	_
138-18	26757-26758	.	_

#Text=Our sample included a higher proportion of men which is aligned with findings regarding sex differences in service use in the USA.
139-1	26759-26762	Our	_
139-2	26763-26769	sample	_
139-3	26770-26778	included	_
139-4	26779-26780	a	_
139-5	26781-26787	higher	_
139-6	26788-26798	proportion	_
139-7	26799-26801	of	_
139-8	26802-26805	men	_
139-9	26806-26811	which	_
139-10	26812-26814	is	_
139-11	26815-26822	aligned	_
139-12	26823-26827	with	_
139-13	26828-26836	findings	_
139-14	26837-26846	regarding	_
139-15	26847-26850	sex	_
139-16	26851-26862	differences	_
139-17	26863-26865	in	_
139-18	26866-26873	service	_
139-19	26874-26877	use	_
139-20	26878-26880	in	_
139-21	26881-26884	the	_
139-22	26885-26888	USA	_
139-23	26888-26889	.	_

#Text=The pattern of findings regarding the association between symptomatic change and resting-state functional connectivity appeared independent of sex, but studies with greater representation of women would be important for confirming our observations.
140-1	26890-26893	The	_
140-2	26894-26901	pattern	_
140-3	26902-26904	of	_
140-4	26905-26913	findings	_
140-5	26914-26923	regarding	_
140-6	26924-26927	the	_
140-7	26928-26939	association	_
140-8	26940-26947	between	_
140-9	26948-26959	symptomatic	_
140-10	26960-26966	change	_
140-11	26967-26970	and	_
140-12	26971-26984	resting-state	_
140-13	26985-26995	functional	_
140-14	26996-27008	connectivity	_
140-15	27009-27017	appeared	_
140-16	27018-27029	independent	_
140-17	27030-27032	of	_
140-18	27033-27036	sex	_
140-19	27036-27037	,	_
140-20	27038-27041	but	_
140-21	27042-27049	studies	_
140-22	27050-27054	with	_
140-23	27055-27062	greater	_
140-24	27063-27077	representation	_
140-25	27078-27080	of	_
140-26	27081-27086	women	_
140-27	27087-27092	would	_
140-28	27093-27095	be	_
140-29	27096-27105	important	_
140-30	27106-27109	for	_
140-31	27110-27120	confirming	_
140-32	27121-27124	our	_
140-33	27125-27137	observations	_
140-34	27137-27138	.	_

#Text=We did not examine drug naïve patients but we ensured that antipsychotic exposure prior to the baseline scan was minimal.
141-1	27139-27141	We	_
141-2	27142-27145	did	_
141-3	27146-27149	not	_
141-4	27150-27157	examine	_
141-5	27158-27162	drug	_
141-6	27163-27168	naïve	_
141-7	27169-27177	patients	_
141-8	27178-27181	but	_
141-9	27182-27184	we	_
141-10	27185-27192	ensured	_
141-11	27193-27197	that	_
141-12	27198-27211	antipsychotic	_
141-13	27212-27220	exposure	_
141-14	27221-27226	prior	_
141-15	27227-27229	to	_
141-16	27230-27233	the	_
141-17	27234-27242	baseline	_
141-18	27243-27247	scan	_
141-19	27248-27251	was	_
141-20	27252-27259	minimal	_
141-21	27259-27260	.	_

#Text=Although the daily antipsychotic dose did not correlate with any neuroimaging measure at follow-up, the effect of medication at baseline cannot be conclusively excluded.
142-1	27261-27269	Although	_
142-2	27270-27273	the	_
142-3	27274-27279	daily	_
142-4	27280-27293	antipsychotic	_
142-5	27294-27298	dose	_
142-6	27299-27302	did	_
142-7	27303-27306	not	_
142-8	27307-27316	correlate	_
142-9	27317-27321	with	_
142-10	27322-27325	any	_
142-11	27326-27338	neuroimaging	_
142-12	27339-27346	measure	_
142-13	27347-27349	at	_
142-14	27350-27359	follow-up	_
142-15	27359-27360	,	_
142-16	27361-27364	the	_
142-17	27365-27371	effect	_
142-18	27372-27374	of	_
142-19	27375-27385	medication	_
142-20	27386-27388	at	_
142-21	27389-27397	baseline	_
142-22	27398-27404	cannot	_
142-23	27405-27407	be	_
142-24	27408-27420	conclusively	_
142-25	27421-27429	excluded	_
142-26	27429-27430	.	_

#Text=The results reported here are dependent on the severity of patients’ symptoms which varies across samples and within the same patient over time.
143-1	27431-27434	The	_
143-2	27435-27442	results	_
143-3	27443-27451	reported	_
143-4	27452-27456	here	_
143-5	27457-27460	are	_
143-6	27461-27470	dependent	_
143-7	27471-27473	on	_
143-8	27474-27477	the	_
143-9	27478-27486	severity	_
143-10	27487-27489	of	_
143-11	27490-27498	patients	_
143-12	27498-27499	’	_
143-13	27500-27508	symptoms	_
143-14	27509-27514	which	_
143-15	27515-27521	varies	_
143-16	27522-27528	across	_
143-17	27529-27536	samples	_
143-18	27537-27540	and	_
143-19	27541-27547	within	_
143-20	27548-27551	the	_
143-21	27552-27556	same	_
143-22	27557-27564	patient	_
143-23	27565-27569	over	_
143-24	27570-27574	time	_
143-25	27574-27575	.	_

#Text=Confirmation of the reproducibility of our findings requires replication in larger samples and in longitudinal studies.
144-1	27576-27588	Confirmation	_
144-2	27589-27591	of	_
144-3	27592-27595	the	_
144-4	27596-27611	reproducibility	_
144-5	27612-27614	of	_
144-6	27615-27618	our	_
144-7	27619-27627	findings	_
144-8	27628-27636	requires	_
144-9	27637-27648	replication	_
144-10	27649-27651	in	_
144-11	27652-27658	larger	_
144-12	27659-27666	samples	_
144-13	27667-27670	and	_
144-14	27671-27673	in	_
144-15	27674-27686	longitudinal	_
144-16	27687-27694	studies	_
144-17	27694-27695	.	_

#Text=Our study provides novel evidence of neuroimaging predictors of the short-term clinical outcome in schizophrenia.
145-1	27696-27699	Our	_
145-2	27700-27705	study	_
145-3	27706-27714	provides	_
145-4	27715-27720	novel	_
145-5	27721-27729	evidence	_
145-6	27730-27732	of	_
145-7	27733-27745	neuroimaging	_
145-8	27746-27756	predictors	_
145-9	27757-27759	of	_
145-10	27760-27763	the	_
145-11	27764-27774	short-term	_
145-12	27775-27783	clinical	_
145-13	27784-27791	outcome	_
145-14	27792-27794	in	_
145-15	27795-27808	schizophrenia	_
145-16	27808-27809	.	_

#Text=These neural network phenotypes can be further interrogated in future studies with regards to their relevance to genetic and molecular mechanisms.
146-1	27810-27815	These	_
146-2	27816-27822	neural	_
146-3	27823-27830	network	_
146-4	27831-27841	phenotypes	_
146-5	27842-27845	can	_
146-6	27846-27848	be	_
146-7	27849-27856	further	_
146-8	27857-27869	interrogated	_
146-9	27870-27872	in	_
146-10	27873-27879	future	_
146-11	27880-27887	studies	_
146-12	27888-27892	with	_
146-13	27893-27900	regards	_
146-14	27901-27903	to	_
146-15	27904-27909	their	_
146-16	27910-27919	relevance	_
146-17	27920-27922	to	_
146-18	27923-27930	genetic	_
146-19	27931-27934	and	_
146-20	27935-27944	molecular	_
146-21	27945-27955	mechanisms	_
146-22	27955-27956	.	_

#Text=For example, the patterns of dysconnectivity observed point to testable hypotheses involving (among several possible alternatives) abnormalities in NMDA receptors and the GABA system.
147-1	27957-27960	For	_
147-2	27961-27968	example	_
147-3	27968-27969	,	_
147-4	27970-27973	the	_
147-5	27974-27982	patterns	_
147-6	27983-27985	of	_
147-7	27986-28001	dysconnectivity	_
147-8	28002-28010	observed	_
147-9	28011-28016	point	_
147-10	28017-28019	to	_
147-11	28020-28028	testable	_
147-12	28029-28039	hypotheses	_
147-13	28040-28049	involving	_
147-14	28050-28051	(	_
147-15	28051-28056	among	_
147-16	28057-28064	several	_
147-17	28065-28073	possible	_
147-18	28074-28086	alternatives	_
147-19	28086-28087	)	_
147-20	28088-28101	abnormalities	_
147-21	28102-28104	in	_
147-22	28105-28109	NMDA	_
147-23	28110-28119	receptors	_
147-24	28120-28123	and	_
147-25	28124-28127	the	_
147-26	28128-28132	GABA	_
147-27	28133-28139	system	_
147-28	28139-28140	.	_

#Text=The present findings also have the potential to inform cognitive neuroscientists and clinicians aiming to develop or refine neuromodulatory or psychological interventions that target neural networks most likely to be involved in clinical improvement.
148-1	28141-28144	The	_
148-2	28145-28152	present	_
148-3	28153-28161	findings	_
148-4	28162-28166	also	_
148-5	28167-28171	have	_
148-6	28172-28175	the	_
148-7	28176-28185	potential	_
148-8	28186-28188	to	_
148-9	28189-28195	inform	_
148-10	28196-28205	cognitive	_
148-11	28206-28221	neuroscientists	_
148-12	28222-28225	and	_
148-13	28226-28236	clinicians	_
148-14	28237-28243	aiming	_
148-15	28244-28246	to	_
148-16	28247-28254	develop	_
148-17	28255-28257	or	_
148-18	28258-28264	refine	_
148-19	28265-28280	neuromodulatory	_
148-20	28281-28283	or	_
148-21	28284-28297	psychological	_
148-22	28298-28311	interventions	_
148-23	28312-28316	that	_
148-24	28317-28323	target	_
148-25	28324-28330	neural	_
148-26	28331-28339	networks	_
148-27	28340-28344	most	_
148-28	28345-28351	likely	_
148-29	28352-28354	to	_
148-30	28355-28357	be	_
148-31	28358-28366	involved	_
148-32	28367-28369	in	_
148-33	28370-28378	clinical	_
148-34	28379-28390	improvement	_
148-35	28390-28391	.	_

#Text=Supplementary Material
#Text=Supplementary information is available at MP’s website.
149-1	28392-28405	Supplementary	_
149-2	28406-28414	Material	_
149-3	28415-28428	Supplementary	_
149-4	28429-28440	information	_
149-5	28441-28443	is	_
149-6	28444-28453	available	_
149-7	28454-28456	at	_
149-8	28457-28459	MP	_
149-9	28459-28460	’	_
149-10	28460-28461	s	_
149-11	28462-28469	website	_
149-12	28469-28470	.	_

#Text=Financial Disclosures:
#Text=The authors report no conflict of interest.
150-1	28471-28480	Financial	_
150-2	28481-28492	Disclosures	_
150-3	28492-28493	:	_
150-4	28494-28497	The	_
150-5	28498-28505	authors	_
150-6	28506-28512	report	_
150-7	28513-28515	no	_
150-8	28516-28524	conflict	_
150-9	28525-28527	of	_
150-10	28528-28536	interest	_
150-11	28536-28537	.	_

#Text=References:
#Text=Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
#Text=The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies
#Text=Treatment of patients with first-episode psychosis: two-year outcome data from the Danish National Schizophrenia Project
#Text=Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation
#Text=Incomes and Outcomes: Social Security Disability Benefits in First-Episode Psychosis
#Text=Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014
#Text=A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?
151-1	28538-28548	References	_
151-2	28548-28549	:	_
151-3	28550-28569	Disability-adjusted	_
151-4	28570-28574	life	_
151-5	28575-28580	years	_
151-6	28581-28582	(	_
151-7	28582-28587	DALYs	_
151-8	28587-28588	)	_
151-9	28589-28592	for	_
151-10	28593-28596	291	_
151-11	28597-28605	diseases	_
151-12	28606-28609	and	_
151-13	28610-28618	injuries	_
151-14	28619-28621	in	_
151-15	28622-28624	21	_
151-16	28625-28632	regions	_
151-17	28632-28633	,	_
151-18	28634-28638	1990	_
151-19	28638-28639	–	_
151-20	28639-28643	2010	_
151-21	28643-28644	:	_
151-22	28645-28646	a	_
151-23	28647-28657	systematic	_
151-24	28658-28666	analysis	_
151-25	28667-28670	for	_
151-26	28671-28674	the	_
151-27	28675-28681	Global	_
151-28	28682-28688	Burden	_
151-29	28689-28691	of	_
151-30	28692-28699	Disease	_
151-31	28700-28705	Study	_
151-32	28706-28710	2010	_
151-33	28711-28714	The	_
151-34	28715-28721	course	_
151-35	28722-28724	of	_
151-36	28725-28738	schizophrenia	_
151-37	28739-28741	in	_
151-38	28742-28745	the	_
151-39	28746-28751	light	_
151-40	28752-28754	of	_
151-41	28755-28761	modern	_
151-42	28762-28771	follow-up	_
151-43	28772-28779	studies	_
151-44	28779-28780	:	_
151-45	28781-28784	the	_
151-46	28785-28788	ABC	_
151-47	28789-28792	and	_
151-48	28793-28796	WHO	_
151-49	28797-28804	studies	_
151-50	28805-28814	Treatment	_
151-51	28815-28817	of	_
151-52	28818-28826	patients	_
151-53	28827-28831	with	_
151-54	28832-28845	first-episode	_
151-55	28846-28855	psychosis	_
151-56	28855-28856	:	_
151-57	28857-28865	two-year	_
151-58	28866-28873	outcome	_
151-59	28874-28878	data	_
151-60	28879-28883	from	_
151-61	28884-28887	the	_
151-62	28888-28894	Danish	_
151-63	28895-28903	National	_
151-64	28904-28917	Schizophrenia	_
151-65	28918-28925	Project	_
151-66	28926-28936	Functional	_
151-67	28937-28947	impairment	_
151-68	28948-28950	in	_
151-69	28951-28957	people	_
151-70	28958-28962	with	_
151-71	28963-28976	schizophrenia	_
151-72	28976-28977	:	_
151-73	28978-28983	focus	_
151-74	28984-28986	on	_
151-75	28987-29000	employability	_
151-76	29001-29004	and	_
151-77	29005-29016	eligibility	_
151-78	29017-29020	for	_
151-79	29021-29031	disability	_
151-80	29032-29044	compensation	_
151-81	29045-29052	Incomes	_
151-82	29053-29056	and	_
151-83	29057-29065	Outcomes	_
151-84	29065-29066	:	_
151-85	29067-29073	Social	_
151-86	29074-29082	Security	_
151-87	29083-29093	Disability	_
151-88	29094-29102	Benefits	_
151-89	29103-29105	in	_
151-90	29106-29119	First-Episode	_
151-91	29120-29129	Psychosis	_
151-92	29130-29139	Mortality	_
151-93	29140-29143	gap	_
151-94	29144-29147	for	_
151-95	29148-29154	people	_
151-96	29155-29159	with	_
151-97	29160-29167	bipolar	_
151-98	29168-29176	disorder	_
151-99	29177-29180	and	_
151-100	29181-29194	schizophrenia	_
151-101	29194-29195	:	_
151-102	29196-29204	UK-based	_
151-103	29205-29211	cohort	_
151-104	29212-29217	study	_
151-105	29218-29222	2000	_
151-106	29222-29223	–	_
151-107	29223-29227	2014	_
151-108	29228-29229	A	_
151-109	29230-29240	systematic	_
151-110	29241-29247	review	_
151-111	29248-29250	of	_
151-112	29251-29260	mortality	_
151-113	29261-29263	in	_
151-114	29264-29277	schizophrenia	_
151-115	29277-29278	:	_
151-116	29279-29281	is	_
151-117	29282-29285	the	_
151-118	29286-29298	differential	_
151-119	29299-29308	mortality	_
151-120	29309-29312	gap	_
151-121	29313-29322	worsening	_
151-122	29323-29327	over	_
151-123	29328-29332	time	_
151-124	29332-29333	?	_

#Text=The varied outcomes of schizophrenia
#Text=The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects
#Text=Rates and predictors of 18-months remission in an epidemiological cohort of 661 patients with first-episode psychosis
#Text=Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach
#Text=A systematic review of longitudinal outcome studies of first-episode psychosis
#Text=Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review
#Text=Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder-a systematic review of the magnetic resonance neuroimaging literature
#Text=Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium
#Text=Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 controls via the ENIGMA consortium
#Text=Dysfunction of Large-Scale Brain Networks in Schizophrenia: A Meta-analysis of Resting-State Functional Connectivity
#Text=Resting-state network connectivity and metastability predict clinical symptoms in schizophrenia
#Text=Pre-surgery resting-state local graph-theory measures predict neurocognitive outcomes after brain surgery in temporal lobe epilepsy
#Text=Prognostic classification of mild cognitive impairment and Alzheimer’s disease: MRI independent component analysis
#Text=Longitudinal study of brain morphology in first episode schizophrenia
#Text=Time course and biologic correlates of treatment response in first-episode schizophrenia
#Text=Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia
#Text=Multi-center MRI prediction models: Predicting sex and illness course in first episode psychosis patients
#Text=Cortical folding defects as markers of poor treatment response in first-episode psychosis
#Text=Brain volume changes in the first year of illness and 5-year outcome of schizophrenia
#Text=Dorsolateral prefrontal cortex morphology and short-term outcome in first-episode schizophrenia
#Text=Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up
#Text=The parahippocampal gyrus as a neural marker of early remission in first-episode psychosis: a voxel-based morphometry study
#Text=Neural markers of early remission in first-episode schizophrenia: a volumetric neuroimaging study of the parahippocampus
#Text=Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics
#Text=Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naive schizophrenia patients
#Text=Aberrant Hippocampal Connectivity in Unmedicated Patients With Schizophrenia and Effects of Antipsychotic Medication: A Longitudinal Resting State Functional MRI Study
#Text=Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment
#Text=Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR.
152-1	29334-29337	The	_
152-2	29338-29344	varied	_
152-3	29345-29353	outcomes	_
152-4	29354-29356	of	_
152-5	29357-29370	schizophrenia	_
152-6	29371-29374	The	_
152-7	29375-29387	Longitudinal	_
152-8	29388-29394	Course	_
152-9	29395-29397	of	_
152-10	29398-29411	Schizophrenia	_
152-11	29412-29418	Across	_
152-12	29419-29422	the	_
152-13	29423-29431	Lifespan	_
152-14	29431-29432	:	_
152-15	29433-29441	Clinical	_
152-16	29441-29442	,	_
152-17	29443-29452	Cognitive	_
152-18	29452-29453	,	_
152-19	29454-29457	and	_
152-20	29458-29473	Neurobiological	_
152-21	29474-29481	Aspects	_
152-22	29482-29487	Rates	_
152-23	29488-29491	and	_
152-24	29492-29502	predictors	_
152-25	29503-29505	of	_
152-26	29506-29508	18	_
152-27	29508-29509	-	_
152-28	29509-29515	months	_
152-29	29516-29525	remission	_
152-30	29526-29528	in	_
152-31	29529-29531	an	_
152-32	29532-29547	epidemiological	_
152-33	29548-29554	cohort	_
152-34	29555-29557	of	_
152-35	29558-29561	661	_
152-36	29562-29570	patients	_
152-37	29571-29575	with	_
152-38	29576-29589	first-episode	_
152-39	29590-29599	psychosis	_
152-40	29600-29609	Multisite	_
152-41	29610-29620	prediction	_
152-42	29621-29623	of	_
152-43	29624-29625	4	_
152-44	29625-29626	-	_
152-45	29626-29630	week	_
152-46	29631-29634	and	_
152-47	29635-29637	52	_
152-48	29637-29638	-	_
152-49	29638-29642	week	_
152-50	29643-29652	treatment	_
152-51	29653-29661	outcomes	_
152-52	29662-29664	in	_
152-53	29665-29673	patients	_
152-54	29674-29678	with	_
152-55	29679-29692	first-episode	_
152-56	29693-29702	psychosis	_
152-57	29702-29703	:	_
152-58	29704-29705	a	_
152-59	29706-29713	machine	_
152-60	29714-29722	learning	_
152-61	29723-29731	approach	_
152-62	29732-29733	A	_
152-63	29734-29744	systematic	_
152-64	29745-29751	review	_
152-65	29752-29754	of	_
152-66	29755-29767	longitudinal	_
152-67	29768-29775	outcome	_
152-68	29776-29783	studies	_
152-69	29784-29786	of	_
152-70	29787-29800	first-episode	_
152-71	29801-29810	psychosis	_
152-72	29811-29816	Early	_
152-73	29817-29828	Improvement	_
152-74	29829-29831	As	_
152-75	29832-29833	a	_
152-76	29834-29843	Predictor	_
152-77	29844-29846	of	_
152-78	29847-29852	Later	_
152-79	29853-29861	Response	_
152-80	29862-29864	to	_
152-81	29865-29879	Antipsychotics	_
152-82	29880-29882	in	_
152-83	29883-29896	Schizophrenia	_
152-84	29896-29897	:	_
152-85	29898-29899	A	_
152-86	29900-29910	Diagnostic	_
152-87	29911-29915	Test	_
152-88	29916-29922	Review	_
152-89	29923-29928	Brain	_
152-90	29929-29938	structure	_
152-91	29938-29939	,	_
152-92	29940-29948	function	_
152-93	29948-29949	,	_
152-94	29950-29953	and	_
152-95	29954-29968	neurochemistry	_
152-96	29969-29971	in	_
152-97	29972-29985	schizophrenia	_
152-98	29986-29989	and	_
152-99	29990-29997	bipolar	_
152-100	29998-30008	disorder-a	_
152-101	30009-30019	systematic	_
152-102	30020-30026	review	_
152-103	30027-30029	of	_
152-104	30030-30033	the	_
152-105	30034-30042	magnetic	_
152-106	30043-30052	resonance	_
152-107	30053-30065	neuroimaging	_
152-108	30066-30076	literature	_
152-109	30077-30088	Subcortical	_
152-110	30089-30094	brain	_
152-111	30095-30101	volume	_
152-112	30102-30115	abnormalities	_
152-113	30116-30118	in	_
152-114	30119-30123	2028	_
152-115	30124-30135	individuals	_
152-116	30136-30140	with	_
152-117	30141-30154	schizophrenia	_
152-118	30155-30158	and	_
152-119	30159-30163	2540	_
152-120	30164-30171	healthy	_
152-121	30172-30180	controls	_
152-122	30181-30184	via	_
152-123	30185-30188	the	_
152-124	30189-30195	ENIGMA	_
152-125	30196-30206	consortium	_
152-126	30207-30215	Cortical	_
152-127	30216-30221	brain	_
152-128	30222-30235	abnormalities	_
152-129	30236-30238	in	_
152-130	30239-30243	4474	_
152-131	30244-30255	individuals	_
152-132	30256-30260	with	_
152-133	30261-30274	schizophrenia	_
152-134	30275-30278	and	_
152-135	30279-30283	5098	_
152-136	30284-30292	controls	_
152-137	30293-30296	via	_
152-138	30297-30300	the	_
152-139	30301-30307	ENIGMA	_
152-140	30308-30318	consortium	_
152-141	30319-30330	Dysfunction	_
152-142	30331-30333	of	_
152-143	30334-30345	Large-Scale	_
152-144	30346-30351	Brain	_
152-145	30352-30360	Networks	_
152-146	30361-30363	in	_
152-147	30364-30377	Schizophrenia	_
152-148	30377-30378	:	_
152-149	30379-30380	A	_
152-150	30381-30394	Meta-analysis	_
152-151	30395-30397	of	_
152-152	30398-30411	Resting-State	_
152-153	30412-30422	Functional	_
152-154	30423-30435	Connectivity	_
152-155	30436-30449	Resting-state	_
152-156	30450-30457	network	_
152-157	30458-30470	connectivity	_
152-158	30471-30474	and	_
152-159	30475-30488	metastability	_
152-160	30489-30496	predict	_
152-161	30497-30505	clinical	_
152-162	30506-30514	symptoms	_
152-163	30515-30517	in	_
152-164	30518-30531	schizophrenia	_
152-165	30532-30543	Pre-surgery	_
152-166	30544-30557	resting-state	_
152-167	30558-30563	local	_
152-168	30564-30576	graph-theory	_
152-169	30577-30585	measures	_
152-170	30586-30593	predict	_
152-171	30594-30608	neurocognitive	_
152-172	30609-30617	outcomes	_
152-173	30618-30623	after	_
152-174	30624-30629	brain	_
152-175	30630-30637	surgery	_
152-176	30638-30640	in	_
152-177	30641-30649	temporal	_
152-178	30650-30654	lobe	_
152-179	30655-30663	epilepsy	_
152-180	30664-30674	Prognostic	_
152-181	30675-30689	classification	_
152-182	30690-30692	of	_
152-183	30693-30697	mild	_
152-184	30698-30707	cognitive	_
152-185	30708-30718	impairment	_
152-186	30719-30722	and	_
152-187	30723-30732	Alzheimer	_
152-188	30732-30733	’	_
152-189	30733-30734	s	_
152-190	30735-30742	disease	_
152-191	30742-30743	:	_
152-192	30744-30747	MRI	_
152-193	30748-30759	independent	_
152-194	30760-30769	component	_
152-195	30770-30778	analysis	_
152-196	30779-30791	Longitudinal	_
152-197	30792-30797	study	_
152-198	30798-30800	of	_
152-199	30801-30806	brain	_
152-200	30807-30817	morphology	_
152-201	30818-30820	in	_
152-202	30821-30826	first	_
152-203	30827-30834	episode	_
152-204	30835-30848	schizophrenia	_
152-205	30849-30853	Time	_
152-206	30854-30860	course	_
152-207	30861-30864	and	_
152-208	30865-30873	biologic	_
152-209	30874-30884	correlates	_
152-210	30885-30887	of	_
152-211	30888-30897	treatment	_
152-212	30898-30906	response	_
152-213	30907-30909	in	_
152-214	30910-30923	first-episode	_
152-215	30924-30937	schizophrenia	_
152-216	30938-30948	Anatomical	_
152-217	30949-30952	and	_
152-218	30953-30963	functional	_
152-219	30964-30969	brain	_
152-220	30970-30979	variables	_
152-221	30980-30990	associated	_
152-222	30991-30995	with	_
152-223	30996-31005	clozapine	_
152-224	31006-31014	response	_
152-225	31015-31017	in	_
152-226	31018-31037	treatment-resistant	_
152-227	31038-31051	schizophrenia	_
152-228	31052-31064	Multi-center	_
152-229	31065-31068	MRI	_
152-230	31069-31079	prediction	_
152-231	31080-31086	models	_
152-232	31086-31087	:	_
152-233	31088-31098	Predicting	_
152-234	31099-31102	sex	_
152-235	31103-31106	and	_
152-236	31107-31114	illness	_
152-237	31115-31121	course	_
152-238	31122-31124	in	_
152-239	31125-31130	first	_
152-240	31131-31138	episode	_
152-241	31139-31148	psychosis	_
152-242	31149-31157	patients	_
152-243	31158-31166	Cortical	_
152-244	31167-31174	folding	_
152-245	31175-31182	defects	_
152-246	31183-31185	as	_
152-247	31186-31193	markers	_
152-248	31194-31196	of	_
152-249	31197-31201	poor	_
152-250	31202-31211	treatment	_
152-251	31212-31220	response	_
152-252	31221-31223	in	_
152-253	31224-31237	first-episode	_
152-254	31238-31247	psychosis	_
152-255	31248-31253	Brain	_
152-256	31254-31260	volume	_
152-257	31261-31268	changes	_
152-258	31269-31271	in	_
152-259	31272-31275	the	_
152-260	31276-31281	first	_
152-261	31282-31286	year	_
152-262	31287-31289	of	_
152-263	31290-31297	illness	_
152-264	31298-31301	and	_
152-265	31302-31303	5	_
152-266	31303-31304	-	_
152-267	31304-31308	year	_
152-268	31309-31316	outcome	_
152-269	31317-31319	of	_
152-270	31320-31333	schizophrenia	_
152-271	31334-31346	Dorsolateral	_
152-272	31347-31357	prefrontal	_
152-273	31358-31364	cortex	_
152-274	31365-31375	morphology	_
152-275	31376-31379	and	_
152-276	31380-31390	short-term	_
152-277	31391-31398	outcome	_
152-278	31399-31401	in	_
152-279	31402-31415	first-episode	_
152-280	31416-31429	schizophrenia	_
152-281	31430-31437	Initial	_
152-282	31438-31446	magnetic	_
152-283	31447-31456	resonance	_
152-284	31457-31464	imaging	_
152-285	31465-31475	volumetric	_
152-286	31476-31481	brain	_
152-287	31482-31494	measurements	_
152-288	31495-31498	and	_
152-289	31499-31506	outcome	_
152-290	31507-31509	in	_
152-291	31510-31523	schizophrenia	_
152-292	31523-31524	:	_
152-293	31525-31526	a	_
152-294	31527-31538	prospective	_
152-295	31539-31551	longitudinal	_
152-296	31552-31557	study	_
152-297	31558-31562	with	_
152-298	31563-31564	5	_
152-299	31564-31565	-	_
152-300	31565-31569	year	_
152-301	31570-31579	follow-up	_
152-302	31580-31583	The	_
152-303	31584-31599	parahippocampal	_
152-304	31600-31605	gyrus	_
152-305	31606-31608	as	_
152-306	31609-31610	a	_
152-307	31611-31617	neural	_
152-308	31618-31624	marker	_
152-309	31625-31627	of	_
152-310	31628-31633	early	_
152-311	31634-31643	remission	_
152-312	31644-31646	in	_
152-313	31647-31660	first-episode	_
152-314	31661-31670	psychosis	_
152-315	31670-31671	:	_
152-316	31672-31673	a	_
152-317	31674-31685	voxel-based	_
152-318	31686-31697	morphometry	_
152-319	31698-31703	study	_
152-320	31704-31710	Neural	_
152-321	31711-31718	markers	_
152-322	31719-31721	of	_
152-323	31722-31727	early	_
152-324	31728-31737	remission	_
152-325	31738-31740	in	_
152-326	31741-31754	first-episode	_
152-327	31755-31768	schizophrenia	_
152-328	31768-31769	:	_
152-329	31770-31771	a	_
152-330	31772-31782	volumetric	_
152-331	31783-31795	neuroimaging	_
152-332	31796-31801	study	_
152-333	31802-31804	of	_
152-334	31805-31808	the	_
152-335	31809-31824	parahippocampus	_
152-336	31825-31834	Optimized	_
152-337	31835-31840	voxel	_
152-338	31841-31846	brain	_
152-339	31847-31858	morphometry	_
152-340	31858-31859	:	_
152-341	31860-31871	association	_
152-342	31872-31879	between	_
152-343	31880-31885	brain	_
152-344	31886-31893	volumes	_
152-345	31894-31897	and	_
152-346	31898-31901	the	_
152-347	31902-31910	response	_
152-348	31911-31913	to	_
152-349	31914-31922	atypical	_
152-350	31923-31937	antipsychotics	_
152-351	31938-31944	Neural	_
152-352	31945-31952	markers	_
152-353	31953-31955	of	_
152-354	31956-31964	negative	_
152-355	31965-31972	symptom	_
152-356	31973-31981	outcomes	_
152-357	31982-31984	in	_
152-358	31985-31996	distributed	_
152-359	31997-32004	working	_
152-360	32005-32011	memory	_
152-361	32012-32017	brain	_
152-362	32018-32026	activity	_
152-363	32027-32029	of	_
152-364	32030-32049	antipsychotic-naive	_
152-365	32050-32063	schizophrenia	_
152-366	32064-32072	patients	_
152-367	32073-32081	Aberrant	_
152-368	32082-32093	Hippocampal	_
152-369	32094-32106	Connectivity	_
152-370	32107-32109	in	_
152-371	32110-32121	Unmedicated	_
152-372	32122-32130	Patients	_
152-373	32131-32135	With	_
152-374	32136-32149	Schizophrenia	_
152-375	32150-32153	and	_
152-376	32154-32161	Effects	_
152-377	32162-32164	of	_
152-378	32165-32178	Antipsychotic	_
152-379	32179-32189	Medication	_
152-380	32189-32190	:	_
152-381	32191-32192	A	_
152-382	32193-32205	Longitudinal	_
152-383	32206-32213	Resting	_
152-384	32214-32219	State	_
152-385	32220-32230	Functional	_
152-386	32231-32234	MRI	_
152-387	32235-32240	Study	_
152-388	32241-32249	Baseline	_
152-389	32250-32258	Striatal	_
152-390	32259-32269	Functional	_
152-391	32270-32282	Connectivity	_
152-392	32283-32285	as	_
152-393	32286-32287	a	_
152-394	32288-32297	Predictor	_
152-395	32298-32300	of	_
152-396	32301-32309	Response	_
152-397	32310-32312	to	_
152-398	32313-32326	Antipsychotic	_
152-399	32327-32331	Drug	_
152-400	32332-32341	Treatment	_
152-401	32342-32344	Jr	_
152-402	32344-32345	.	_
152-403	32345-32346	,	_
152-404	32347-32351	Kane	_
152-405	32352-32354	JM	_
152-406	32354-32355	,	_
152-407	32356-32362	Lasser	_
152-408	32363-32365	RA	_
152-409	32365-32366	,	_
152-410	32367-32373	Marder	_
152-411	32374-32376	SR	_
152-412	32376-32377	,	_
152-413	32378-32388	Weinberger	_
152-414	32389-32391	DR	_
152-415	32391-32392	.	_

#Text=Remission in schizophrenia: proposed criteria and rationale for consensus
#Text=Remission as perceived by people with schizophrenia, family members and psychiatrists
#Text=Association between symptom dimensions and categorical diagnoses of psychosis: a cross-sectional and longitudinal investigation
#Text=Metabolic syndrome and insulin resistance significantly correlate with body mass index
#Text=Gottesman II.
153-1	32393-32402	Remission	_
153-2	32403-32405	in	_
153-3	32406-32419	schizophrenia	_
153-4	32419-32420	:	_
153-5	32421-32429	proposed	_
153-6	32430-32438	criteria	_
153-7	32439-32442	and	_
153-8	32443-32452	rationale	_
153-9	32453-32456	for	_
153-10	32457-32466	consensus	_
153-11	32467-32476	Remission	_
153-12	32477-32479	as	_
153-13	32480-32489	perceived	_
153-14	32490-32492	by	_
153-15	32493-32499	people	_
153-16	32500-32504	with	_
153-17	32505-32518	schizophrenia	_
153-18	32518-32519	,	_
153-19	32520-32526	family	_
153-20	32527-32534	members	_
153-21	32535-32538	and	_
153-22	32539-32552	psychiatrists	_
153-23	32553-32564	Association	_
153-24	32565-32572	between	_
153-25	32573-32580	symptom	_
153-26	32581-32591	dimensions	_
153-27	32592-32595	and	_
153-28	32596-32607	categorical	_
153-29	32608-32617	diagnoses	_
153-30	32618-32620	of	_
153-31	32621-32630	psychosis	_
153-32	32630-32631	:	_
153-33	32632-32633	a	_
153-34	32634-32649	cross-sectional	_
153-35	32650-32653	and	_
153-36	32654-32666	longitudinal	_
153-37	32667-32680	investigation	_
153-38	32681-32690	Metabolic	_
153-39	32691-32699	syndrome	_
153-40	32700-32703	and	_
153-41	32704-32711	insulin	_
153-42	32712-32722	resistance	_
153-43	32723-32736	significantly	_
153-44	32737-32746	correlate	_
153-45	32747-32751	with	_
153-46	32752-32756	body	_
153-47	32757-32761	mass	_
153-48	32762-32767	index	_
153-49	32768-32777	Gottesman	_
153-50	32778-32780	II	_
153-51	32780-32781	.	_

#Text=Just one g: consistent results from three test batteries
#Text=Genetics and intelligence differences: five special findings
#Text=Multivariate associations among behavioral, clinical and multimodal imaging phenotypes in psychosis
#Text=The association between weight change and symptom reduction in the CATIE schizophrenia trial
#Text=Remission and recovery during the first outpatient year of the early course of schizophrenia
#Text=A penalized matrix decomposition, with applications to sparse principal components and canonical correlation analysis
#Text=Predicting multivariate responses in multiple linear regression
#Text=Bayesian canonical correlation analysis
#Text=
#Text=
#Text=
#Text=The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes
#Text=Training and quality assurance with the Brief Psychiatric Rating Scale
#Text=Consistency of Brief Psychiatric Rating Scale factor structure across a broad spectrum of schizophrenia patients
#Text=International consensus study of antipsychotic dosing
#Text=Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
#Text=Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study
#Text=An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest
#Text=Elevated Body Mass Index is Associated with Increased Integration and Reduced Cohesion of Sensory-Driven and Internally Guided Resting-State Functional Brain Networks
#Text=Emergence of system roles in normative neurodevelopment
#Text=Whole-brain anatomical networks: does the choice of nodes matter?
154-1	32782-32786	Just	_
154-2	32787-32790	one	_
154-3	32791-32792	g	_
154-4	32792-32793	:	_
154-5	32794-32804	consistent	_
154-6	32805-32812	results	_
154-7	32813-32817	from	_
154-8	32818-32823	three	_
154-9	32824-32828	test	_
154-10	32829-32838	batteries	_
154-11	32839-32847	Genetics	_
154-12	32848-32851	and	_
154-13	32852-32864	intelligence	_
154-14	32865-32876	differences	_
154-15	32876-32877	:	_
154-16	32878-32882	five	_
154-17	32883-32890	special	_
154-18	32891-32899	findings	_
154-19	32900-32912	Multivariate	_
154-20	32913-32925	associations	_
154-21	32926-32931	among	_
154-22	32932-32942	behavioral	_
154-23	32942-32943	,	_
154-24	32944-32952	clinical	_
154-25	32953-32956	and	_
154-26	32957-32967	multimodal	_
154-27	32968-32975	imaging	_
154-28	32976-32986	phenotypes	_
154-29	32987-32989	in	_
154-30	32990-32999	psychosis	_
154-31	33000-33003	The	_
154-32	33004-33015	association	_
154-33	33016-33023	between	_
154-34	33024-33030	weight	_
154-35	33031-33037	change	_
154-36	33038-33041	and	_
154-37	33042-33049	symptom	_
154-38	33050-33059	reduction	_
154-39	33060-33062	in	_
154-40	33063-33066	the	_
154-41	33067-33072	CATIE	_
154-42	33073-33086	schizophrenia	_
154-43	33087-33092	trial	_
154-44	33093-33102	Remission	_
154-45	33103-33106	and	_
154-46	33107-33115	recovery	_
154-47	33116-33122	during	_
154-48	33123-33126	the	_
154-49	33127-33132	first	_
154-50	33133-33143	outpatient	_
154-51	33144-33148	year	_
154-52	33149-33151	of	_
154-53	33152-33155	the	_
154-54	33156-33161	early	_
154-55	33162-33168	course	_
154-56	33169-33171	of	_
154-57	33172-33185	schizophrenia	_
154-58	33186-33187	A	_
154-59	33188-33197	penalized	_
154-60	33198-33204	matrix	_
154-61	33205-33218	decomposition	_
154-62	33218-33219	,	_
154-63	33220-33224	with	_
154-64	33225-33237	applications	_
154-65	33238-33240	to	_
154-66	33241-33247	sparse	_
154-67	33248-33257	principal	_
154-68	33258-33268	components	_
154-69	33269-33272	and	_
154-70	33273-33282	canonical	_
154-71	33283-33294	correlation	_
154-72	33295-33303	analysis	_
154-73	33304-33314	Predicting	_
154-74	33315-33327	multivariate	_
154-75	33328-33337	responses	_
154-76	33338-33340	in	_
154-77	33341-33349	multiple	_
154-78	33350-33356	linear	_
154-79	33357-33367	regression	_
154-80	33368-33376	Bayesian	_
154-81	33377-33386	canonical	_
154-82	33387-33398	correlation	_
154-83	33399-33407	analysis	_
154-84	33411-33414	The	_
154-85	33415-33421	impact	_
154-86	33422-33424	of	_
154-87	33425-33434	premorbid	_
154-88	33435-33438	and	_
154-89	33439-33446	current	_
154-90	33447-33456	intellect	_
154-91	33457-33459	in	_
154-92	33460-33473	schizophrenia	_
154-93	33473-33474	:	_
154-94	33475-33484	cognitive	_
154-95	33484-33485	,	_
154-96	33486-33493	symptom	_
154-97	33493-33494	,	_
154-98	33495-33498	and	_
154-99	33499-33509	functional	_
154-100	33510-33518	outcomes	_
154-101	33519-33527	Training	_
154-102	33528-33531	and	_
154-103	33532-33539	quality	_
154-104	33540-33549	assurance	_
154-105	33550-33554	with	_
154-106	33555-33558	the	_
154-107	33559-33564	Brief	_
154-108	33565-33576	Psychiatric	_
154-109	33577-33583	Rating	_
154-110	33584-33589	Scale	_
154-111	33590-33601	Consistency	_
154-112	33602-33604	of	_
154-113	33605-33610	Brief	_
154-114	33611-33622	Psychiatric	_
154-115	33623-33629	Rating	_
154-116	33630-33635	Scale	_
154-117	33636-33642	factor	_
154-118	33643-33652	structure	_
154-119	33653-33659	across	_
154-120	33660-33661	a	_
154-121	33662-33667	broad	_
154-122	33668-33676	spectrum	_
154-123	33677-33679	of	_
154-124	33680-33693	schizophrenia	_
154-125	33694-33702	patients	_
154-126	33703-33716	International	_
154-127	33717-33726	consensus	_
154-128	33727-33732	study	_
154-129	33733-33735	of	_
154-130	33736-33749	antipsychotic	_
154-131	33750-33756	dosing	_
154-132	33757-33768	Comparative	_
154-133	33769-33777	efficacy	_
154-134	33778-33781	and	_
154-135	33782-33794	tolerability	_
154-136	33795-33797	of	_
154-137	33798-33800	15	_
154-138	33801-33814	antipsychotic	_
154-139	33815-33820	drugs	_
154-140	33821-33823	in	_
154-141	33824-33837	schizophrenia	_
154-142	33837-33838	:	_
154-143	33839-33840	a	_
154-144	33841-33860	multiple-treatments	_
154-145	33861-33874	meta-analysis	_
154-146	33875-33888	Effectiveness	_
154-147	33889-33891	of	_
154-148	33892-33905	antipsychotic	_
154-149	33906-33916	treatments	_
154-150	33917-33919	in	_
154-151	33920-33921	a	_
154-152	33922-33932	nationwide	_
154-153	33933-33939	cohort	_
154-154	33940-33942	of	_
154-155	33943-33951	patients	_
154-156	33952-33954	in	_
154-157	33955-33964	community	_
154-158	33965-33969	care	_
154-159	33970-33975	after	_
154-160	33976-33981	first	_
154-161	33982-33997	hospitalisation	_
154-162	33998-34001	due	_
154-163	34002-34004	to	_
154-164	34005-34018	schizophrenia	_
154-165	34019-34022	and	_
154-166	34023-34038	schizoaffective	_
154-167	34039-34047	disorder	_
154-168	34047-34048	:	_
154-169	34049-34062	observational	_
154-170	34063-34072	follow-up	_
154-171	34073-34078	study	_
154-172	34079-34081	An	_
154-173	34082-34091	automated	_
154-174	34092-34100	labeling	_
154-175	34101-34107	system	_
154-176	34108-34111	for	_
154-177	34112-34123	subdividing	_
154-178	34124-34127	the	_
154-179	34128-34133	human	_
154-180	34134-34142	cerebral	_
154-181	34143-34149	cortex	_
154-182	34150-34152	on	_
154-183	34153-34156	MRI	_
154-184	34157-34162	scans	_
154-185	34163-34167	into	_
154-186	34168-34173	gyral	_
154-187	34174-34179	based	_
154-188	34180-34187	regions	_
154-189	34188-34190	of	_
154-190	34191-34199	interest	_
154-191	34200-34208	Elevated	_
154-192	34209-34213	Body	_
154-193	34214-34218	Mass	_
154-194	34219-34224	Index	_
154-195	34225-34227	is	_
154-196	34228-34238	Associated	_
154-197	34239-34243	with	_
154-198	34244-34253	Increased	_
154-199	34254-34265	Integration	_
154-200	34266-34269	and	_
154-201	34270-34277	Reduced	_
154-202	34278-34286	Cohesion	_
154-203	34287-34289	of	_
154-204	34290-34304	Sensory-Driven	_
154-205	34305-34308	and	_
154-206	34309-34319	Internally	_
154-207	34320-34326	Guided	_
154-208	34327-34340	Resting-State	_
154-209	34341-34351	Functional	_
154-210	34352-34357	Brain	_
154-211	34358-34366	Networks	_
154-212	34367-34376	Emergence	_
154-213	34377-34379	of	_
154-214	34380-34386	system	_
154-215	34387-34392	roles	_
154-216	34393-34395	in	_
154-217	34396-34405	normative	_
154-218	34406-34422	neurodevelopment	_
154-219	34423-34434	Whole-brain	_
154-220	34435-34445	anatomical	_
154-221	34446-34454	networks	_
154-222	34454-34455	:	_
154-223	34456-34460	does	_
154-224	34461-34464	the	_
154-225	34465-34471	choice	_
154-226	34472-34474	of	_
154-227	34475-34480	nodes	_
154-228	34481-34487	matter	_
154-229	34487-34488	?	_

#Text=Cognitive relevance of the community structure of the human brain functional coactivation network
#Text=An integrated brain-behavior model for working memory
#Text=Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later
#Text=Neural systems for visual orienting and their relationships to spatial working memory
#Text=Brain activity at rest: a multiscale hierarchical functional organization
#Text=The human brain is intrinsically organized into dynamic, anticorrelated functional networks
#Text=The brain’s default mode network
#Text=The maturing architecture of the brain’s default network
#Text=The brain’s default network and its adaptive role in internal mentation
#Text=Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
#Text=Resting state functional hyperconnectivity within a triple network model in paranoid schizophrenia
#Text=Sex differences in schizophrenia
#Text=Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
#Text=NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia
#Text=Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations
#Text=Cognitive training in mental disorders: update and future directions
#Text=Spatial Distribution of the Resting-State Networks and Subnetworks.
155-1	34489-34498	Cognitive	_
155-2	34499-34508	relevance	_
155-3	34509-34511	of	_
155-4	34512-34515	the	_
155-5	34516-34525	community	_
155-6	34526-34535	structure	_
155-7	34536-34538	of	_
155-8	34539-34542	the	_
155-9	34543-34548	human	_
155-10	34549-34554	brain	_
155-11	34555-34565	functional	_
155-12	34566-34578	coactivation	_
155-13	34579-34586	network	_
155-14	34587-34589	An	_
155-15	34590-34600	integrated	_
155-16	34601-34615	brain-behavior	_
155-17	34616-34621	model	_
155-18	34622-34625	for	_
155-19	34626-34633	working	_
155-20	34634-34640	memory	_
155-21	34641-34650	Remission	_
155-22	34651-34653	in	_
155-23	34654-34667	schizophrenia	_
155-24	34667-34668	:	_
155-25	34669-34677	validity	_
155-26	34677-34678	,	_
155-27	34679-34688	frequency	_
155-28	34688-34689	,	_
155-29	34690-34700	predictors	_
155-30	34700-34701	,	_
155-31	34702-34705	and	_
155-32	34706-34714	patients	_
155-33	34714-34715	’	_
155-34	34716-34727	perspective	_
155-35	34728-34729	5	_
155-36	34730-34735	years	_
155-37	34736-34741	later	_
155-38	34742-34748	Neural	_
155-39	34749-34756	systems	_
155-40	34757-34760	for	_
155-41	34761-34767	visual	_
155-42	34768-34777	orienting	_
155-43	34778-34781	and	_
155-44	34782-34787	their	_
155-45	34788-34801	relationships	_
155-46	34802-34804	to	_
155-47	34805-34812	spatial	_
155-48	34813-34820	working	_
155-49	34821-34827	memory	_
155-50	34828-34833	Brain	_
155-51	34834-34842	activity	_
155-52	34843-34845	at	_
155-53	34846-34850	rest	_
155-54	34850-34851	:	_
155-55	34852-34853	a	_
155-56	34854-34864	multiscale	_
155-57	34865-34877	hierarchical	_
155-58	34878-34888	functional	_
155-59	34889-34901	organization	_
155-60	34902-34905	The	_
155-61	34906-34911	human	_
155-62	34912-34917	brain	_
155-63	34918-34920	is	_
155-64	34921-34934	intrinsically	_
155-65	34935-34944	organized	_
155-66	34945-34949	into	_
155-67	34950-34957	dynamic	_
155-68	34957-34958	,	_
155-69	34959-34973	anticorrelated	_
155-70	34974-34984	functional	_
155-71	34985-34993	networks	_
155-72	34994-34997	The	_
155-73	34998-35003	brain	_
155-74	35003-35004	’	_
155-75	35004-35005	s	_
155-76	35006-35013	default	_
155-77	35014-35018	mode	_
155-78	35019-35026	network	_
155-79	35027-35030	The	_
155-80	35031-35039	maturing	_
155-81	35040-35052	architecture	_
155-82	35053-35055	of	_
155-83	35056-35059	the	_
155-84	35060-35065	brain	_
155-85	35065-35066	’	_
155-86	35066-35067	s	_
155-87	35068-35075	default	_
155-88	35076-35083	network	_
155-89	35084-35087	The	_
155-90	35088-35093	brain	_
155-91	35093-35094	’	_
155-92	35094-35095	s	_
155-93	35096-35103	default	_
155-94	35104-35111	network	_
155-95	35112-35115	and	_
155-96	35116-35119	its	_
155-97	35120-35128	adaptive	_
155-98	35129-35133	role	_
155-99	35134-35136	in	_
155-100	35137-35145	internal	_
155-101	35146-35155	mentation	_
155-102	35156-35169	Hyperactivity	_
155-103	35170-35173	and	_
155-104	35174-35191	hyperconnectivity	_
155-105	35192-35194	of	_
155-106	35195-35198	the	_
155-107	35199-35206	default	_
155-108	35207-35214	network	_
155-109	35215-35217	in	_
155-110	35218-35231	schizophrenia	_
155-111	35232-35235	and	_
155-112	35236-35238	in	_
155-113	35239-35251	first-degree	_
155-114	35252-35261	relatives	_
155-115	35262-35264	of	_
155-116	35265-35272	persons	_
155-117	35273-35277	with	_
155-118	35278-35291	schizophrenia	_
155-119	35292-35299	Resting	_
155-120	35300-35305	state	_
155-121	35306-35316	functional	_
155-122	35317-35334	hyperconnectivity	_
155-123	35335-35341	within	_
155-124	35342-35343	a	_
155-125	35344-35350	triple	_
155-126	35351-35358	network	_
155-127	35359-35364	model	_
155-128	35365-35367	in	_
155-129	35368-35376	paranoid	_
155-130	35377-35390	schizophrenia	_
155-131	35391-35394	Sex	_
155-132	35395-35406	differences	_
155-133	35407-35409	in	_
155-134	35410-35423	schizophrenia	_
155-135	35424-35433	Long-term	_
155-136	35434-35444	healthcare	_
155-137	35445-35450	costs	_
155-138	35451-35454	and	_
155-139	35455-35465	functional	_
155-140	35466-35474	outcomes	_
155-141	35475-35485	associated	_
155-142	35486-35490	with	_
155-143	35491-35495	lack	_
155-144	35496-35498	of	_
155-145	35499-35508	remission	_
155-146	35509-35511	in	_
155-147	35512-35525	schizophrenia	_
155-148	35525-35526	:	_
155-149	35527-35528	a	_
155-150	35529-35537	post-hoc	_
155-151	35538-35546	analysis	_
155-152	35547-35549	of	_
155-153	35550-35551	a	_
155-154	35552-35563	prospective	_
155-155	35564-35577	observational	_
155-156	35578-35583	study	_
155-157	35584-35588	NMDA	_
155-158	35589-35597	receptor	_
155-159	35598-35606	function	_
155-160	35607-35609	in	_
155-161	35610-35621	large-scale	_
155-162	35622-35636	anticorrelated	_
155-163	35637-35643	neural	_
155-164	35644-35651	systems	_
155-165	35652-35656	with	_
155-166	35657-35669	implications	_
155-167	35670-35673	for	_
155-168	35674-35683	cognition	_
155-169	35684-35687	and	_
155-170	35688-35701	schizophrenia	_
155-171	35702-35711	Cognitive	_
155-172	35712-35723	dysfunction	_
155-173	35724-35726	in	_
155-174	35727-35740	schizophrenia	_
155-175	35740-35741	:	_
155-176	35742-35753	convergence	_
155-177	35754-35756	of	_
155-178	35757-35775	gamma-aminobutyric	_
155-179	35776-35780	acid	_
155-180	35781-35784	and	_
155-181	35785-35794	glutamate	_
155-182	35795-35806	alterations	_
155-183	35807-35816	Cognitive	_
155-184	35817-35825	training	_
155-185	35826-35828	in	_
155-186	35829-35835	mental	_
155-187	35836-35845	disorders	_
155-188	35845-35846	:	_
155-189	35847-35853	update	_
155-190	35854-35857	and	_
155-191	35858-35864	future	_
155-192	35865-35875	directions	_
155-193	35876-35883	Spatial	_
155-194	35884-35896	Distribution	_
155-195	35897-35899	of	_
155-196	35900-35903	the	_
155-197	35904-35917	Resting-State	_
155-198	35918-35926	Networks	_
155-199	35927-35930	and	_
155-200	35931-35942	Subnetworks	_
155-201	35942-35943	.	_

#Text=Details of the regions comprising each resting-state subnetwork are provided in Supplementary Table 3.
156-1	35944-35951	Details	_
156-2	35952-35954	of	_
156-3	35955-35958	the	_
156-4	35959-35966	regions	_
156-5	35967-35977	comprising	_
156-6	35978-35982	each	_
156-7	35983-35996	resting-state	_
156-8	35997-36007	subnetwork	_
156-9	36008-36011	are	_
156-10	36012-36020	provided	_
156-11	36021-36023	in	_
156-12	36024-36037	Supplementary	_
156-13	36038-36043	Table	_
156-14	36044-36045	3	_
156-15	36045-36046	.	_

#Text=Sparse Canonical Correlation Analysis of the Rs-fMRI and the Clinical Datasets.
157-1	36047-36053	Sparse	_
157-2	36054-36063	Canonical	_
157-3	36064-36075	Correlation	_
157-4	36076-36084	Analysis	_
157-5	36085-36087	of	_
157-6	36088-36091	the	_
157-7	36092-36099	Rs-fMRI	_
157-8	36100-36103	and	_
157-9	36104-36107	the	_
157-10	36108-36116	Clinical	_
157-11	36117-36125	Datasets	_
157-12	36125-36126	.	_

#Text=(A) Single significant canonical mode linked the rs-fMRI measures and the clinical features (r=0.70, p=0.04).
158-1	36127-36128	(	_
158-2	36128-36129	A	_
158-3	36129-36130	)	_
158-4	36131-36137	Single	_
158-5	36138-36149	significant	_
158-6	36150-36159	canonical	_
158-7	36160-36164	mode	_
158-8	36165-36171	linked	_
158-9	36172-36175	the	_
158-10	36176-36183	rs-fMRI	_
158-11	36184-36192	measures	_
158-12	36193-36196	and	_
158-13	36197-36200	the	_
158-14	36201-36209	clinical	_
158-15	36210-36218	features	_
158-16	36219-36220	(	_
158-17	36220-36221	r	_
158-18	36221-36222	=	_
158-19	36222-36226	0.70	_
158-20	36226-36227	,	_
158-21	36228-36229	p	_
158-22	36229-36230	=	_
158-23	36230-36234	0.04	_
158-24	36234-36235	)	_
158-25	36235-36236	.	_

#Text=(B) Weights of each clinical variable in the sparse canonical correlation analysis; rs-fMRI=resting state functional magnetic resonance imaging
#Text=Brain Functional Predictors of Symptomatic Response in Schizophrenia.
159-1	36237-36238	(	_
159-2	36238-36239	B	_
159-3	36239-36240	)	_
159-4	36241-36248	Weights	_
159-5	36249-36251	of	_
159-6	36252-36256	each	_
159-7	36257-36265	clinical	_
159-8	36266-36274	variable	_
159-9	36275-36277	in	_
159-10	36278-36281	the	_
159-11	36282-36288	sparse	_
159-12	36289-36298	canonical	_
159-13	36299-36310	correlation	_
159-14	36311-36319	analysis	_
159-15	36319-36320	;	_
159-16	36321-36328	rs-fMRI	_
159-17	36328-36329	=	_
159-18	36329-36336	resting	_
159-19	36337-36342	state	_
159-20	36343-36353	functional	_
159-21	36354-36362	magnetic	_
159-22	36363-36372	resonance	_
159-23	36373-36380	imaging	_
159-24	36381-36386	Brain	_
159-25	36387-36397	Functional	_
159-26	36398-36408	Predictors	_
159-27	36409-36411	of	_
159-28	36412-36423	Symptomatic	_
159-29	36424-36432	Response	_
159-30	36433-36435	in	_
159-31	36436-36449	Schizophrenia	_
159-32	36449-36450	.	_

#Text=(A) Links depict the canonical weights of the association between the clinical variate and the connectivity of the subnetworks depicted; Red links represent positive predictors, Blue links represent negative predictors.
160-1	36451-36452	(	_
160-2	36452-36453	A	_
160-3	36453-36454	)	_
160-4	36455-36460	Links	_
160-5	36461-36467	depict	_
160-6	36468-36471	the	_
160-7	36472-36481	canonical	_
160-8	36482-36489	weights	_
160-9	36490-36492	of	_
160-10	36493-36496	the	_
160-11	36497-36508	association	_
160-12	36509-36516	between	_
160-13	36517-36520	the	_
160-14	36521-36529	clinical	_
160-15	36530-36537	variate	_
160-16	36538-36541	and	_
160-17	36542-36545	the	_
160-18	36546-36558	connectivity	_
160-19	36559-36561	of	_
160-20	36562-36565	the	_
160-21	36566-36577	subnetworks	_
160-22	36578-36586	depicted	_
160-23	36586-36587	;	_
160-24	36588-36591	Red	_
160-25	36592-36597	links	_
160-26	36598-36607	represent	_
160-27	36608-36616	positive	_
160-28	36617-36627	predictors	_
160-29	36627-36628	,	_
160-30	36629-36633	Blue	_
160-31	36634-36639	links	_
160-32	36640-36649	represent	_
160-33	36650-36658	negative	_
160-34	36659-36669	predictors	_
160-35	36669-36670	.	_

#Text=Panels (B) and (C) provide illustrative examples of the associations between functional integration and improvement in positive symptoms.
161-1	36671-36677	Panels	_
161-2	36678-36679	(	_
161-3	36679-36680	B	_
161-4	36680-36681	)	_
161-5	36682-36685	and	_
161-6	36686-36687	(	_
161-7	36687-36688	C	_
161-8	36688-36689	)	_
161-9	36690-36697	provide	_
161-10	36698-36710	illustrative	_
161-11	36711-36719	examples	_
161-12	36720-36722	of	_
161-13	36723-36726	the	_
161-14	36727-36739	associations	_
161-15	36740-36747	between	_
161-16	36748-36758	functional	_
161-17	36759-36770	integration	_
161-18	36771-36774	and	_
161-19	36775-36786	improvement	_
161-20	36787-36789	in	_
161-21	36790-36798	positive	_
161-22	36799-36807	symptoms	_
161-23	36807-36808	.	_

#Text=Improvement in positive symptoms was chosen because it had the highest canonical weight to the rs-fMRI variate.
162-1	36809-36820	Improvement	_
162-2	36821-36823	in	_
162-3	36824-36832	positive	_
162-4	36833-36841	symptoms	_
162-5	36842-36845	was	_
162-6	36846-36852	chosen	_
162-7	36853-36860	because	_
162-8	36861-36863	it	_
162-9	36864-36867	had	_
162-10	36868-36871	the	_
162-11	36872-36879	highest	_
162-12	36880-36889	canonical	_
162-13	36890-36896	weight	_
162-14	36897-36899	to	_
162-15	36900-36903	the	_
162-16	36904-36911	rs-fMRI	_
162-17	36912-36919	variate	_
162-18	36919-36920	.	_

#Text=DMN1=medial temporal default mode subnetwork; DMN3=anterior precuneus/posterior cingulate cortex; DMN4= dorsal posterior precuneus; SMN2=sensorimotor network, dorsal subnetwork; rs-fMRI=resting state functional magnetic resonance imaging; details of the spatial distribution of the networks are provided in Figure 1 and Supplementary Table 3.
163-1	36921-36925	DMN1	_
163-2	36925-36926	=	_
163-3	36926-36932	medial	_
163-4	36933-36941	temporal	_
163-5	36942-36949	default	_
163-6	36950-36954	mode	_
163-7	36955-36965	subnetwork	_
163-8	36965-36966	;	_
163-9	36967-36971	DMN3	_
163-10	36971-36972	=	_
163-11	36972-36980	anterior	_
163-12	36981-36990	precuneus	_
163-13	36990-36991	/	_
163-14	36991-37000	posterior	_
163-15	37001-37010	cingulate	_
163-16	37011-37017	cortex	_
163-17	37017-37018	;	_
163-18	37019-37023	DMN4	_
163-19	37023-37024	=	_
163-20	37025-37031	dorsal	_
163-21	37032-37041	posterior	_
163-22	37042-37051	precuneus	_
163-23	37051-37052	;	_
163-24	37053-37057	SMN2	_
163-25	37057-37058	=	_
163-26	37058-37070	sensorimotor	_
163-27	37071-37078	network	_
163-28	37078-37079	,	_
163-29	37080-37086	dorsal	_
163-30	37087-37097	subnetwork	_
163-31	37097-37098	;	_
163-32	37099-37106	rs-fMRI	_
163-33	37106-37107	=	_
163-34	37107-37114	resting	_
163-35	37115-37120	state	_
163-36	37121-37131	functional	_
163-37	37132-37140	magnetic	_
163-38	37141-37150	resonance	_
163-39	37151-37158	imaging	_
163-40	37158-37159	;	_
163-41	37160-37167	details	_
163-42	37168-37170	of	_
163-43	37171-37174	the	_
163-44	37175-37182	spatial	_
163-45	37183-37195	distribution	_
163-46	37196-37198	of	_
163-47	37199-37202	the	_
163-48	37203-37211	networks	_
163-49	37212-37215	are	_
163-50	37216-37224	provided	_
163-51	37225-37227	in	_
163-52	37228-37234	Figure	_
163-53	37235-37236	1	_
163-54	37237-37240	and	_
163-55	37241-37254	Supplementary	_
163-56	37255-37260	Table	_
163-57	37261-37262	3	_
163-58	37262-37263	.	_

#Text=Study sample characteristics at the initial (T1) and the 24-week follow-up (T2) assessments
#Text=\tPatients with SchizophreniaN=76\t \tAge (years)\t26.9 (7.0)\t \tAge of onset (years)\t21.6 (5.1)\t \tSex (% Female)\t19 (25.0%)\t \tIQ\t95.0 (15.1)\t \t\tT1\tT2\t \tBMI\t26.7 (6.3)\t27 (6)\t \tBPRS Total Score*\t50.2 (18.6)\t36.9 (14.2)\t \tBPRS Positive Symptoms*\t12.1 (6.2)\t7.7 (5.1)\t \tBPRS Negative Symptoms*\t6.9 (3.7)\t5.4 (3.0)\t \tBPRS Anxiety/Depression*\t9.3 (5.5)\t6.6 (3.7)\t \tBPRS Agitation/Disorganization*\t7.6 (4.3)\t6.2 (3.1)\t \tAntipsychotic dose (in CPZE)\t256 (266)\t280 (317)\t \t
#Text=Continuous data are shown as mean (standard deviation); Categorical variables are shown as number of cases (percentage, %); BMI: Body Mass Index; BPRS: 24-Item Brief Psychotic Rating Scale, in the Brief Psychiatric Rating Scale each item is rated from 1 (absent) to 7 (extremely severe); CPZE: Chlorpromazine equivalents; IQ: Intelligence Quotient;
#Text=paired t-tests, p-value<0.001.
164-1	37264-37269	Study	_
164-2	37270-37276	sample	_
164-3	37277-37292	characteristics	_
164-4	37293-37295	at	_
164-5	37296-37299	the	_
164-6	37300-37307	initial	_
164-7	37308-37309	(	_
164-8	37309-37311	T1	_
164-9	37311-37312	)	_
164-10	37313-37316	and	_
164-11	37317-37320	the	_
164-12	37321-37323	24	_
164-13	37323-37324	-	_
164-14	37324-37328	week	_
164-15	37329-37338	follow-up	_
164-16	37339-37340	(	_
164-17	37340-37342	T2	_
164-18	37342-37343	)	_
164-19	37344-37355	assessments	_
164-20	37357-37365	Patients	_
164-21	37366-37370	with	_
164-22	37371-37385	SchizophreniaN	_
164-23	37385-37386	=	_
164-24	37386-37388	76	_
164-25	37391-37394	Age	_
164-26	37395-37396	(	_
164-27	37396-37401	years	_
164-28	37401-37402	)	_
164-29	37403-37407	26.9	_
164-30	37408-37409	(	_
164-31	37409-37412	7.0	_
164-32	37412-37413	)	_
164-33	37416-37419	Age	_
164-34	37420-37422	of	_
164-35	37423-37428	onset	_
164-36	37429-37430	(	_
164-37	37430-37435	years	_
164-38	37435-37436	)	_
164-39	37437-37441	21.6	_
164-40	37442-37443	(	_
164-41	37443-37446	5.1	_
164-42	37446-37447	)	_
164-43	37450-37453	Sex	_
164-44	37454-37455	(	_
164-45	37455-37456	%	_
164-46	37457-37463	Female	_
164-47	37463-37464	)	_
164-48	37465-37467	19	_
164-49	37468-37469	(	_
164-50	37469-37474	25.0%	_
164-51	37474-37475	)	_
164-52	37478-37480	IQ	_
164-53	37481-37485	95.0	_
164-54	37486-37487	(	_
164-55	37487-37491	15.1	_
164-56	37491-37492	)	_
164-57	37496-37498	T1	_
164-58	37499-37501	T2	_
164-59	37504-37507	BMI	_
164-60	37508-37512	26.7	_
164-61	37513-37514	(	_
164-62	37514-37517	6.3	_
164-63	37517-37518	)	_
164-64	37519-37521	27	_
164-65	37522-37523	(	_
164-66	37523-37524	6	_
164-67	37524-37525	)	_
164-68	37528-37532	BPRS	_
164-69	37533-37538	Total	_
164-70	37539-37544	Score	_
164-71	37544-37545	*	_
164-72	37546-37550	50.2	_
164-73	37551-37552	(	_
164-74	37552-37556	18.6	_
164-75	37556-37557	)	_
164-76	37558-37562	36.9	_
164-77	37563-37564	(	_
164-78	37564-37568	14.2	_
164-79	37568-37569	)	_
164-80	37572-37576	BPRS	_
164-81	37577-37585	Positive	_
164-82	37586-37594	Symptoms	_
164-83	37594-37595	*	_
164-84	37596-37600	12.1	_
164-85	37601-37602	(	_
164-86	37602-37605	6.2	_
164-87	37605-37606	)	_
164-88	37607-37610	7.7	_
164-89	37611-37612	(	_
164-90	37612-37615	5.1	_
164-91	37615-37616	)	_
164-92	37619-37623	BPRS	_
164-93	37624-37632	Negative	_
164-94	37633-37641	Symptoms	_
164-95	37641-37642	*	_
164-96	37643-37646	6.9	_
164-97	37647-37648	(	_
164-98	37648-37651	3.7	_
164-99	37651-37652	)	_
164-100	37653-37656	5.4	_
164-101	37657-37658	(	_
164-102	37658-37661	3.0	_
164-103	37661-37662	)	_
164-104	37665-37669	BPRS	_
164-105	37670-37677	Anxiety	_
164-106	37677-37678	/	_
164-107	37678-37688	Depression	_
164-108	37688-37689	*	_
164-109	37690-37693	9.3	_
164-110	37694-37695	(	_
164-111	37695-37698	5.5	_
164-112	37698-37699	)	_
164-113	37700-37703	6.6	_
164-114	37704-37705	(	_
164-115	37705-37708	3.7	_
164-116	37708-37709	)	_
164-117	37712-37716	BPRS	_
164-118	37717-37726	Agitation	_
164-119	37726-37727	/	_
164-120	37727-37742	Disorganization	_
164-121	37742-37743	*	_
164-122	37744-37747	7.6	_
164-123	37748-37749	(	_
164-124	37749-37752	4.3	_
164-125	37752-37753	)	_
164-126	37754-37757	6.2	_
164-127	37758-37759	(	_
164-128	37759-37762	3.1	_
164-129	37762-37763	)	_
164-130	37766-37779	Antipsychotic	_
164-131	37780-37784	dose	_
164-132	37785-37786	(	_
164-133	37786-37788	in	_
164-134	37789-37793	CPZE	_
164-135	37793-37794	)	_
164-136	37795-37798	256	_
164-137	37799-37800	(	_
164-138	37800-37803	266	_
164-139	37803-37804	)	_
164-140	37805-37808	280	_
164-141	37809-37810	(	_
164-142	37810-37813	317	_
164-143	37813-37814	)	_
164-144	37818-37828	Continuous	_
164-145	37829-37833	data	_
164-146	37834-37837	are	_
164-147	37838-37843	shown	_
164-148	37844-37846	as	_
164-149	37847-37851	mean	_
164-150	37852-37853	(	_
164-151	37853-37861	standard	_
164-152	37862-37871	deviation	_
164-153	37871-37872	)	_
164-154	37872-37873	;	_
164-155	37874-37885	Categorical	_
164-156	37886-37895	variables	_
164-157	37896-37899	are	_
164-158	37900-37905	shown	_
164-159	37906-37908	as	_
164-160	37909-37915	number	_
164-161	37916-37918	of	_
164-162	37919-37924	cases	_
164-163	37925-37926	(	_
164-164	37926-37936	percentage	_
164-165	37936-37937	,	_
164-166	37938-37939	%	_
164-167	37939-37940	)	_
164-168	37940-37941	;	_
164-169	37942-37945	BMI	_
164-170	37945-37946	:	_
164-171	37947-37951	Body	_
164-172	37952-37956	Mass	_
164-173	37957-37962	Index	_
164-174	37962-37963	;	_
164-175	37964-37968	BPRS	_
164-176	37968-37969	:	_
164-177	37970-37972	24	_
164-178	37972-37973	-	_
164-179	37973-37977	Item	_
164-180	37978-37983	Brief	_
164-181	37984-37993	Psychotic	_
164-182	37994-38000	Rating	_
164-183	38001-38006	Scale	_
164-184	38006-38007	,	_
164-185	38008-38010	in	_
164-186	38011-38014	the	_
164-187	38015-38020	Brief	_
164-188	38021-38032	Psychiatric	_
164-189	38033-38039	Rating	_
164-190	38040-38045	Scale	_
164-191	38046-38050	each	_
164-192	38051-38055	item	_
164-193	38056-38058	is	_
164-194	38059-38064	rated	_
164-195	38065-38069	from	_
164-196	38070-38071	1	_
164-197	38072-38073	(	_
164-198	38073-38079	absent	_
164-199	38079-38080	)	_
164-200	38081-38083	to	_
164-201	38084-38085	7	_
164-202	38086-38087	(	_
164-203	38087-38096	extremely	_
164-204	38097-38103	severe	_
164-205	38103-38104	)	_
164-206	38104-38105	;	_
164-207	38106-38110	CPZE	_
164-208	38110-38111	:	_
164-209	38112-38126	Chlorpromazine	_
164-210	38127-38138	equivalents	_
164-211	38138-38139	;	_
164-212	38140-38142	IQ	_
164-213	38142-38143	:	_
164-214	38144-38156	Intelligence	_
164-215	38157-38165	Quotient	_
164-216	38165-38166	;	_
164-217	38167-38173	paired	_
164-218	38174-38181	t-tests	_
164-219	38181-38182	,	_
164-220	38183-38190	p-value	_
164-221	38190-38191	<	_
164-222	38191-38196	0.001	_
164-223	38196-38197	.	_

#Text=Variables are defined in Supplementary Table 1.
165-1	38198-38207	Variables	_
165-2	38208-38211	are	_
165-3	38212-38219	defined	_
165-4	38220-38222	in	_
165-5	38223-38236	Supplementary	_
165-6	38237-38242	Table	_
165-7	38243-38244	1	_
165-8	38244-38245	.	_
